

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 November 2001 (01.11.2001)

PCT

(10) International Publication Number
WO 01/81363 A1

(51) International Patent Classification⁷: **C07H 21/04**,
C12P 21/06, C12N 9/00, 1/20, 15/00

Hill, PA 19444 (US). **XIANG, Zhaoying** [CN/US]; 2413
Ridgeway, Fort Lee, NJ 07024 (US). **KABNICK, Karen**,
S. [US/US]; 4138 Presidential Drive, Lafayette Hill, PA
19444 (US). **LAI, Ying-Ta** [—/US]; 516 Spruce Avenue,
Upper Darby, PA 19082 (US). **XIE, Qing** [CN/US]; 310
Sawmill Lane, Horsham, PA 19044 (US).

(21) International Application Number: **PCT/US01/13360**

(22) International Filing Date: 26 April 2001 (26.04.2001)

(25) Filing Language: English

(74) Agents: **GIMMI, Edward, R.** et al.; SmithKline Beecham
Corporation, Corporate Intellectual Property, UW2220,
709 Swedeland Road, P.O. Box 1539, King of Prussia, PA
19406-0939 (US).

(30) Priority Data:
60/199,963 27 April 2000 (27.04.2000) US
60/203,336 11 May 2000 (11.05.2000) US
60/207,087 25 May 2000 (25.05.2000) US
60/207,546 26 May 2000 (26.05.2000) US

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicants (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US). **SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New
Horizons Court, Great West Road, Brentford, Middlesex
TW8 9EP (GB).

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Published:

— with international search report

(75) Inventors/Applicants (for US only): **AGARWAL, Pankaj** [IN/US]; 251 West DeKalb Pike, King of Prussia, PA 19406 (US). **MURDOCK, Paul, R.** [GB/GB]; New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **RIZVI, Safia, K.** [PK/US]; 4617 Pine Street, Philadelphia, PA 19143 (US). **SMITH, Randall, F.** [US/US]; 4138 Presidential Drive, Lafayette

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/81363 A1

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Polypeptides and polynucleotides of the genes set forth in Table I and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.

Novel Compounds

Field of Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polynucleotides and polypeptides of the present invention also relate to proteins with signal sequences which allow them to be secreted extracellularly or membrane-associated (hereinafter often referred collectively as secreted proteins or secreted polypeptides).

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Proteins and polypeptides that are naturally secreted into blood, lymph and other body fluids, or secreted into the cellular membrane are of primary interest for pharmaceutical research and development. The reason for this interest is the relative ease to target protein therapeutics into their place of action (body fluids or the cellular membrane). The natural pathway for protein secretion into extracellular space is the endoplasmic reticulum in eukaryotes and the inner membrane in prokaryotes (Palade, 1975, *Science*, 189, 347; Milstein, Brownlee, Harrison, and Mathews, 1972, *Nature New Biol.*, 239, 117; Blobel, and Dobberstein, 1975, *J. Cell. Biol.*, 67, 835). On the other hand, there is no known natural pathway for exporting a protein from the exterior of the cells into the cytosol (with the exception of pinocytosis, a mechanism of snake venom toxin intrusion into cells). Therefore targeting protein therapeutics into cells poses extreme difficulties.

The secreted and membrane-associated proteins include but are not limited to all peptide hormones and their receptors (including but not limited to insulin, growth hormones, chemokines, cytokines, neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic hormones, neuropsin, neurtropins, pituitary 5 hormones, pleiotropins, prostaglandins, secretogranins, selectins, thromboglobulins, thymosins), the breast and colon cancer gene products, leptin, the obesity gene protein and its receptors, serum albumin, superoxide dismutase, spliceosome proteins, 7TM (transmembrane) proteins also called as G-protein coupled receptors, immunoglobulins, several families of serine proteinases (including but not limited 10 to proteins of the blood coagulation cascade, digestive enzymes), deoxyribonuclease I, etc.

Therapeutics based on secreted or membrane-associated proteins approved by FDA or foreign agencies include but are not limited to insulin, glucagon, growth hormone, chorionic gonadotropin, follicle stimulating hormone, luteinizing 15 hormone, calcitonin, adrenocorticotrophic hormone (ACTH), vasopressin, interleukines, interferones, immunoglobulins, lactoferrin (diverse products marketed by several companies), tissue-type plasminogen activator (Alteplase by Genentech), hyaluronidase (Wydase by Wyeth-Ayerst), dornase alpha (Pulmozyme by Genentech), Chymodiactin (chymopapain by Knoll), alglucerase (Ceredase by 20 Genzyme), streptokinase (Kabikinase by Pharmacia) (Streptase by Astra), etc. This indicates that secreted and membrane-associated proteins have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further secreted and membrane-associated proteins which can play a role in preventing, ameliorating or correcting dysfunction or disease, 25 including but not limited to diabetes, breast-, prostate-, colon cancer and other malignant tumors, hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities, asthma, manic depression, dementia, delirium, mental retardation, Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including 30 those leading to stroke. The proteins of the present invention which include the signal sequences are also useful to further elucidate the mechanism of protein transport which at present is not entirely understood, and thus can be used as research tools.

Summary of the Invention

The present invention relates to particular polypeptides and polynucleotides of the genes set forth in Table I, including recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, the diseases set forth in Tables III and V,

5 hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with imbalance of polypeptides and/or polynucleotides of the genes set forth in Table I with the identified compounds. In still a further aspect, the invention relates to diagnostic assays for detecting

10 diseases associated with inappropriate activity or levels the genes set forth in Table I. Another aspect of the invention concerns a polynucleotide comprising any of the nucleotide sequences set forth in the Sequence Listing and a polypeptide comprising a polypeptide encoded by the nucleotide sequence. In another aspect, the invention relates to a polypeptide comprising any of the polypeptide sequences set forth in the Sequence Listing and

15 recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such polypeptides and polynucleotides. Such uses include the treatment of diseases, abnormalities and disorders (hereinafter simply referred to as diseases) caused by abnormal expression, production, function and or metabolism of the genes of this invention, and such diseases are readily apparent by those skilled in the art from the homology

20 to other proteins disclosed for each attached sequence. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with the imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels of the secreted proteins of the present

25 invention.

Description of the Invention

In a first aspect, the present invention relates to polypeptides the genes set forth in Table I. Such polypeptides include:

30 (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in the Sequence Listing, herein when referring to polynucleotides or polypeptides of the Sequence Listing, a reference is also made to the Sequence Listing referred to in the Sequence Listing;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%,

35 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;

- (c) an isolated polypeptide comprising a polypeptide sequence set forth in the Sequence Listing;
- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- 5 (e) a polypeptide sequence set forth in the Sequence Listing; and
- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing;
- (g) fragments and variants of such polypeptides in (a) to (f).

10 Polypeptides of the present invention are believed to be members of the gene families set forth in Table II. They are therefore of therapeutic and diagnostic interest for the reasons set forth in Tables III and V. The biological properties of the polypeptides and polynucleotides of the genes set forth in Table I are hereinafter referred to as "the biological activity" of polypeptides and polynucleotides of the genes set forth in Table I. Preferably, a 15 polypeptide of the present invention exhibits at least one biological activity of the genes set forth in Table I.

Polypeptides of the present invention also include variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be 20 conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated 25 polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from an amino acid sequence set forth in the Sequence Listing, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence set forth in the Sequence Listing. Preferred fragments are biologically active fragments that mediate the biological 30 activity of polypeptides and polynucleotides of the genes set forth in Table I, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of a polypeptide of the invention may be employed for producing the 35 corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be

employed as intermediates for producing the full-length polypeptides of the invention. A polypeptide of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-
5 sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance
10 automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to polynucleotides of the genes set forth in Table I. Such polynucleotides include:

- (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%,
15 96%, 97%, 98%, or 99% identity to a polynucleotide sequence set forth in the Sequence Listing;
- (b) an isolated polynucleotide comprising a polynucleotide set forth in the Sequence Listing;
- (c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to a
20 polynucleotide set forth in the Sequence Listing;
- (d) an isolated polynucleotide set forth in the Sequence Listing;
- (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing;
- (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (h) an isolated polynucleotide encoding a polypeptide set forth in the Sequence Listing;
- (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polynucleotide sequence set forth in the Sequence Listing;

(j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing; and
5 polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from a sequence set forth in the Sequence Listing, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides 10 truncated or deleted from a sequence set forth in the Sequence Listing.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding 15 polypeptide variants that comprise an amino acid sequence set forth in the Sequence Listing and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts 20 of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

- (a) comprises an RNA transcript of the DNA sequence encoding a polypeptide set forth in the Sequence Listing;
- (b) is a RNA transcript of a DNA sequence encoding a polypeptide set forth in the 25 Sequence Listing;
- (c) comprises an RNA transcript of a DNA sequence set forth in the Sequence Listing; or
- (d) is a RNA transcript of a DNA sequence set forth in the Sequence Listing; and RNA polynucleotides that are complementary thereto.

30 The polynucleotide sequences set forth in the Sequence Listing show homology with the polynucleotide sequences set forth in Table II. A polynucleotide sequence set forth in the Sequence Listing is a cDNA sequence that encodes a polypeptide set forth in the Sequence Listing. A polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing may be identical to a polypeptide encoding a sequence set forth in the 35 Sequence Listing or it may be a sequence other than a sequence set forth in the Sequence

Listing, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes a polypeptide set forth in the Sequence Listing. A polypeptide of a sequence set forth in the Sequence Listing is related to other proteins of the gene families set forth in Table II, having homology and/or structural similarity with the polypeptides set forth in Table II. Preferred 5 polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one activity of the genes set forth in Table I.

Polynucleotides of the present invention may be obtained using standard cloning 10 and screening techniques from a cDNA library derived from mRNA from the tissues set forth in Table IV (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available 15 techniques.

When polynucleotides of the present invention are used for the recombinant 20 production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused 25 polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. A polynucleotide may also contain non-coding 5' and 3' sequences, such as 30 transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide 35 sequence set forth in the Sequence Listing, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from other species) that have a high sequence similarity to sequences set forth in the Sequence Listing, typically at least 95% identity. Preferred probes and primers will

generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

5 A polynucleotide encoding a polypeptide of the present invention, including homologs from other species, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having a sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing the

10 10 polynucleotide sequence set forth in the Sequence Listing. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA;

15 15 followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides.

20 20 The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the

25 25 mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified

30 30 by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and

35 35 adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested'

primers, that is, primers designed to anneal within the amplified product (typically an adapter specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by

5 joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems.

10 Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of

15 the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.

20 Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., *Basic Methods in Molecular Biology* (1986) and Sambrook et al. (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, micro-injection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

25 Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

30 A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and

35 bacteriophage genetic elements, such as cosmids and phagemids. The expression systems

may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine

5 techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

10 If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before

15 the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography,

20 hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents,

25 through detecting mutations in the associated gene. Detection of a mutated form of a gene is characterized by the polynucleotides set forth in the Sequence Listing in the cDNA or genomic sequence and which is associated with a dysfunction. Will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of

30 the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-

35 PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used

in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled nucleotide sequences of the genes set forth in Table I. Perfectly matched sequences can be distinguished from mismatched duplexes by 5 RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, *Science* (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage 10 method (see Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising polynucleotide sequences or 15 fragments thereof of the genes set forth in Table I can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M. Chee *et al.*, *Science*, 274, 610-613 15 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression 20 may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample 25 derived from a host are well-known to those of skill in the art. Such assay methods include radio-immunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence set forth in the Sequence Listing, or a fragment or an RNA transcript thereof;
- 30 (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide set forth in the Sequence Listing or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide set forth in the Sequence Listing.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequences set forth in the Sequence Listing are specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available online through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (*Hum Mol Genet* 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridization techniques to clones arrayed on a grid, such as cDNA microarray hybridization (Schena *et al*, *Science*,

270, 467-470, 1995 and Shalon *et al*, *Genome Res*, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, 5 comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply 10 quantitative nature.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the 15 polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal 20 antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al*., *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al*., *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, 25 Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

30 The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

35 Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for

inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the
5 individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired
10 cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous,
15 intra-muscular, intravenous, or intra-dermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or
20 multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily
25 determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present
30 invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections
35 of chemical compounds, and natural product mixtures. Such agonists or antagonists so-

identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule. Such small molecules preferably have a molecular weight below 2,000 daltons, more preferably 5 between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. 10 Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. 15 Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring an activity of the genes set forth in Table I in the mixture, and 20 comparing activity of the mixture of the genes set forth in Table I to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well 25 micotiter plates but also emerging methods such as the nanowell method described by Schullek *et al.*, Anal Biochem., 246, 20-29, (1997). Fusion proteins, such as those made from Fc portion and polypeptide of the genes set forth in Table I, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J 30 Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA 35 assay may be constructed for measuring secreted or cell associated levels of polypeptide

using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or 5 soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell 10 supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

15 Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, *e.g.*, a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the 20 polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and the genes set forth in Table I. The art of constructing transgenic animals is well established. For example, the genes set forth in Table I may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation 25 embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic 30 animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic 35 animal technology also offers a whole animal expression-cloning system in which

introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- 5 (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that set forth in the Sequence Listing.

- 10 10 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Glossary

- 15 The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

- 20 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a
- 25 polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

- 30 "Secreted protein activity or secreted polypeptide activity" or "biological activity of the secreted protein or secreted polypeptide" refers to the metabolic or physiologic function of said secreted protein including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said secreted protein.

"Secreted protein gene" refers to a polynucleotide comprising any of the attached nucleotide sequences or allelic variants thereof and/or their complements.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxyribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and

5 RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and

10 DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.

15 "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides

20 or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as

25 in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of

30 ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent

35 attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-

linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation,

5 racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, 10 New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol*, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci*, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence set forth in the Sequence Listing.

15 "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a 20 polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded 25 by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included 30 35 as variants are polypeptides having one or more post-translational modifications, for

instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like.

Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

5 "Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

10 "Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match 15 one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

20 "Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

25 "Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

30 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global 35 alignment), that is particularly suitable for sequences of the same or very similar length, or

over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147, 195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99,

1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988,
available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and
5 Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide
sequence comparisons including where nucleotide sequences are first translated into amino
acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query
10 polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a
polypeptide sequence, the query and the reference sequence being optimally aligned and the
parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to
compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence.
Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity
15 Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference
sequence except that the candidate polynucleotide sequence may include on average up to
five differences per each 100 nucleotides of the reference sequence. Such differences are
selected from the group consisting of at least one nucleotide deletion, substitution, including
transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal
20 positions of the reference polynucleotide sequence or anywhere between these terminal
positions, interspersed either individually among the nucleotides in the reference sequence
or in one or more contiguous groups within the reference sequence. In other words, to
obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference
polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the
reference sequence may be deleted, substituted or inserted, or any combination thereof, as
25 hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity
Index, for instance 0.96, 0.97, 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example,
an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the
reference sequence except that the polypeptide sequence may include an average of up to
30 five differences per each 100 amino acids of the reference sequence. Such differences are
selected from the group consisting of at least one amino acid deletion, substitution,
including conservative and non-conservative substitution, or insertion. These differences
may occur at the amino- or carboxy-terminal positions of the reference polypeptide
sequence or anywhere between these terminal positions, interspersed either individually
35 among the amino acids in the reference sequence or in one or more contiguous groups

within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

5 The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \cdot I),$$

in which:

10 n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in a sequence set forth in the Sequence Listing,

I is the Identity Index,

• is the symbol for the multiplication operator, and

15 in which any non-integer product of x_a and I is rounded down to the nearest integer prior to subtracting it from x_a .

20 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

25 "Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 533-A discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for 30 example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

35 All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to

be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Table I.

Gene Name	GSK Gene ID	Nucleic Acid SEQ ID NO's	Corresponding Protein SEQ ID NO's
sbg318680DNase	318680	SEQ ID NO:1	SEQ ID NO:40
sbg237038SA	237038	SEQ ID NO:2 SEQ ID NO:3	SEQ ID NO:41 SEQ ID NO:42
sbg340871GPV	340871	SEQ ID NO:4	SEQ ID NO:43
sbg293416HNKS	293416	SEQ ID NO:5 SEQ ID NO:6	SEQ ID NO:44 SEQ ID NO:45
sbg257418ZP	257418	SEQ ID NO:7	SEQ ID NO:46
sbg319185CDa	319185	SEQ ID NO:8 SEQ ID NO:9	SEQ ID NO:47 SEQ ID NO:48
sbg323307KIAAa	323307	SEQ ID NO:10	SEQ ID NO:49
sbg315953GPPa	315953	SEQ ID NO:11 SEQ ID NO:12	SEQ ID NO:50 SEQ ID NO:51
sbg318486ONC	318486	SEQ ID NO:13	SEQ ID NO:52
sbg299359LIPO	299359	SEQ ID NO:14	SEQ ID NO:53
sbg230022NGa	230022	SEQ ID NO:15 SEQ ID NO:16	SEQ ID NO:54 SEQ ID NO:55
sbg297169BGP	297169	SEQ ID NO:17 SEQ ID NO:18	SEQ ID NO:56 SEQ ID NO:57

5

sbg253919HSCCAa	253919	SEQ ID NO:19 SEQ ID NO:20	SEQ ID NO:58 SEQ ID NO:59
sbg228137OLF	228137	SEQ ID NO:21 SEQ ID NO:22	SEQ ID NO:60 SEQ ID NO:61
sbg378514Netrin	378514	SEQ ID NO:23 SEQ ID NO:24	SEQ ID NO:62 SEQ ID NO:63
sbg253227.mucous matrix glycoprotein	253227	SEQ ID NO:25 SEQ ID NO:26	SEQ ID NO:64 SEQ ID NO:65
sbg262831SIAa	262831	SEQ ID NO:27 SEQ ID NO:28	SEQ ID NO:66 SEQ ID NO:67
sbg233728LIPASE	233728	SEQ ID NO:29	SEQ ID NO:68
sbg400455.CRF	400455	SEQ ID NO:30	SEQ ID NO:69
sbg400612KINASEa	400612	SEQ ID NO:31	SEQ ID NO:70
sbg381373ACRP	381373	SEQ ID NO:32	SEQ ID NO:71
sbg401294MEX-3	401294	SEQ ID NO:33 SEQ ID NO:34	SEQ ID NO:72 SEQ ID NO:73
sbg247722Cadherin	247722	SEQ ID NO:35 SEQ ID NO:36	SEQ ID NO:74 SEQ ID NO:75
sbg391057THIPa	391057	SEQ ID NO:37 SEQ ID NO:38	SEQ ID NO:76 SEQ ID NO:77
sbg378067TGFc	378067	SEQ ID NO:39	SEQ ID NO:78

Table II

Gene Name	Gene Family	Closest Polynuclotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg318680-DNase	DNase I	GB:AC022471 Submitted (04-FEB-2000) by Lita Annenberg Hazen Genome Sequencing Center, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA.	Human DNase I-like endonuclease, gi:5803007 Parrish JE, Ciccodicola A, Wehhert M, Cox GF, Chen E, and Nelson DL; 1995; Hum. Mol. Genet. 4:1557-1564.	Secreted
sbg237038-SA	SA protein	GB:AC023292 Submitted (11-FEB-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Human SA gene, gi:2988399 Loftus,B.J. et al. Genomics 60 (3), 295- 308 (1999)	Secreted
sbg340871-GPV	Platelet glycoprotein (GPV)	GB:AC025389 Submitted (08-MAR-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Rat platelet glycoprotein V (GPV) precursor, gi:6980974 Ravanat C, Morales M, Azorsa DO, Moog S, Schuhler S, Grunert P, Loew D, Van Dorsselaer A, Cazenave JP, Lanza F; 1997; Blood 89:3253-62.	Secreted
sbg293416-HNKS	HNK-1 sulfotransfere se	JGI:LLNL-R_241B6 Joint Genome Institute, Department of Energy, USA	Human GalNAc 4- sulfotransferase, gi:11990885 Okuda,T., Mita,S., Yamauchi,S., Fukuta,M., Nakano,H., Sawada,T. and Habuchi,O. J. Biol. Chem. 275 (51), 40605- 40613 (2000)	Secreted
sbg257418-ZP	Zona pellucida protein	GB:AP000777 Submitted (25-NOV-1999) to the DDBJ/EMBL/GenBank databases. Masahira Hattori, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC); Kitasato Univ., 1- 15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan.	Mouse zona pellucida glycoprotein, gi:6677653 Epifano,O., Liang,L.F., Familari,M., Moos,M.C. Jr. and Dean,J.; 1995; Development 121:1947- 1956.	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynuclotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg319185-CDa	Leukocyte differentiation antigen	GB:AC024004 Submitted (20-FEB-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Human leukocyte differentiation antigen CD84 isoform CD84s, gi:6650112 Submitted (20-MAR-1998) by Servel d'Immunologia, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain	Secreted
sbg32330-7-KIAAa	Slit-like	GB:AL160156, Submitted (10-MAR-2000) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human unnamed protein, gi:10439289 Submitted (29-AUG-2000) by Sumio Sugano, Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure Analysis, Human Genome Center; Shirokane-dai, 4-6-1, Minato-ku, Tokyo 108-8639, Japan	Secreted
sbg31595-3-GPPa	Granulocyte peptide A	GB:AC011666 Submitted (09-OCT-1999) by Department Of Chemistry And Biochemistry, The University Of Oklahoma, 620 Parrington Oval, Room 208, Norman, OK 73019, USA	Human hypothetical protein SBB167, gi:9966869 Submitted (08-MAR-2000) by Department of Immunology, Second Military Medical University & Shanghai Brilliance Biotechnology Institute, 800 Xiangyin Rd., Shanghai 200433, P.R. China	Secreted
sbg31848-6-ONC	Oncotrophoblast glycoprotein	GB:AC022045 Submitted (25-JAN-2000) by tehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Canine 5T4 tumour-associated antigen' geneseqp:Y94351 Submitted by OXFORD BIOMEDICA UK LTD Publication number and date: WO200029428-A2, 25-MAY-00	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg29935 9-LIPO	Lipocalin	SC:AL139041 Submitted (16-NOV-2000) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK	Mouse major urinary protein (MUP) 4, gi:6678968 Shahan K, Gilmartin M, and Derman E; 1987; <i>Mol Cell Biol</i> 7:1938- 1946.	Secreted
sbg23002 2-NGa	Plasmacytoma -associated neuronal glycoprotein	GB:AC066608 GB:AC022002 Submitted (25-APR-2000) and (24-JAN-2000) by Human Genomic Center, Institute of Genetics, Chinese Academy of Sciences, Datun Road, Beijing, Beijing 100101, P.R.China	Rat neural cell adhesion protein BIG-2 precursor, gi :1016012 Yoshihara, Y., Kawasaki,M., Tamada,A., Nagata,S., Kagamiyama,H. and Mori,K. <i>J. Neurobiol.</i> 28 (1), 51-69 (1995)	Membrane- bound
sbg29716 9-BGP	Biliary glycoprotein (BGP)	JGI: CITB- E1_2616J11 Submitted by Joint Genome Institute, Department of Energy, USA	Mouse biliary glycoprotein (BGP), gi:312584 McCuaig K, Rosenberg M, Nedellec P, Turbide C, and Beauchemin N; 1993; <i>Gene</i> 127:173- 83.	Secreted
sbg25391 9- HSCCAa	Human squamous cell carcinoma antigen (SCCA)	GB:AC019355 Submitted (02-JAN-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Human squamous cell carcinoma antigen 2 (SCCA-2) (LEUPIN). gi:1710877. Schneider,S.S., Schick,C., Fish,K.E., Miller,E., Pena,J.C., Treter,S.D., Hui,S.M. and Silverman,G.A. <i>Proc. Natl. Acad. Sci.</i> U.S.A. 92 (8), 3147- 3151 (1995).	Secreted
sbg22813 7-OLF	Olfactomedin -related protein	GB:AC022606 Submitted (06- FEB-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Rat neuronal olfactomedin-related protein precursor, gi:3024210 Danielson,P.E., Forss- Petter,S., Battenberg,E.L., deLecea,L., Bloom,F.E., and Sutcliffe,J.G., 1994, <i>J.</i> <i>Neurosci. Res.</i> 38:468- 478.	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynuclotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg378514-Netrin	Netrin precursor	SC:BA5N16 Submitted (09-APR-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse Netrin-G1a protein gi:9909148 Nakashiba, T., Ikeda, T., Nishimura, S., Tashiro, K., Honjo, T., Culotti, J.G. and Itohara, S. <i>J. Neurosci.</i> 20 (17), 6540-6550 (2000)	Secreted
sbg253227. mucous matrix glycoprotein (EMMG)	Extracellular mucous matrix glycoprotein (EMMG)	GB:AC011647 Submitted (08-OCT-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Human colon specific protein, geneseqp:Y54368 Submitted by DIADEXUS LLC Publication number and date: WO9960161-A1, 25-NOV-99	Secreted
sbg262831-SIAa	Sialoadhesin	JGI:CITB- E1_3073N11 Found at Joint Genome Institute	Human sialic acid binding immunoglobulin-like lectin 8 long splice variant, gi: 9837433 Foussias, G., Yousef, G.M. and Diamandis, E.P. <i>Biochem. Biophys. Res. Commun.</i> 278 (3), 775- 781 (2000)	Secreted
sbg233728-LIPASE	Pancreatic lipase	GB:AC011098 Submitted (01-OCT-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Human pancreatic lipase precursor, gi:126318 Lowe ME, Rosenblum JL, and Strauss AW; 1989; <i>J Biol Chem</i> 264:20042-8.	Secreted
sbg400455.-CRF	C1q-related factor (CRF)	GB:AC024339 Submitted (28-FEB-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	MouseGliacolin, gi:10566471 Koide, T., Aso, A., Yorihizi, T. and Nagata, K. <i>J. Biol. Chem.</i> 275 (36), 27957- 27963 (2000)	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg400612-KINASEa	Protein kinase	GB:AP001615 Submitted (04-APR-2000) to the DDBJ/EMBL/GenBank databases. Nobuyoshi Shimizu, Keio University, School of Medicine, Molecular Biology; 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan	Murine protein kinase/ankyrin homologue, geneseqp:Y76079 Submitted by GENESIS RES & DEV CORP LTD Publication number and date: WO9955865-A1 04-NOV-99	Secreted
sbg381373-ACRP	Adipocyte complement-related protein (ACRP30)	JGI:RPCI-11_161M6 Found at Joint Genome Institute, Department of Energy, USA	Human adipocyte Complement-Related Protein (ACRP30R2), geneseqp:Y44487. Submitted by SMITHKLINE BEECHAM CORP Publication number and date: WO9964629-A1, 16-DEC-99	Secreted
sbg401294-MEX-3	MEX-3(IAP)	GB:AC026956 Submitted (25-MAR-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Caenorhabditis elegans MEX-3, gi:1644450 Draper,B.W., Mello,C.C., Bowerman,B., Hardin,J. and Priess,J.R. Cell 87 (2), 205-216 (1996)	Cytosolic (RNA-binding protein)
sbg247722-Cadherin	OB-Cadherin	GB:AL132780 Submitted (02-NOV-1999) by Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE	Human OB-cadherin-1, gi:1377894 Okazaki,M., Takeshita,S., Kawai,S., Kikuno,R., Tsujimura,A., Kudo,A. and Armann,E. J. Biol. Chem. 269 (16), 12092-12098 (1994)	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynuclotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg391057-THIPa	Thyroid hormone induced protein	SC:AL158153, SC:AL392044 Submitted (22-MAR-2001) and (02-MAR-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human TANGO 239, geneseqp:B01432 Submitted by MILLENNIUM PHARM INC Publication number and date: WO200039284-A1, 06-JUL-00	Secreted
sbg378067-TGFc	TGF beta (transforming growth factor beta)	SC:AL162502 Submitted (06-APR-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human persephin growth factor, geneseqp:Y16714 Submitted by UNIV WASHINGTON Publication number and date: WO9914235-A1 25-MAR-99	Secreted

Table III.

Gene Name	Uses	Associated Diseases
sbg318680-DNase	An embodiment of the invention is the use of sbg318680-Dnase to treat respiratory diseases and target parasites or cancer cells as a chromosome degrading agent to cause death of those cells. Close homologues of sbg318680-DNase are DNases. DNase can be used to treat respiratory diseases, such as pneumonia, cystic fibrosis and asthma, by reducing viscosity of bronchopulmonary secretions (MacConnachie AM; 1999; <i>Intensive Crit Care Nurs</i> 14:101-2).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation and respiratory diseases
sbg237038-SA	An embodiment of the invention is the use of sbg237038SA in blood pressure control. A close homologue of sbg237038SA is the rat SA gene. The SA gene is expressed at higher levels in the kidney of genetically hypertensive rats (Yang T, Hassan SA, Singh I, Smart A, Brosius FC, Holzman LB, Schnermann JB, Briggs JP; 1996; <i>Hypertension</i> 27:541-51).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and hypertension
sbg340871-GPV	An embodiment of the invention is the use of sbg340871-GPV in hemostasis and platelet aggregation. A close homologue of sbg340871-GPV is platelet glycoprotein (GP) V. Platelet glycoprotein (GP) V is a major surface protein which is cleaved by thrombin during platelet activation, and associates with GPIb-IX complex to form GPIb-V-IX, a receptor for von Willebrand factor and thrombin. Its functional role in hemostasis is possibly related to thrombin-induced platelet aggregation (Ravanat C, Morales M, Azorsa DO, Moog S, Schuhler S, Grunert P, Loew D, Van Dorsselaer A, Cazenave JP, Lanza F; 1997; <i>Blood</i> 89:3253-62).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and Bernard-Soulier disease
sbg293416-HNKS	An embodiment of the invention is the use of sbg293416-HNKS in cell interactions and the development of the nervous system. Close homologues of sbg293416-HNKS are sulfotransferases. Sulfotransferases are considered to be key enzymes in the biosynthesis of the HNK-1 carbohydrate epitope, which is expressed on several neural adhesion glycoproteins and as a glycolipid, and is involved in cell interactions (Bakker,H., Friedmann,I., Oka,S., Kawasaki,T., Nifant'ev,N., Schachner,M. and Mantei,N., 1997, <i>J. Biol. Chem.</i> 272:29942-29946). The HNK-1 epitope is spatially and temporally regulated during the development of the nervous system. The biological function of the HNK-1 sulfotransferase may be related to the development of the nervous system, and also may be involved in the preferential reinnervation of muscle nerves by motor axons after lesion (Jungalwala FB, 1994, <i>Neurochem Res</i> 19:945-57).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and peripheral neuropathies

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg257418-ZP	An embodiment of the invention is the use of sbg257418ZP in fertilization. A close homologue of sbg257418ZP is zona pellucida. Zona pellucida protein is an extracellular matrix that surrounds growing oocytes, ovulated eggs, and early embryos and it is critically involved in fertilization (Epifano,O., Liang,L.F., Familaro,M., Moos,M.C. Jr. and Dean,J.; 1995; Development 121:1947-1956). The zona pellucida also provides a post-fertilization block to polyspermy and protects the growing embryo as it passes down the oviduct (Rankin T, and Dean J; 1996; Mol Hum Reprod 2:889-94).	Infertility
sbg319185-CDa	An embodiment of the invention is the use of sbg319185CDa, a secreted protein, in the diagnosis and treatment of cancer and autoimmune disorders. Close homologues of sbg319185CDa are leukocyte differentiation antigen CD84 isoforms. CD84's are members of the immunoglobulin superfamily, show high homology with several molecules belonging to the CD2 family of differentiation antigens and is proposed to be useful in the diagnosis and treatment of cancer and autoimmune disorders (Palou E, Pirotto F, Sole J, Freed JH, Peral B, Vilardell C, Vilella R, Vives J, Gaya A. Genomic characterization of CD84 reveals the existence of five isoforms differing in their cytoplasmic domains. <i>Tissue Antigens</i> 2000 Feb;55(2):118-27).	Cancer, autoimmune disorders, wound healing disorders, infections and hematopoietic disorders
sbg323307-KIAAa	An embodiment of the invention is the use of sbg323307-KIAAa, a secreted protein, to regulate cell signaling, motility, and nucleic acid management. A close homologue of sbg323307-KIAAa is human KIAA0918 protein. Human KIAA0918 protein, a slit-like protein is functionally related to cell signaling/communication, cell structure/motility and nucleic acid management (Nagase,T., Ishikawa,K., Suyama,M., Kikuno,R., Hirosawa,M., Miyajima,N., Tanaka,A., Kotani,H., Nomura,N. and Ohara,O. KIAA0918 protein [Homo sapiens], <i>DNA Res.</i> 5 (6), 355-364 (1998)).	Cancer, autoimmune disorders, infections, wound healing disorders and hematopoietic disorders

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg315953-GPPa	An embodiment of the invention is the use of sbg315953GPPa, a secreted protein, to treat disorders associated with lipopolysaccharides. A close homologue to sbg315953GPPa is Bovine granulocyte peptide A precursor. Bovine granulocyte peptide A precursors are used in human and veterinary medicine, particularly to treat disorders associated with lipopolysaccharides, e.g. sepsis and endotoxaemia (1. Selsted ME, Bovine granulocyte peptide A precursor (antimicrobial BGP-A). Accession Number W23722, Publication Date 21-AUG-97. 2. Yount NY, Yuan J, Tarver A, Castro T, Diamond G, Tran PA, Levy JN, McCullough C, Cullor JS, Bevins CL, Selsted ME. Cloning and expression of bovine neutrophil beta-defensins. Biosynthetic profile during neutrophilic maturation and localization of mature peptide to novel cytoplasmic dense granules. <i>J Biol Chem</i> 1999 Sep 10;274(37):26249-58)).	Infections, cancer, autoimmune disorders, wounder healing disorders and hematopoietic disorders.
sbg318486-ONC	An embodiment of the invention is the use of sbg318486ONC in the growth and invasion events of trophoblast and tumor cells. A close homologue to sbg318486ONC is oncotrophoblast glycoproteins. It has been shown that oncotrophoblast protein was expressed by tumor cells with metastatic spread, suggesting a role in invasion during cancer (King,K.W., Sheppard,F.C., Westwater,C., Stern,P.L. and Myers,K.A.; 1999; <i>Biochim. Biophys. Acta</i> 1445, 257-270).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation
sbg299359-LIPO	An embodiment of the invention is the use of sbg299359LIPO in sperm maturation, taste recognition, and transportation of some molecules across the blood brain barrier. A close homologue to sbg299359LIPO is Lipocalin. Lipocalins transport small hydrophobic molecules such as steroids, bilins, retinoids, and lipids, and they have various effects on a number of tissues. It has been shown that lipocalins are involved in sperm maturation, taste recognition, and transportation of some molecules across the blood brain barrier (Newcomer M.E.; 1993; Structure 1:7-18; Achen M.G., Harms P.J., Thomas T., Richardson S.J., Wettenhall R.E.H., Schreiber G.; 1992; <i>J. Biol. Chem.</i> 267:23170-23174)	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation

Table III (cont).

Gene Name	Uses	Associated Diseases
sbg230022-NGa	An embodiment of the invention is the use of sbg230022Nga in the formation and maintenance of neuron type-specific networks in the brain. Close homologues to sbg230022Nga are mouse plasmacytoma-associated neuronal glycoprotein and rat BIG-1 protein. Mouse plasmacytoma-associated neuronal glycoprotein, is ectopically activated by intracisternal A-type particle long terminal repeats in murine plasmacytomas. Rat BIG-1 protein, is a TAG-1/F3-related member of the immunoglobulin superfamily with neurite outgrowth-promoting activity and involved in the formation and maintenance of neuron type-specific networks in the brain (1. Connelly MA, Grady RC, Mushinski JF, Marcu KB. PANG, a gene encoding a neuronal glycoprotein, is ectopically activated by intracisternal A-type particle long terminal repeats in murine plasmacytomas. Proc Natl Acad Sci U S A 1994 Feb 15;91(4):1337-41 2. Yoshihara Y, Kawasaki M, Tani A, Tamada A, Nagata S, Kagamiyama H, Mori K. BIG-1: a new TAG-1/F3-related member of the immunoglobulin superfamily with neurite outgrowth-promoting activity. Neuron 1994 Aug;13(2):415-26).	Cancer, infections, autoimmune disorders, wound healing disorders and hematopoietic disorders
sbg297169-BGP	An embodiment of the invention is the use of sbg297169BGP in renewal and/or differentiation of epithelial cells. A close homologue to sbg297169BGP is BGP protein. BGP proteins are expressed at the cell surface and function <i>in vitro</i> as cell adhesion molecules. The expression of the many BGP isoforms at the surface of epithelial cells, such as the colon, suggests that these proteins play a major role in renewal and/or differentiation of their epithelia (McCuaig K, Rosenberg M, Nedellec P, Turbide C, and Beauchemin N; 1993; Gene 127:173-83).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg253919-HSCCAa	An embodiment of the invention is the use of sbg253919-HSCCAa for treatment of cancer or psoriasis or in development of more aggressive squamous cell carcinomas. Close homologues of sbg253919-HSCCAa are Psoriastatin type II and a human leupin precursor. Psoriastatin type II, is claimed to modulate activity of psoriastatin type I and II genes, e.g. using (ant)agonists, useful for treatment of cancer or psoriasis. The other, a human leupin precursor, contains a tandem duplication of the human squamous cell carcinoma antigen gene playing a causal role in development of more aggressive squamous cell carcinomas (1. Goetinck PF, Hibino T, Takahashi T and Baciu PC. Modulating cell proliferation or apoptosis - by modulating activity of psoriastatin type I and II genes, e.g. using (ant) agonists, useful for treatment of cancer or psoriasis. Accession Number W15242, publication date 24-APR-97. 2. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM, Silverman GA. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci U S A 1995 Apr 11;92(8):3147-51. 3. Barnes RC, Worrall DM. Identification of a novel human serpin gene; cloning sequencing and expression of leupin. FEBS Lett 1995 Oct 2; 373 (1): 61-5).	Cancers, such as squamous cell carcinomas
sbg228137-OLF	An embodiment of the invention is the use of sbg228137OLF in functional roles in chemoreception and in the central nervous system. A close homologue to sbg228137OLF is olfactomedin. Olfactomedin is a glycoprotein, and reacts with proteins of olfactory cilia. It was originally discovered at the mucociliary surface of the amphibian olfactory neuroepithelium and subsequently found throughout the mammalian brain (Danielson, P.E., Forss-Petter, S., Battenberg, E.L., deLecea, L., Bloom, F.E., and Sutcliffe, J.G., 1994, J. Neurosci. Res. 38:468-478). Its noticeable deposition at the chemosensory surface of the olfactory neuroepithelium suggest a role for this protein in chemoreception (Snyder DA, Rivers AM, Yokoe H, Menco BP, and Anholt RR, 1991, Biochemistry 30:9143-53). The widespread occurrence of olfactomedin among mammals in the brains also suggests its new functions in the central nervous system (Karavanich CA, and Anholt RR, 1998, Mol Biol Evol 15:718-26).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and nervous system disorders

Table III (cont).

Gene Name	Uses	Associated Diseases
sbg378514-Netrin	An embodiment of the invention is the use of sbg378514-Netrin in roles of the central nervous system. A close homologue to sbg378514-Netrin is Netrin. Netrins possess commissural axon outgrowth-promoting activity, and control guidance of CNS commissural axons and peripheral motor axons (Serafini T, Kennedy TE, Galko MJ, Mirzayan C, Jessell TM, and Tessier-Lavigne M; 1994; <i>Cell</i> 78:409-24). Diffusible and substrate-bound cues, including netrins and their receptors, can guide axonal pathway choice via attractive and repulsive signals (Tear G; 1998; <i>Essays Biochem</i> 33:1-13).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and nervous system disorder
sbg253227. mucous matrix glycoprotein	An embodiment of the invention is the use of sbg253227. mucous matrix glycoprotein for the treatment of gastrointestinal disorders and cancer. Close homologues of sbg253227. mucous matrix glycoprotein have been used in combination for treatment of infections associated with EMMG. EMMG is useful for the treatment of gastrointestinal disorders and cancer, e.g. dysphagia, abdominal angina, pancreatitis, colonic carcinoma, Crohn's disease and the Mallory-Weiss syndrome (US5929033-A, CORLEY NC, TANG YT, Submitted by INCYTE PHARM INC. Reference number, WPI; 99-429518/36, 1999).	Hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, autoimmune diseases Neurological disorders, gastrointestinal disorders, dysphagia, abdominal angina, pancreatitis, colonic carcinoma, Crohn's disease and the Mallory-Weiss syndrome.
sbg262831-SIAa	An embodiment of the invention is the use of sbg262831SIAa to mediate sialic acid-dependent ligand recognition and to function as an inhibitory receptor in human natural killer cells. A close homologue of sbg262831SIAa is human QA79 membrane protein. QA79 belongs to the sialoadhesin family and is proposed to mediate sialic acid-dependent ligand recognition and to function as an inhibitory receptor in human natural killer cells (Falco,M., Biassoni,R., Bottino,C., Vitale,M., Sivori,S., Augugliaro,R., Moretta,L. and Moretta,A. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. <i>J Exp Med</i> 1999 Sep 20;190(6):793-802).	Cancer, autoimmune disorders, infection, wound healing disorders, and hematopoietic disorders.

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg233728-LIPASE	An embodiment of the invention is the use of sbg233728LIPASE to treat pancreatitis via replacement therapy. A close homologue of sbg233728-LIPASE is pancreatic lipase. Pancreatic lipase can be used as replacement enzymes for patients with chronic pancreatitis. Pancreatic lipase hydrolyzes dietary long chain triacylglycerol to free fatty acids and monoacylglycerols in the intestinal lumen (Lowe ME, Rosenblum JL, and Strauss AW; 1989; <i>J Biol Chem</i> 264:20042-8). Pancreatic steatorrhea and pancreatic diabetes are the dominant symptoms of patients in a certain stage of chronic pancreatitis. In this stage, the nutritional state is greatly disturbed and hypoglycemia and labile infection are involved. Pancreatic enzyme replacement therapy is the principal treatment method for pancreatic steatorrhea. (Nakamura T, Takeuchi T, and Tando Y; 1998; <i>Pancreas</i> 16:329-36).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and pancreatitis.
sbg400455.-CRF	An embodiment of the invention is the use of sbg400455.CRF in the areas of the nervous system involved in motor function, such as the Purkinje cells of the cerebellum, the accessory olfactory nucleus, the pons, and the red nucleus. Close homologues of sbg400455.CRF include CRF transcripts. CRF transcripts are most abundant in areas of the nervous system and have been used to develop products for modulating energy balance or insulin production in mammals ((W09639429-A2) Schere, P.E.; Submitted by Whithead Institute of Biomedical Research; Berube NG, Swanson XH, Bertram MJ, Kittle JD, Didenko V, Baskin DS, Smith JR and Pereira-Smith OM., <i>Brain Res. Mol. Brain Res.</i> 63 (2), 233-240 (1999)).	Hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, autoimmune diseases, energy homeostasis disorder and obesity
sbg400612-KINASEa	An embodiment of the invention is the use of sbg400612-KINASEa in the treatment of inflammation, cancer, neurological diseases, growth and developmental defects, skin wounds, and hair follicle disorders. A close homologue of sbg400612-KINASEa is murine protein kinase/ ankyrin homologue. Murine protein kinase/ ankyrin homologue can stimulate the growth and motility of keratinocytes, inhibit the growth of cancer cells, modulate angiogenesis and tumour vascularisation, modulate skin inflammation and epithelial cell growth and inhibit binding of HIV-1 to leukocytes. Murine protein kinase/ ankyrin homologue can also be used to treat inflammation, cancer, neurological diseases, growth and developmental defects, skin wounds, and hair follicle disorders (Kumble A, Murison JG, Onrust R, Sleeman M, Strachan L and Watson JD. Novel polynucleotides useful for the treatment of various conditions including wounds and cancer. Accession Number: Y76079 Publication Date: 04-NOV-99).	Cancer, wound healing disorders, autoimmune disorders, hematopoietic disorders and infection

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg381373-ACRP	An embodiment of the invention is the use of sbg381373-ACRP in the complex balanced system of energy homeostasis involving food intake, carbohydrate catabolism, and lipid catabolism. A close homologue of sbg381373-ACRP is ACRP30 protein. ACRP30 protein may be a factor that participates in the complex balanced system of energy homeostasis involving food intake, carbohydrate catabolism, and lipid catabolism. ACRP30 is structurally similar to complement factor C1q, and it forms large homo-oligomers that undergo a series of post-translational modifications (Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF; 1995; <i>J Biol Chem</i> 270:26746-9).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, obesity, and diabetes
sbg401294-MEX-3	An embodiment of the invention is the use of sbg401294-MEX-3 to develop products for diagnosis and therapy of disease states such as tumor formation, apoptosis regulation in cells to reduce or increase apoptosis and for pharmacological screening.	Hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, tumor formation, autoimmune diseases, inhibition of apoptosis
sbg247722-Cadherin	An embodiment of the invention is the use of sbg247722-Cadherin for treatment and diagnosis of bone metabolic diseases. A close homologue of sbg247722-Cadherin is cadherin, a Ca ²⁺ dependent cell adhesion protein.	Hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, autoimmune diseases, energy homeostasis disorder and bone metabolic disease
sbg391057-THIPa	An embodiment of the invention is the use of sbg391057-THIPa in controlling thyroid hormone synthesis. A close homologue of sbg391057-THIPa is <i>xenopus laevis</i> thyroid hormone-induced protein. <i>Xenopus laevis</i> thyroid hormone-induced protein has been implicated in controlling thyroid hormone synthesis in <i>Xenopus</i> tadpoles and provided insights into the biology of metamorphosis (Brown,D.D., Wang,Z., Furlow,J.D., Kanamori,A., Schwartzman, R.A., Remo,B.F. and Pinder,A. The thyroid hormone-induced tail resorption program during <i>Xenopus laevis</i> metamorphosis. <i>Proc Natl Acad Sci U S A</i> 1996 Mar 5;93(5):1924-9).	Autoimmune disorders, wound healing disorders, cancer, infection and hematopoietic disorders

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg378067-TGF β	An embodiment of the invention is the use of sbg378067-TGF β in cellular growth control in the etiology of cancer and cell differentiation and development. The sbg378067-TGF β protein contains a close approximation of the prosite consensus pattern (PDOC00223) for TGF- β family members. TGF- β proteins have been known to be involved in growth control and hence the etiology of cancer (<i>Anticancer Res</i> 1999 Nov-Dec;19(6A):4791-807), cell differentiation and development. A TGF- β signaling pathway constitutes a tumor suppressor path (<i>Cytokine Growth Factor Rev</i> 2000 Apr 1;11(1-2):159-168). A close homologue of sbg378067-TGF β is TGF- β protein.	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, preventing or treating cellular degeneration or insufficiency, e.g. neuronal degeneration resulting from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, acute brain injury, acute spinal cord injury, nervous system tumours, multiple sclerosis, or infection (viral, bacterial, fungal, parasitic), hematopoietic cell degeneration or insufficiency resulting from eosinopenia, anemias, thrombocytopenia, or stem-cell insufficiencies, cardiac muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure, peripheral nerve trauma or injury, exposure to neurotoxins, metabolic diseases such as diabetes or renal dysfunctions and damage caused by infectious agents

Table IV. Quantitative, Tissue-specific mRNA expression detected using SybrMan

Quantitative, tissue-specific, mRNA expression patterns of the genes were measured using SYBR-Green Quantitative PCR (Applied Biosystems, Foster City, CA; see Schmittgen T.D. et al., Analytical Biochemistry 285:194-204, 2000) and human cDNAs prepared from various human tissues. Gene-specific PCR primers were designed using the first nucleic acid sequence listed in the Sequence List for each gene. Results are presented as the number of copies of each specific gene's mRNA detected in 1ng mRNA pool from each tissue. Two replicate mRNA measurements were made from each tissue RNA.

Gene Name	Tissue-Specific mRNA Expression (copies per ng mRNA; avg. \pm range for 2 data points per tissue)									
	Brain	Heart	Lung	Liver	Kidney	Skeletal muscle	Intestine	Spleen/lymph	Placenta	Testis
sbg237038SA	14 \pm 1	27 \pm 1	39 \pm 1	14 \pm 0	18 \pm 1	12 \pm 0	21 \pm 3	45 \pm 2	19 \pm 3	40 \pm 9
sbg340871-GPV	0 \pm 0	200 \pm 46	363 \pm 10	-9 \pm 6	33 \pm 13	93 \pm 17	74 \pm 9	305 \pm 9	2902 \pm 114	36 \pm 4
sbg293416-HNKS	553 \pm 15	65 \pm 1	39 \pm 4	27 \pm 4	39 \pm 1	38 \pm 1	53 \pm 4	225 \pm 9	43 \pm 0	108 \pm 9
sbg257418ZP	37 \pm 3	28 \pm 6	6 \pm 0	-12 \pm 3	-4 \pm 2	19 \pm 7	15 \pm 2	5 \pm 2	10 \pm 2	605 \pm 10
sbg319185-CDa	54 \pm 5	113 \pm 3	696 \pm 140	95 \pm 37	317 \pm 31	708 \pm 30	540 \pm 64	5987 \pm 158	326 \pm 2	258 \pm 31
sbg323307-KIAAa	293 \pm 8	633 \pm 15	1269 \pm 58	15 \pm 1	136 \pm 5	26 \pm 6	1400 \pm 91	33 \pm 12	632 \pm 12	196 \pm 10
sbg315953-GPPa	232 \pm 31	16 \pm 0	54 \pm 2	1 \pm 6	14 \pm 7	4 \pm 8	15 \pm 3	99 \pm 4	61 \pm 7	126 \pm 6
sbg318486-ONC	52 \pm 7	3 \pm 2	8 \pm 0	4 \pm 0	4 \pm 2	2 \pm 1	6 \pm 2	1 \pm 7	4 \pm 1	122 \pm 9
sbg299359-LIPO	1701 \pm 95	39 \pm 0	60 \pm 14	21 \pm 1	135 \pm 13	41 \pm 3	49 \pm 2	26 \pm 7	40 \pm 5	138 \pm 2

Table IV (cont.)

Gene Name	Tissue-Specific mRNA Expression (copies per ng mRNA; avg. \pm range for 2 data points per tissue)									
	Brain	Heart	Lung	Liver	Kidney	Skeletal muscle	Intestine	Spleen /lymph	Placenta	Testis
sbg230022-NGa	3443 \pm 112	684 \pm 2	386 \pm 7	712 \pm 16	1956 \pm 63	36 \pm 0	588 \pm 7	1293 \pm 17	43 \pm 7	358 \pm 2
sbg297169-BGP	417 \pm 29	141 \pm 8	236 \pm 5	170 \pm 11	322 \pm 0	74 \pm 4	231 \pm 1	370 \pm 0	223 \pm 3	968 \pm 32
sbg253919-HSCCAa	-5 \pm 1	1 \pm 1	2 \pm 1	-14 \pm 2	-10 \pm 0	-4 \pm 3	0 \pm 1	6 \pm 1	4 \pm 3	119 \pm 9
sbg228137-OLF	5174 \pm 138	58 \pm 4	99 \pm 5	9 \pm 3	63 \pm 7	167 \pm 12	98 \pm 0	719 \pm 9	32 \pm 8	67 \pm 4
sbg253227. mucous matrix glycoprotein	5 \pm 0	11 \pm 1	21 \pm 1	0 \pm 1	28 \pm 2	1 \pm 0	13 \pm 2	24 \pm 3	26 \pm 4	118 \pm 1
sbg262831-SIAa	9 \pm 1	6 \pm 1	59 \pm 1	59 \pm 1	5 \pm 0	-4 \pm 2	134 \pm 6	2657 \pm 97	45 \pm 4	25 \pm 0
sbg233728-LIPASE	2 \pm 1	6 \pm 1	4 \pm 2	6 \pm 2	1 \pm 0	4 \pm 0	1 \pm 3	1 \pm 2	3 \pm 2	28 \pm 3
sbg400455-CRF	8735 \pm 257	345 \pm 14	434 \pm 54	191 \pm 14	4038 \pm 147	705 \pm 32	379 \pm 1	847 \pm 59	434 \pm 8	97 \pm 8
sbg400612-KINASEa	10 \pm 0	24 \pm 4	276 \pm 87	145 \pm 2	431 \pm 10	7 \pm 0	59 \pm 5	23 \pm 4	82 \pm 9	34 \pm 3
sbg381373-ACRP	112 \pm 40	11 \pm 3	15 \pm 5	14 \pm 5	10 \pm 2	11 \pm 8	14 \pm 4	-3 \pm 8	6 \pm 2	11 \pm 8
sbg401294-MEX-3	49 \pm 8	39 \pm 2	122 \pm 1	35 \pm 9	151 \pm 8	6 \pm 5	16 \pm 1	15 \pm 3	71 \pm 8	683 \pm 56
sbg247722-Cadherin	2626 \pm 18	1140 \pm 22	1733 \pm 62	78 \pm 4	2007 \pm 12	213 \pm 52	1175 \pm 47	1701 \pm 167	3487 \pm 263	1814 \pm 30
sbg391057-THIPa	332 \pm 3	3010 \pm 30	8567 \pm 84	136 \pm 1	1013 \pm 90	1499 \pm 172	2469 \pm 86	3512 \pm 23	1393 \pm 32	2408 \pm 174
sbg378067-TGFc	33 \pm 8	58 \pm 6	52 \pm 4	3 \pm 1	48 \pm 1	49 \pm 22	21 \pm 4	116 \pm 28	74 \pm 24	59 \pm 4

Table V. Additional diseases based on mRNA expression in specific tissues

Tissue Expression	Additional Diseases
Brain	Neurological and psychiatric diseases, including Alzheimers, parasupranuclear palsey, Huntington's disease, myotonic dystrophy, anorexia, depression, schizophrenia, headache, amnesias, anxiety disorders, sleep disorders, multiple sclerosis
Heart	Cardiovascular diseases, including congestive heart failure, dilated cardiomyopathy, cardiac arrhythmias, Hodgson's Disease, myocardial infarction, cardiac arrhythmias
Lung	Respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, cystic fibrosis, acute bronchitis, adult respiratory distress syndrome
Liver	Dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cirrhosis, hepatic encephalopathy, fatty hepatocirrhosis, viral and nonviral hepatitis, Type II Diabetes Mellitis, impaired glucose tolerance
Kidney	Renal diseases, including acute and chronic renal failure, acute tubular necrosis, cystinuria, Fanconi's Syndrome, glomerulonephritis, renal cell carcinoma, renovascular hypertension
Skeletal muscle	Eulenburg's Disease, hypoglycemia, obesity, tendinitis, periodic paralyses, malignant hyperthermia, paramyotonia congenita, myotonia congenita
Intestine	Gastrointestinal diseases, including Myotonia congenita, Ileus, Intestinal Obstruction, Tropical Sprue, Pseudomembranous Enterocolitis
Spleen/lymph	Lymphangiectasia, hypersplenism, angiomas, ankylosing spondylitis, Hodgkin's Disease, macroglobulinemia, malignant lymphomas, rheumatoid arthritis
Placenta	Choriocarcinoma, hydatidiform mole, placenta previa
Testis	Testicular cancer, male reproductive diseases, including low testosterone and male infertility
Pancreas	Diabetic ketoacidosis, Type 1 & 2 diabetes, obesity, impaired glucose tolerance

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
 - (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in Table I;
 - (b) an isolated polypeptide comprising a polypeptide sequence set forth in Table I; and
 - (c) a polypeptide sequence of a gene set forth in Table I.
2. An isolated polynucleotide selected from the group consisting of:
 - (a) an isolated polynucleotide comprising a polynucleotide sequence set forth in Table I;
 - (b) an isolated polynucleotide of a gene set forth in Table I;
 - (c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in Table I;
 - (d) an isolated polynucleotide encoding a polypeptide set forth in Table I;
 - (e) a polynucleotide which is an RNA equivalent of the polynucleotide of (a) to (d); or a polynucleotide sequence complementary to said isolated polynucleotide.
3. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.
4. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a cell such that the host cell, under appropriate culture conditions, produces said polypeptide.
5. A recombinant host cell produced by the process of claim 4.
6. A membrane of a recombinant host cell of claim 5 expressing said polypeptide.
7. A process for producing a polypeptide which comprises culturing a host cell of claim 5 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

SEQUENCE LISTING

<110> SMITHKLINE BEECHAM CORPORATION
SMITHKLINE BEECHAM p.l.c.

<120> NOVEL COMPOUNDS

<130> GP50025

<140> TO BE ASSIGNED
<141> 2001-04-26

<150> 60/199,963
<151> 2000-04-27

<150> 60/203,336
<151> 2000-05-11

<150> 60/207,087
<151> 2000-05-25

<150> 60/207,546
<151> 2000-05-26

<160> 78

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 831

<212> DNA
<213> Homo sapiens

<400> 1

atgcgtggcc ttgttatggc tccctgctc attctcctgg ttggtggac tgaagcctt	60
cgtatctgtc cttcaatgc ccacagactg acactggccaa agctaaccaa ggagtcagt	120
atggataccct tagttcagat cctagcccgaa tgtgatatca tggtgcttca ggaggttagta	180
gattcttccc agaatactgt cccctttctg cttcaaaaac ttaaaaagtcc caggagttac	240
agttcctaa acagctcatt gctggggcgc agcacataca aggaaaagta tgtgtatatc	300
tacaggctcg acaagacaca ggtcctaaat ttctaccaat acaacgacac agatgtatatt	360
tttgcggcgg aaccatttgt ggcccatttc actctcccta gcaaaaactct tccaagtgt	420
gtgctggttc ctctccacac cactccaaag gatgttgaga aggagctgaa tgccctctat	480
gatgtgtttc tggatgtcta ccagcgctgg cagaatgaga atgtgattct gcttggagac	540
ttcaatgcag actgtgcattc gctgacaaaaaa aaacgtctga aaagcctgct actccggact	600
aaggcaggct tccactgggt gattcctgat ggggaggata ctacagtgcg ggccagtact	660
aactgtacct atgaccgaat tttgtgtcat ggacagggtc gccaaatgtc gctgaaggct	720
gcagctacct ttgactttcc caagaggttt cagctgactg aggaagaggc tctccgcattc	780
agtgaccatt atccctgtttaga agtgaaactg agccaggcca ctccactgag t	831

<210> 2

<211> 1443

<212> DNA

<213> Homo sapiens

<400> 2

atgctaggcc gatttcaacc ctctccttg gtccggagtt tcagactggg atttggagcc	60
tgctgctatc caaacaaaaa atgtgctact cagaccatca gacccctga ctccagggtc	120
ctagtccaaag cagtttctca gaacttaat tttgcaaaagg atgtgttggatcagttggcc	180

cagctggaaa	aggacggact	cagagggcct	tacccgc	tctggaaagg	tagtgc	240
ggagaagagg	acaaatggag	cttggaaagg	atgactcaac	tctccaagaa	ggccgc	300
atccctctca	acaccgtgc	ccttagccat	ggagaccgc	tgatgataat	cttgc	360
acacctgaag	cctactggat	ctgcctggc	tgtgtgc	tggaaatcac	cttgc	420
gggagccccc	agctgactgc	caagaaaatt	cgctatcaat	tacgc	taaggccc	480
tgcattgtgg	ctaattgaagc	tatggcc	gttgtaaact	ctgcgtgc	cgactg	540
acctgaaa	ccaagctcct	ggtgtcagat	aagagctatg	atgggtgg	ggatttcaag	600
aagtgtatc	aagttgccc	tccaaagcag	acctacatga	ggaccaaaag	ccaagatcca	660
atggccat	tcttcaccaa	gggtacaaca	ggagctccc	aatggtc	gtattccc	720
tatggtttgg	gaatgggatt	cagccaggct	tccagacgg	gatggatct	ccagccaa	780
gatgtcttgc	ggagtc	tgtgc	gttggatctt	tatccctgag	cgctgtctt	840
ggaacttgg	tccaggagc	ctgtgtgtt	ctgtgtcaca	tgccaac	ctgc	900
actgttctaa	atgtc	ctgtgtc	ctgtgtcaca	tccagagatg	960	
taccaggaa	tgcttc	caagtgtt	accagctaca	gattcaagag	tctgaagc	1020
tgtgtggct	caggaggacc	catcagcc	gggggtgattt	aggactggaa	acgc	1080
aagtggaca	tctatgaagg	ctatggc	acggaaactg	gtctactct	tgccactt	1140
aaaacaataa	aattgaagcc	aagctct	gggaagccat	tgccac	tattgtcc	1200
attgtggatg	aaaactcaaa	tctc	ccagggaaag	aaggaaat	tgcaatcc	1260
ataaaaactaa	accaac	ttct	tgtcc	tggtagct	ggaggaat	1320
gcttc	gcaaa	ttt	tgcc	tttac	acaggtgaca	1380
ggctacttct	ggtgtctgg	tagagtt	gatgttgc	atgcatt	ggatgaagac	1440
tga						1443

<210> 3

<211> 1752

<212> DNA

<213> Homo sapiens

<400> 3

atgctaggcc	gatttcaacc	cttcc	gtccggagtt	tcagactgg	at	ttggagcc	60
tgc	tatc	caa	acaaa	atgt	ctact	cagaccatca	120
ctag	tcaag	cag	tttctca	gaactt	ttt	ttgcaaa	180
cag	ctggaaa	agg	acggact	cag	agg	ccccccc	240
ggaga	aggagg	acaaatgg	cttggaaagg	atgact	caac	tctccaagaa	300
atcc	ctc	acac	ctgtgc	ccttagcc	ggagac	ggcc	360
acac	ctgaa	cct	actggat	ctgc	ccat	tgatgataat	420
gggag	ccccc	agc	tgtactgc	caagaaaatt	cgctat	ta	480
tgcatt	gtgg	cta	atg	tttca	ttt	ggatccc	540
ac	ttgaaa	cca	ggc	tttca	ttt	ctgcgtgc	600
aagt	ttgttgc	gggt	tcag	tttca	ttt	cgactg	660
atggccat	at	tttca	tttca	tttca	ttt	ccat	720
tatggtttgg	gaat	gggatt	cagccagg	tcc	ttt	tttca	780
gatgtcttgc	ggagt	ctgg	tgt	tttca	ttt	ccat	840
ggaacttgg	tcc	aggagc	ctgtgtgtt	ctgtgtcaca	tttca	tttca	900
actgttctaa	atgt	ctgtgc	caagtgtt	acc	tttca	tttca	960
taccaggaa	tgctt	cagca	caagtgtt	acc	tttca	tttca	1020
tgtgtggct	caggaggacc	catcagcc	gggggtgattt	aggactggaa	acgc	tttca	1080
aagtggaca	tctat	gaagg	ctatggc	acggaaactg	gtctactct	tttca	1140
aaaacaataa	aatt	gaagcc	aagctct	gggaagccat	tgccac	tttca	1200
attgtggatg	aaaactcaaa	tctc	ccagg	tttca	tttca	tttca	1260
ataaaaactaa	accaac	ttct	tttca	tttca	tttca	tttca	1320
gcttc	gcaaa	ttt	tgcc	tttac	acaggtgaca	tttca	1380
ggctacttct	ggtgtctgg	tagagtt	gatgttgc	atgcatt	ggatgaagac	tttca	1440
tctcgcccc	gggcggccgc	ggcggca	gtgg	tttgc	tttgc	tttca	1500
tcattatgt	cctctgt	catt	gtgg	tttgc	tttgc	tttca	1560
cattcctgt	ccc	atgac	gggc	tttgc	tttgc	tttca	1620
gtgacaggcc	catg	caagta	ccaa	tttgc	tttgc	tttca	1680
gtcactggca	agat	aaac	gg	tttgc	tttgc	tttca	1740
agaaatgact	ga						1752

<210> 4
 <211> 1746
 <212> DNA
 <213> Homo sapiens

<400> 4

atgccactga agcattatct cctttgtcgt gtgggctgcc aagcctgggg tgcagggttg 60
 gcctaccatg gctgccctag cgagtgtacc tgctccaggg cctcccaaggt ggagtgcacc 120
 ggggcacgca ttgtggcggt gcccacccct ctgcctggaa acgccatgag cctgcagatc 180
 ctcacacgc acatcaactga actcaatgag tccccgttcc tcaatatttc agccctcatc 240
 gcccgtgagga ttgagaagaa tgagctgtcg cgcatcacgc ctggggcctt ccgaaacctg 300
 ggctcgctgc gctatctcag cctcgccaaac aacaagctgc aggttctgcc catggccctc 360
 ttccaggggcc ttggacagcct tgagtctc cttctgtcca gtaaccagct gttgcagatc 420
 cagccggccc acttctccca gtgcagcaac ctcaaggagc tgcagttgca cggcaaccac 480
 ctggaataca tccctgacgg agcccttcgcac cacctggtag gactcacgaa gctcaatctg 540
 ggcaagaata gcctcaccca catctcaccac agggcttcc agcacctggg caatctccag 600
 gtcctccggc tttatgagaa caggctcaagc gatattccca tgggactt tttatgggctt 660
 gttaaacctgc aggaactggc tctacagcag aaccagatg gactgctctc ccctggctc 720
 ttccacaaca accacaacct ccagagactc tacctgttcca acaaccacat ctcccagctg 780
 ccaccaggca tcttcatgca gtcggggcag ctcaaccgtc ttactcttcc ttggaaattcc 840
 ctgaaggagc tctctctggg gatcttcggg cccatgccc acctgcggga gctttggctc 900
 tatgacaacc acatctctc tctacccggc aatgttccca gcaaccctccg ccagttgcag 960
 gtcctgattc tttagccgcaa tcagatcagc ttcatctccc cgggtgcctt caacgggcta 1020
 acggagcttc gggagctgc ctcacacc aacgcactgc aggacctggg cgggaatgtc 1080
 ttcccatgt tggccaaacct gcagaacatc tccctgaga acaatcgctt cagacagctc 1140
 ccaggaaata tcttcgccaa cgtcaatggc ctcatggca tccagctgca gaacaaaccag 1200
 ctggagaact tggccctcg catcttcgtt cacctgggg aactgtgtga gtcgggctg 1260
 tatgacaacc cttggagggt tgacttcagac atccttccgc tccgcaactg gtcctgctc 1320
 aaccaggcta ggttagggac ggacactgtc cttgtgtgtt tcagccccagc caatgtccga 1380
 ggccagttcc tcattatcat caatgtcaac gttgtgttc caagcgttca ttttacctgag 1440
 gtgccttagtt acccagaaaac accatggtac ccagacacac ccagttaccc tgacaccaca 1500
 tccgtcttcc ttaaccactga gctaaccaggc cttgtggaaactacactga tctgactacc 1560
 attcaaggta ctgtatgaccg cagcttggg ggcattgaccat gcccatacg cgggctggcc 1620
 attggccca ttgttaattgg cattgtcgcc ctggcctgtt ccctggctgc ctgcgtcgcc 1680
 ttttgcgtt gcaagaagag gagccaagct gtcctgtatgc agatgaaggc acccaatgag 1740
 tgtaaa 1746

<210> 5
 <211> 1887
 <212> DNA
 <213> Homo sapiens

<400> 5

atgccccgggtc ctccagactg gagccttaat tcctccagaa atgcacgcag cctggagggg 60
 ctgcctctgt gtccgtgggt ggctctcttc gtcccgagag cagctgcgt gttggactt 120
 caaagggaaacggc agggaaaacag ctcagatatac ttcttttagt ctcccttcac ggtgacccca 180
 gaccccctac caacagccat tacatggag cacattccgt ttgcaaaagct ggcgggtcta 240
 attgcaggggc ttggggatgtc gatgtgcagg cagaggctaa gcaaaaggtt tgaggcctt 300
 aaaggggaaat tcaggggactt cgggactgt cttccaggag cccagcgggg gaaacagaatc 360
 actaaacggaa acaagtgcgg tcagagccgt caggcgctca tcggccagag acaggaagat 420
 gcaggctccg ctccctctgca gatgcacccca agtgcgtctg cgctggggc aggagctgcg 480
 ctgcgggaga ttcaaggccct gcaaaaggaa ccagagctgtt catcaggccc caggaacagc 540
 cggctccctgt gctggggcag ccctgcccacc tggaaacccca cgtacccgtc ccgtgtccta 600
 gggcaggcagg tggccctgtac ttttgcgtt gctgggtctcc aggctgtgcc ctggggaccc 660
 agcagagaat ttaatgcccggc gggctctagc tcagcgagca tttagatggg acagccccag 720
 aagcttaggc tcagactca gagggtccagg agacagtgtc cccctgtcca gtcctcacag 780
 gaccccccac caggcgccgtc ccaggatggt gacttgaagg aaccacaga gagggtcact 840
 cgggacttat ccagtggggc cccgaggggc cgcaaccctgc cagcgcctga ccagcctcaa 900

ccccccgtgc	agaggggaac	ccgtctgcgg	ctccgcacg	gccgtcgccg	tctgtctatc	960
aagaaaatgc	cagctgcgc	gaccatccc	gccaacagct	cggacgcgccc	cttcatccgg	1020
ccgggaccgg	ggacgctgga	tggccgtgg	gtcagcctgc	accggagcc	gcaggagcgc	1080
aagcggtga	tgcaggaggc	ctgcgccaag	taccggcga	gcagcagccg	ccgggcccgtc	1140
acgccccgccc	acgtgtcccg	tatcttcgtg	gaggaccgccc	accgcgtgt	ctactgcgag	1200
gtgcccagg	ccggctgctc	caatttggaaag	cgggtgtca	ttgtgtctggc	ccggctggcc	1260
tcgtccactg	ccgacatcca	gcacaacacc	gtccactatg	gcagcgtct	caaggcctg	1320
gacaccttcg	accggccaggg	tatcttgcac	cgtctcagca	cctacaccaa	gatgtcttt	1380
gtccgcgagc	ccttcgagag	gctgggtgtcc	gccttcccg	acaagttga	gcaccccaac	1440
agctactatc	accgggtctt	cggcaaggcc	atccctggccc	gttaccgcgc	caatgcctct	1500
cggggaggccc	tgcggaccgg	ctctggggtg	cgttttcccg	agttcgtcca	gtacctgtcg	1560
gacgtgcacc	ggcccggtgg	gatggacatt	cactgggacc	atgtcagccg	gctctgcagc	1620
ccctgcctca	tcgactacga	tttcgttagc	aagttcgaga	gcatggagga	cgatgccaac	1680
ttcttcctga	gcctctatccg	cgcgcgcgg	aacctgac	tcccccggtt	caaggaccgg	1740
cactcgcagg	aggcgccggac	cacagcgg	atcgcacc	agtacttcgc	ccaaactctcg	1800
gcccgtcaaa	ggcagcgcac	tttgcagatct	tactacatgg	attacctgtat	gttcaactat	1860
tccaaaggccct	tttgcagatct	gtactga				1887

<210> 6

<211> 1275

<212> DNA

<213> *Homo sapiens*

<400> 6

atgacccttcgc	gacctggAAC	aatgcggCTG	gcctgcATGt	tctcttccat	cctgtgttC	60
ggagctgcag	gcctccTcCt	cttcatacAGC	ctgcaggacc	ctacggagCT	cgccccccAG	120
cagggtccAG	gaataaaAGTt	caacatcagg	ccaaGGcAGC	cccaccacGA	cctcccaCca	180
ggcggctccc	aggatggtGA	cttgaaggAA	cccacAGAGA	gggtcactCG	ggacttatCC	240
agtggggccc	cgagggggCCG	caacctgCCA	gcgcctgACC	agcctcaACC	cccgctgcAG	300
aggggaacCC	gtctgcggGT	ccgcccAGcGc	cgtcggcGTC	tgctcatCAA	gaaaatgcCA	360
gctgcggcGA	ccatccccGGc	caacagCTCG	gacgcGCCt	tcatccggCC	gggaccGGG	420
acgctggatG	gcccgtgggt	cagcctgcAC	cgagGCCAGC	aggagcGAA	gcccgtgtAG	480
caggaggcCT	gcgccaAGTA	ccgggcgAGC	agcagCCGcC	gggcccgtAC	gccccGCCAC	540
gtgtccccGTA	tctcgtggA	ggaccgcAC	cgcgtgtCT	actgcgAGGT	gcccaaggCC	600
ggctgctCCA	attggaaAGCG	ggtgctcatG	gtgctggCCG	gcctggcCTC	gtccactgCC	660
gacatccAGC	acaacaccGT	ccactatGGC	agcgctCTCA	agcgccttGA	cacccTcgAC	720
cgccaggGTA	tcttcacCG	tctcagcACC	tacaccaAGA	tgctcttGT	ccgcgagCC	780
ttcgagaggc	tgggtccGc	cttccgcGAC	aaggTTGAGC	accccaacAG	ctactatCac	840
ccggtcttcG	gcaaggCCAT	cctggccCGG	taccgcGCCA	atgcctctCG	ggaggcccTG	900
cgaccgcGCT	ctggggTcGc	ttttccccGAG	ttcgTCCAGT	acctgcgtGA	cgtgcaccGG	960
cccgTggGGA	tggacattCA	ctgggaccAT	gtcagCCGc	tctgcagcccc	ctgcctcatC	1020
gactacgatt	tcgtaggcAA	gttcgagAGC	atggaggACG	atgccaactT	cttcctgAGC	1080
ctcatccGCG	cgccgcggAA	cctgacCTTC	ccccggTTCA	aggaccGGCA	ctcgaggAG	1140
gcgccggacCA	cagcgaggAT	cgcccaccAG	tacttcGCC	aactctcgC	cctgcaaagg	1200
cagcgcacCT	acgacttcta	ctacatggat	tacctgtatGT	tcaactattC	caagccCTT	1260
gcagatctgt	actgA					1275

<210> 7

<211> 1917

<212> DNA

<213> *Homo sapiens*

<400> 7

atggcaggag	gctcagccac	gacctgggg	taccctgtgg	ccctgctact	gctgggtgcc	60
accctggggc	tgggttagtg	gctccagccc	gaccctggcc	tcccaggcct	ccggcacacgc	120
taclactgtg	ggatcaaggg	aatgcagctg	ctgggtttcc	ccaggccagg	ccagactctc	180
cgttcaagg	tgggtggatga	atttgggaac	cgatttgatg	tcaacaactg	ctccatctgc	240
taccactggg	tcacctccag	gccgcaggag	cctgcagtct	tctcggccga	ttacagaggc	300
tgccacgtgc	tggagaagga	tgggcgttcc	cacctgaggg	tgttcatgg	ggctgtgctg	360

ccaaatggtc	gtgtggatgt	ggcacaagac	gctactctga	tctgtccaa	acctgacccc	420
tcccgactc	tggactccca	gctggcacca	cccgcctgt	tctctgtctc	aaccccacaa	480
acccttcct	tcctccccac	ctctggccat	acctcccaag	gctctggcca	tgcctttccc	540
agcccactgg	acccaggggca	cagctctgtc	cacccaaccc	ctgctttacc	atccccttgg	600
cctggaccta	ccctcgccac	cctggctcaa	ccccacttgg	gcaccttgg	acactggat	660
gtgaacaaaac	gagattacat	aggtacccac	ctgagccagg	agcagtgc	ggtggcctca	720
gggcacctcc	cctgcacatcg	gagaagaact	tcaaaaagaag	cctgtcagca	ggctggctgc	780
tgctatgaca	acaccagaga	ggtccctgt	tactatggca	acacagctac	tgtccagatgc	840
ttcagagatg	gctacttcgt	cctctgtgt	tcccaagaaa	tggcttgac	acacaggatc	900
acactggcca	acatccacct	ggcttatgcc	cccaccagct	gctcccaac	acagcacacg	960
gaagctttcg	tggcttcta	cttccctctc	acccactgtg	gaaccacaat	gcaggtggct	1020
ggcgaccagc	tcatctatga	gaactggctg	gtgtctggca	tccacatcca	aaagggggcca	1080
cagggttcca	tcacgcggga	cagcaccttc	cagttcatg	tgcgtgtgt	tttcaacgcc	1140
agtacttcc	tgccttattca	ggcatccatt	ttcccacccc	catgcctgc	tcctatgacc	1200
cagcccgccc	ccctgcggct	tgagctgcgg	attgccaag	acgagacctt	cagctcgatc	1260
tatggggagg	atgactatcc	catctgtgagg	ctgctccgag	aaccagtcca	tgtggaggatc	1320
cggcttctgc	agaggacaga	ccccaaaccc	gtctctgtc	tgcaccagg	ctggggcgct	1380
cccagtgc	accccttcca	gcagccccag	tggcccatcc	tgtcagacgg	atgccccttc	1440
aaggcgaca	gctacagaac	ccaaatggta	gccttggacg	ggccacacc	tttccagtcg	1500
cactaccagc	gatttactgt	tgccttcc	gccttccctgg	actcaggctc	ccagagagcc	1560
ctcagaggac	tggtttactt	gttctgcagc	acctctgtc	gccacaccc	agggctggag	1620
acttgc	ctgcatgttag	cactggcact	acaagacacg	gacgatcc	aggtcaccgt	1680
aatgacactg	ccaggcccc	ggacatcg	agctctccgg	ggccagtgg	ctttaggat	1740
tcttatgggc	aggagccac	acttggccc	acagactcca	atggaaactc	cagcctgaga	1800
cctctcc	ggcggtcct	tttgcgtc	gctgttgc	tggcccttgg	tttgggtgc	1860
tttggggcc	tgagccagac	ctggggcc	aagctctgg	aaagcaacag	acagtga	1917

<210> 8

<211> 687

<212> DNA

<213> Homo sapiens

<400> 8

atgaaaacctc	ttgctcagct	tccctcttt	ctcctccagt	ttcagaaagg	aatcttagt	60
tcacaaagca	gctcaacccc	attgtatgg	aatgggg	tggggagtc	agtaactt	120
cccctggagt	ttcctgcagg	agagaggatc	cagttcatca	cttggctt	aatggaaaca	180
tctttgcct	tcctagaacc	ctatgaaggc	aaaagtccaa	aaatctacgt	gactcatcc	240
aatggcaaa	agcgactgag	cttcacccag	tcctactccc	cgcagctc	caacctggag	300
atgaaaaca	taggcttta	cagtgc	atagccacag	agac	ctgc	360
atgtacactc	tgaggatatt	caagcag	ccaaggcc	aagttagat	ggattctatc	420
atctctgaaa	atgggatctg	taatgc	ttgaggtt	ctgtggagga	aggaggag	480
accatcacat	atgatgtggac	atcaatgg	ccagggctg	ctgtgtcc	cgtggcc	540
catgacctgg	attggatcta	cactgc	gctctga	ctgttag	cagcaact	600
actttaacc	ttgctgcaca	gcttgc	agtaagag	cccttctgg	ctctctag	660
ccccctggaa	atgtttgtc	tgg				687

<210> 9

<211> 933

<212> DNA

<213> Homo sapiens

<400> 9

atgaaaacctc	ttgctcagct	tccctcttt	ctcctccagt	ttcagaaagg	aatcttagt	60
tcacaaagca	gctcaacccc	attgtatgg	aatgggg	tggggagtc	agtaactt	120
cccctggagt	ttcctgcagg	agagaggatc	cagttcatca	cttggctt	aatggaaaca	180
tctttgcct	tcctagaacc	ctatgaaggc	aaaagtccaa	aaatctacgt	gactcatcc	240
aatggcaaa	agcgactgag	cttcacccag	tcctactccc	cgcagctc	caacctggag	300
atgaaaaca	taggcttta	cagtgc	atagccacag	agac	ctgc	360
atgtacactc	tgaggatatt	caagcag	ccaaggcc	aagttagat	ggattctatc	420

atctctgaaa	atgggatctg	taatgcac	ttgagggttt	ctgtggagga	aggaggagag	480
accatcacat	atgagtggac	atcaatggga	ccaggggctg	ctgtgtccca	cgtgggcctt	540
catgacctgg	attggatcta	cacttgac	gctctgaatc	ctgttagcta	cagcaactct	600
actcttaccc	ttgctgcaca	gotttgc	agtctcaagg	cagctgaagg	cacctattgc	660
ccagtgaaat	ggatttcct	ggggaaacagg	cttcttctcc	ttgtgttct	tgggtgccta	720
cgaacttggc	atattcaggc	acaggtgctc	agcaaaccct	tgaggcctaa	ctcaggggaa	780
cttgcataat	tttcctcaat	ccataccct	tgggaaccat	ctcacacagc	tgatgccact	840
tggcttggga	agtgggggtgg	aagtgggggg	gagagaaaaga	gcacgtggaa	tataaggcacc	900
acaaaaagac	actggaaaag	cttctataaa	taa			933

<210> 10
<211> 2526
<212> DNA
<213> *Homo sapiens*

<400> 10

atgaagctgt	ggattcatct	cttttattca	tcttccttg	cctgtatata	tttacactcc	60
caaactccag	tgcctctcatc	cagaggctct	tgtgattctc	tttgcatttg	tgaggaaaaaa	120
gatggcacaa	tgctaataaa	ttgtgaagca	aaaggatata	agatggatc	tgaataatagt	180
gtgccaccat	cacgacctt	ccaactaaggc	ttattaaata	acggcttgac	gatgcttcac	240
acaaatgact	tttctggct	taccaatgt	atttcaatac	accttggatt	taacaatatt	300
gcagatattg	agatagggtc	atttaatggc	cttgcctcc	tgaaacaact	tcatatcaat	360
cacaattctt	tagaaatct	taaagaggat	acttccatg	gactggaaaa	cctggaattc	420
ctgcaagcag	ataacaat	tatcacagt	attgaacca	gtgcctttag	caagctcaac	480
agactcaaag	tgttaat	aatgacaat	gctattgaga	gtcttcctcc	aaacatcttc	540
cgatttgc	cttaaccca	tctagatctt	cgtggaaatc	aattacaaac	attgccttat	600
gttggtttc	tcgaacacat	tggccgaata	ttgatctc	agttggagga	caacaaatgg	660
gcctgcaatt	gtgactt	gcagttaaaa	acttggttgg	agaacatgc	tccacagtc	720
ataattgg	atgttgc	caacagccct	ccattttta	aaggaagtat	actcagtaga	780
ctaaagaagg	aatctat	ccctactcca	ccagtgtatg	aagaacatga	ggatcctca	840
ggatcattac	atctggc	aacatctca	ataaattgata	gtcgcatgc	aactaagacc	900
acgtccattc	aaaactacc	caccaaa	ccagg	taccc	tata	960
tccactcaac	ttccaggacc	ttactgc	ccct	ttat	tacaa	1020
tcaggactc	taatacattt	tcaggagc	ccat	ttat	tttt	1080
cctccgc	aaaat	gctcatt	ttat	ttat	tttt	1140
tctgatotag	tggaaat	cactt	ttat	ttat	tttt	1200
gttcttgaag	aaggatcg	tatgaa	ttat	ttat	tttt	1260
aaccacctga	ccaaat	acgagat	ttat	ttat	tttt	1320
tatcttgaat	acaatgc	taaggaa	ttat	ttat	tttt	1380
cttaaaagtcc	tgtat	taacaac	ttat	ttat	tttt	1440
ggggttcc	taacta	ttat	ttat	ttat	tttt	1500
aatatttgg	atgat	tttacta	ttat	ttat	tttt	1560
tgctcctgt	acctgg	actgc	ttat	ttat	tttt	1620
acagatgaca	tcctctgc	tttcccc	catct	ttat	tttt	1680
aatagt	ttctctgt	agg	ttat	ttat	tttt	1740
taccttatgg	tcaccact	ttat	ttat	ttat	tttt	1800
cttacggac	ctgt	ttat	ttat	ttat	tttt	1860
attgtt	gtgt	ttat	ttat	ttat	tttt	1920
aagaaaacaag	tagat	ttat	ttat	ttat	tttt	1980
tatggccata	aaacc	ttat	ttat	ttat	tttt	2040
cacatggta	gccccat	ttat	ttat	ttat	tttt	2100
gaagaggaag	aagagagg	ttat	ttat	ttat	tttt	2160
cttttgg	aggaaat	ttcacc	ttat	ttat	tttt	2220
aaccaatcaa	cagaat	ttat	ttat	ttat	tttt	2280
aaaaaaagaaa	gggaactt	ttat	ttat	ttat	tttt	2340
cagctcc	ctgat	ttat	ttat	ttat	tttt	2400
gaaacattaa	tgtact	ttat	ttat	ttat	tttt	2460
tttgaactt	aagcta	ttat	ttat	ttat	tttt	2520
acatag						2526

<210> 11
 <211> 726
 <212> DNA
 <213> Homo sapiens

<400> 11

atgggaaacc	ctggcctggc	ctggctggtg	ctgctggct	tggtgcgtct	tctgagctct	60
ttcatggaga	gaggaggcca	cagtcccagc	cctgctgcc	tgtcgccat	ggaaaaccta	120
atcacctatg	ctgtccagaa	gggccacctg	tcatccagtt	atgttcagcc	acttcttgc	180
aaaggcgaga	actgcctggc	ccctcgccag	aagacaagcc	tgaagaaggc	ttgccccggc	240
gttgccttac	ggtctgtgt	gggagccagg	gagacccact	gtcccgaggat	gactctccca	300
gcgaagtatg	gcatcattat	ccacactgcc	gggaggacct	gcaacatttc	tgatgagtg	360
cgccctgtgg	tccgggacat	ccagtcttc	tacatagaca	ggctcaagtc	atgcgacatt	420
gttataact	tcctggtggg	ccaggatggc	gccatttatg	aagggtggg	ctggaatgtc	480
caaggctct	ccaccctgg	ctacgatgac	attgcccgg	gcattacctt	catgggcacc	540
ttcacaggt	taccacccaa	tgctgcagca	ctagaggcag	cccaagacct	gatccagttgt	600
gcccattgt	aagggtacct	gactccaaac	tacctgctgg	tggccacag	tgatgtggcc	660
cgaacattgt	ctcctggca	ggcttgtac	aacatcatca	gcacctggcc	tcatttcaaa	720
cactga						726

<210> 12
 <211> 1110
 <212> DNA
 <213> Homo sapiens

<400> 12

atgctgccgt	ggcttcttgt	cttctctgct	ctgggtctcc	aggcctgggg	tgattcctcc	60
tggAACAAAA	cacaagctaa	acaggtatca	gaggggcctcc	agtacctatt	tgagaacatc	120
tcccaagctca	ctgaaaaaaga	tgtctccacc	acggctcttc	gcaaggcatg	gggggcagaa	180
gctgtggct	gcagttatca	gctgaccacg	ccagtgaaatg	tcctgttat	acaccatgtc	240
cctggactgg	agtgtcacga	ccggacagtc	tgcagccaga	gactgcggga	actgcaggcc	300
catcatgtcc	acaacaacag	tgggtgtat	gtggcctaca	acttcttgg	tggggatgat	360
ggcagggtgt	atgaagggtgt	tggctgaaat	atccaaggag	tgcacaccca	aggctacaac	420
aacatctccc	tgggcttgc	cttcttcggc	actaagaaag	gccacagtcc	cagccctgct	480
gccctgtcg	ccatggaaaa	cctaattcacc	tatgctgtcc	agaagggcca	cctgtcatcc	540
agttatgttc	agccacttct	tgtgaaaggc	gagaactgcc	tggccctcg	gcagaagaca	600
agcctgaaga	aggcttgc	cgccgttgc	ccacggctcg	tgtggggagc	cagggagacc	660
cactgtccca	ggatgactct	cccacgcaag	tatggcatca	ttatccacac	tgccgggagg	720
acctgcaaca	tttctgtatga	gtggccctg	ctggccgggg	acatccagtc	tttctacata	780
gacaggctca	agtcatgca	cattggttat	aacttctgg	tggccagga	tggccatt	840
tatgaagggg	tgggctggaa	tgtccaaggc	tcctccaccc	ctggctacga	tgacattgcc	900
ctgggcatta	ccttcatgg	cacccatcaca	ggtataccac	ccaatgctgc	agcaactagag	960
gcagcccaag	acctgatcca	gtgtgccatg	gtcaaaagggt	acctgactcc	caactacatg	1020
ctggtgggcc	acagtgtatgt	ggcccgaaacc	ttgtctctgg	ggcaggcttt	gtacaacatc	1080
atcagcacct	ggcctcattt	caaactactga				1110

<210> 13
 <211> 1149
 <212> DNA
 <213> Homo sapiens

<400> 13

atggccccgc	gcgcgggaca	gccggggctc	caggggctgc	tgctcggtgc	ggcggcgctg	60
agccagcccc	cggcacccctg	ccccctccag	tgctactgt	tcggcgcccc	caagctgtcg	120
ctgcgtcg	cgtcgggagc	cggactccgc	cagecctccgc	gggacgtgcc	gccccacgcg	180
cgcaacctca	ccatcgtagg	cgccaaacctg	acggtgctgc	gcccggccgc	cttcggccggc	240
ggggacgggg	acggcgacca	ggccgggggc	tgccgcctgc	cgctctgtag	cgcgctgcgc	300
ctcacgcaca	accacatcga	ggtggtggag	gacggcgct	tcgacgggct	gcccagccctg	360

gcggcgctcg	acctcagcca	caacccgctg	cgccgcctgg	gccccggcgc	cttccgcggg	420
ctgcccgcgc	tgcgctcgct	gcagctcaac	cacgcgctgg	tgccgcggcgg	ccccgcgctg	480
ctggccgcgc	tggacgctgc	gctggcaccc	ctggccgagc	ttcgctgtct	ggccctagcg	540
ggcaacgcgc	tgagccgtct	gccgcccagcc	gccctgcgcc	tgccgcgcct	ggagcagctg	600
gacgtgcgcc	tcaacgcgt	ggccggcctg	gacccgcacg	agctgcgcgc	gctggagcgc	660
gatggcgccc	tcccccggcc	gcccgcgtct	ctcgccgaca	acccgcgtcg	ctgcggctgt	720
gcccgcacgc	ccctgtggc	ctggctgcgc	aacgcccacgg	agcgcgtgcc	cgactcgcgg	780
cgccctgcgt	gcccgcggcc	gccccggcgtg	ctagaccggc	cgctacttgg	cttggacccgg	840
gcccggcttc	gctgcgcgg	cagcggcgcc	gacgcgcgcg	gagaggaggc	ggaggccgccc	900
gccccggagc	tggaagcctc	ctacgtttc	ttcgggctgg	tgctggact	catcgccctc	960
atcttcctca	tggtgcctca	cctaaaccgc	cgccggcatcc	agcgcgtggat	gccaacactg	1020
cgcgaggcgt	gcccggacca	gatggagggc	taccactacc	gctacgagca	ggacgcccac	1080
ccgcgcgcgc	cgcccgccccc	gccccggctcc	gcccgcaccc	gcccacctc	cccgggctcg	1140
gggctctga						1149

<210> 14
 <211> 558
 <212> DNA
 <213> Homo sapiens

<400> 14

atgatgctgc	tgttgctgtg	tctggggttg	accctcgct	gtgcccagga	ggaagaaaaac	60
aatgatgctg	tgacaagcaa	cttcgatctg	tcaaagattt	caggagagt	gtattcggtt	120
ctcttggcct	ctgactgcag	ggaaaaagata	gaagaagatg	gaagcatgag	ggtttttgc	180
aaacacattt	attacctggg	gaattcttct	ctgacttttta	aattgcatga	aatagaaaaat	240
ggaaaactgt	ctgaaattaa	tttggctgt	aaaccaacag	aaaagaatgc	cataatgttagt	300
actgactata	acggacttaa	tgtcattgac	atacttggaa	cggactatga	taatttatata	360
tatttttata	acaagaatata	caagaatggg	gaaacattcc	taatgctgg	gctctatgtt	420
cgaacaccgg	atgtgagctc	acaactcaag	gagagggttt	tgaatatttgc	tgaagaacat	480
ggatttgata	aggaaaacat	atttgacttgc	accaaaggtttgc	atcgctgtct	ccaggcccgac	540
gatgaggggag	cagccat					558

<210> 15
 <211> 1761
 <212> DNA
 <213> Homo sapiens

<400> 15

atgcattaca	accttcaggg	tcccacgaga	agaatcagaa	tttctttgtt	aaacgatgg	60
ggactcaaaa	tagccaatgt	gactaaagct	gatgctggaa	cttacaccc	catggcagaa	120
aaccaggttt	ggaaaagccaa	tggcacaaca	catttggttt	ttacggacc	aacaagaata	180
actttggcac	catctaaacat	ggatgtttct	gttggtggaa	gcgtcatatt	gccctgccc	240
gtacaacatg	acccgcgttt	agacatcata	tttacctgtt	atttcaatgg	gcccccttgc	300
gattttaaga	aagatggatc	tcacttttt	aaagttgg	ggagttcatc	ttgtgatttt	360
atgatcagaa	acattcagct	gaaacacatgt	gggaaatat	tttgtatgtt	gaaaacccgggg	420
gtggacagt	tttcatctgc	tgctgaccc	atagtaagag	tttccacctgg	accaccagaa	480
aatgtgaagg	tagatgaat	tacagacaca	acagcccaac	tctttggaa	agaaggtaaa	540
gacaaccata	gcccagttat	atccatttct	atccaggctc	ggacaccc	ctccgtgggt	600
tggcaaaccgg	tcacaacatgt	gcctgggtc	atcgatgg	agacgcacac	agccactgt	660
gttgagttaa	acccatgggt	ggaatatgaa	tttccgggtt	tagccagtaa	aaaaatttgg	720
ggttggagaac	caagtttacc	ctcagaaaaaa	gtaagaactg	aagaggcagt	tccagaagtg	780
cctccttctg	aagtcaatgg	aggaggccgg	agccggctgt	aacttgtat	aacctgggat	840
ccagtcctcg	aagaactaca	gaatggtggaa	gtttttgggt	atgttgttgc	tttccgc	900
cttgggttta	ccacctggat	ccagacagt	gtgacatccc	ctgacacccc	aaagatatgt	960
tttaggaatg	aaagcatgt	ccatattca	ccatatgaa	ttaaagtgg	tgtttataat	1020
aacaaagggt	aaggaccatt	tagccagtg	acaacagtgt	tctctgcaga	agaagagcct	1080
acagtggccc	catctcaatgt	ctctgcaat	agccatcttgc	cctcagaaat	tgagggttca	1140
tggaaacacca	ttccttggaa	gttgagcaat	ggacatcc	tgggctatga	ggtgcgggtac	1200
tggaaatgggg	gtggaaagga	ggaatcatcc	agtaagatga	aagtggcagg	aaatgagaca	1260

tcagccagac tacggggcct	gaagagcaac	ctggcctatt	acacggctgt	ccgggcttac	1320
aacagtgcgg	gcgctggcc	ttttagcgcc	acagttaatg	taaccaccaa	1380
cccagtca	caccaggaaa	tgttgttgg	aatgccacag	acactaaagt	1440
tggagcaag	ttaaaagccat	ggagaatgag	tcagaagtaa	caggatataa	1500
aggactagca	gtcaaaaataa	cgtacaagta	ctgaacacaa	ataaaacttc	1560
gtgctgccc	ttaaaagagga	ctacattatt	gaagtcaagg	ccacaacaga	1620
gggaccagta	gtgaacagat	cagattcca	cgaataacca	gtatggatgc	1680
acttcagcca	tctcgaaatgt	ccaccctatg	tcaagttata	tgcctatagt	1740
atgtatatg	tcctgtggtg	a			1761

<210> .16
 <211> 3081
 <212> DNA
 <213> Homo sapiens

<400> 16						
atgctggtgg	tggaaagagt	aatggttctt	cccattgggt	tccccccttgg	tgtgagtgtat	60
gattccacac	tgcatggccc	gattttatt	caagaaccaa	gtccctgtat	gttccctttg	120
gattctgagg	agaaaaaaagt	gaagctcaat	tgtgaagttt	aaggaaatcc	aaaacctcat	180
atcaggtgga	agttaaatgg	aacagatgtt	gacactggta	tggatttccg	ctacagtgtt	240
gttgaaggga	gcttgggtat	caataacccc	aataaaaaccc	aagatgctgg	aacgtaccag	300
tgcacagcga	caaactcgtt	tggaacaatt	gttagcagag	aagcaaagct	tcaagttgtct	360
tatcttgaca	actttaaaac	aagaacaaga	agcactgtgt	ctgtccgtcg	aggtcaagga	420
atgggtctac	tgtgtggccc	gccacccat	tctggagagc	tgagttatgc	ctggatcttc	480
aatgaatacc	cttcctatca	ggataatcgc	cgctttgttt	ctcaagagac	tggaaatctg	540
tatattgcca	aagtggaaaa	atcagatgtt	gggaattata	cctgtgtggt	taccaataacc	600
gtgacaaacc	acaagggtct	ggggccacct	acaccactaa	tattggaaaa	tgatggagtg	660
atgggtgaat	atgagccaa	aatagaagtg	cagttcccag	aaacagtcc	gactgcacaaa	720
ggagcaacgg	tgaagctgga	atgctttgt	ttagggaaatc	cagtagccaac	tattatctgg	780
cgaagagctg	atggaaagcc	aatagcaagg	aaagccagaa	gacacaagtc	aatggaaatt	840
ctttagatcc	ctaattttca	gcaggaggat	gctggtttat	atgaatgtgt	agctgaaaat	900
tccagaggga	aaaatgttagc	aaggggacag	ctaactttct	atgcctcaacc	taattggatt	960
caaaaataa	atgatattca	cgtggccatg	gaagaaaatg	tctttggga	atgtaaagca	1020
aatggaaaggc	ctaaggctac	atacaagtgg	ctaaaaaaatg	gcgaacctct	gtctactcg	1080
gatagaattc	aaatttgagca	aggaacactc	aacataacaa	tagtgaaccc	ctcagatgt	1140
ggcatgtatc	agtgtttggc	agagaataaa	catggagttt	tctttccaa	cgcagagctt	1200
agtgttata	ctgttaggtcc	agattttca	agaacactct	tgaaaagagt	aactcttgtc	1260
aaagtgggag	gtgaagttgt	cattggatgt	aagccaaaag	cgtctccaaa	acctgtttac	1320
accttggaaa	aaggaaggga	tatattaaaa	gaaaatggaa	gaatttccat	ttctgtttagat	1380
ggaaacctca	gaatcatcaa	cgttactaaa	tcagacgtcg	ggagttatac	ctgtatagcc	1440
actaaccatt	tttggaaactgc	tagcgtact	ggaaacttgg	tagtggaaa	tccacaacagg	1500
gtaatggtac	cccccttccag	tatggatgtc	actgttggag	agagtattgt	tttaccgtgc	1560
caggttacgc	atgtacttc	gctagacatc	gtgtttactt	ggtcatttaa	tggacacctg	1620
atagactttg	acagagatgg	ggaccacttt	gaaagagttt	gaggggattc	agctgggtat	1680
tttgatgtatc	gaaacatcca	actgaagcat	gctgggaaat	atgtctgtat	ggtccaaaca	1740
agtgtggaca	ggctatctgc	tgctgcagac	ctgattgtaa	gagggtccccc	aggcccccca	1800
gaggctgtga	caatagacga	aatcacat	accactgttc	agctctctcg	gagacccggg	1860
cctgacaacc	acagcccccatt	caccatgtat	gtcattcaag	ccaggactcc	attctccgtg	1920
ggctggcaag	cagtcaatc	agtcccagaa	ctcattgtat	ggaagacatt	cacagcgacc	1980
gtggggggat	tgaaccccttgc	gggttgaat	gaattccgc	cagttgcagc	caacgtgtt	2040
gggattttgggg	agcccgccg	ccccctcagag	aaacggagaa	cagaagaagc	tctccccgaa	2100
gtcacacccat	cgaatgtcg	tggggcgg	ggcagcaat	ctgaacttgg	tataacctgg	2160
gagacggtcc	ctgagggatt	acagaatgtt	cgaggcttt	gttatgtgg	ggccttccgg	2220
ccctacggta	aaatgatctgc	gatgtcgaca	gtgctggcc	cagctgtatgc	ctctagatac	2280
gtgttcagga	atgagagcgt	gcaccccttc	tctcccttttgc	aggtaaaatgt	aggtgtcttc	2340
aacaacaaag	gagaaggccc	tttcgttccc	accacgggtt	tgtattctgc	agaagaagaa	2400
cccacccaaac	caccagccag	tatctttggc	agaagtcttt	ctgcacacaga	tattgaagtt	2460
ttctggggct	ccccactgga	gaagaataga	ggacgaatac	aaggttatga	ggttaaatat	2520
tggagacatg	aagacaaaga	agaaaatgt	agaaaatatac	gaacagttgg	aaatcagaca	2580

tcaacaaaaa	tcacgaactt	aaaaggcagt	gtgctgtatc	acttagctgt	caaggcataat	2640
aattctgctg	ggacaggccc	ctctagtgca	acagtcaatg	tgacaacccg	aaagccacca	2700
ccaagtcaac	cccccgaaa	catcatatgg	aattcatcatcg	actccaaaat	tatcctgaat	2760
tgggatcaag	tgaagccct	ggataatgag	tcggaagtaa	aaggatacaa	agtcttgcac	2820
agatggaaaca	gacaaggcag	cacatctgtc	attgaaacaa	ataaaacatc	ggtggagctt	2880
tctttgcctt	tcgatgaaga	ttatataata	gaaaattaagc	cattcagcga	cgaggagat	2940
ggcagcaga	gtgaacaaat	tcgaattcca	aagatatacaa	atgcctacgc	gagaggatct	3000
ggggcttcca	cttcgaatgc	atgtacgctg	tcagccatca	gtacaataat	gattccctc	3060
acagcttagt	ccagttatg	a				3081

<210> 17

<211> 2535

<212> DNA

<213> Homo sapiens

<400> 17

atggacaacc	cacaggctct	gcactcttc	ctactcctgg	cctccttgg	agggatcctc	60
accctcagag	cctcttctgg	acttcagcaa	accaacttct	cctctgcctt	ctttcagac	120
tcaaagagct	cttcccaggg	gctgggtgt	gaagttccct	ccatcaaacc	tcccagctgg	180
aaagttccag	atcagttcct	ggattcaaaa	gcctctgctg	aatctctga	ttccagctgg	240
ttcctgagg	ccctgagttc	caacatgtct	gggtccttct	gttcaaatgt	ttctgctgag	300
ggccaagatt	tgagcccggt	ttccccccttc	tctgaaaccc	ctggttctga	agtatttctt	360
gatatttccg	atcctcaagt	tcctgccaaa	gaccccaagc	cttccttcac	tgttaagacc	420
ccagcttcaa	acatttctac	tcaagtctcc	cataccaaac	tgtctgttga	ggcccccagat	480
tcaaaaattct	ccccggatga	tatggatctt	aaactctctg	cccagagccc	tgaatccaaa	540
ttttctgcag	agacccactc	agctgcaagc	tttccccagc	aggtgggggg	cccaactcgct	600
gtgctgggtgg	ggaccaccaat	ccggctcccc	ctagtcccaa	tccccaaccc	tggggccccc	660
acctctctgg	ttgtctggcg	ccggggctca	aagggtctgg	cagctggggg	cctggggcca	720
ggggcacctc	tgatcagect	ggaccctgtc	caccgagacc	acctgcgatt	tgaccaggcc	780
cgggggggttc	ttggagctcgc	ctctgcccag	ctggacgatg	caggggtcta	cacggctgag	840
gtcatccggg	caggggtctc	ccagcagact	cacgagtctca	cgggtgggt	gtatgagccc	900
ctaccccagc	tgtcggttca	gccaaggct	ccagagacag	aggagggggc	ggccgagctc	960
cggctgcgct	gcctgggggt	ggggccagg	cgcggggagc	tgagctggag	ccgggacgga	1020
cgcgccttgg	aggcggcgga	atcggaggga	gcccggacgc	cccggatgcg	ctcagagggc	1080
gaccagctgc	tcatcgtgcg	ccctgtgcgc	agcgaccacg	cccgtacac	ttgcccgcgtc	1140
cgcagccct	tcggccacag	ggaggctgc	gcccga	gcgttctcta	cgccccggac	1200
ccgcccacca	tcacggtctc	ctcgaccgc	gacggccgc	ctgcccgtt	tgtcacccgc	1260
ggcagtaacg	tgaccttgcg	ctgcggcc	gcctcgcggc	cgcccgccga	catcacgtgg	1320
agcctggcg	acccggccga	ggccgcgggt	cccgcggggt	cgcccttct	gtgcccgcg	1380
gtcggaccgg	gcca	cagg	cacccaccc	tgccctggcg	cgaaaccccg	1440
cgcccgccgt	cgctgctaa	ccttacagtg	gcccggggc	ccacacgtgc	taccggccgc	1500
tcagttgaag	gggtccccc	ggacccgcgc	ctccgc	gtgtccgt	gcccggccgg	1560
gcccctgctg	cctccctgca	gttccagggt	cttcccgaa	gcatccgc	cgggccagtg	1620
tcctctgtgc	tgctggcg	cgccccggcc	caccccccgc	tcagggcg	ccccatcacc	1680
tgccttgc	gccacccgtt	ggccacgcgt	acctgcacag	tcacgcgg	ggccccccga	1740
gagggtctgc	tgcatccgc	ggtggcagag	acacggttgg	gggaggcaga	gttggcactg	1800
gaggcctctg	gttgtccccc	accctcacgg	gcatcctgg	cccggaagg	gaggccccctg	1860
gctccaggag	gccccggatcg	cctgcggctc	agtcaagatg	ggcggaaact	ccacatcgcc	1920
aacttcagcc	tggattggga	cctggaaat	tactccgtc	tgtcgttgg	ggcgctgggt	1980
gctggcggt	accagatcac	cctcattgtat	gggcctgctc	tggcaggac	ttccacctac	2040
agggacttgg	tctccctgct	catccctgggg	cctcaggagc	gtcagccgt	gttggccctt	2100
ccacccctcgaa	acccaggggac	ctggacctt	cggatcctgc	ccatcctgg	ggcccgacca	2160
gggactccat	cacaaagccg	ggttacccgg	ggccggccccc	cggtgagcc	tggggccatc	2220
gctggcatcg	tcctgggctc	cctgtgggc	ctggcgctgc	tagccgtact	tctcctcc	2280
tgcacatctgt	gcctgtgc	ctttcgtgg	aagactcctg	agaaaaagaa	gcatccttct	2340
accttggtcc	ccgtggtca	cccctcagaa	aagaagatgc	atagtgtac	cccagtggag	2400
atttcatggc	ctctggac	caaagtccct	ctggaggacc	acagctcaac	tagggcctac	2460
caagccacag	accccagttc	agttgtct	gtaggcggag	gctcaaaagac	tgttcgcgc	2520
gccacacagg	tgtga					2535

<210> 18
 <211> 2349
 <212> DNA
 <213> Homo sapiens

<400> 18

atggacaacc	cacaggctct	gccactcttc	ctactcctgg	cctccttgg	agggatcctc	60
accctcagag	ccttcttctgg	acttcagcaa	accaacttct	cctctgcctt	ctcttcagac	120
tcaaagagct	cttcccaggg	gctgggtgtg	gaagttccct	ccatcaaacc	tcccagctgg	180
aaagttccag	atcagttctt	ggattcaaaa	gcctctgtct	gaatctctga	ttccagctgg	240
tttcttgggg	ccctgagttc	caacatgtct	gggtccttct	ggtcaaatgt	ttctgtctgag	300
ggccaagatt	tgagccccgt	ttcccccttc	tctgaaaccc	ctggttctga	agtattttcct	360
gatatttcgg	atcctcaagt	tcctgccaaa	gaccccaagg	cttccttac	tgttaagacc	420
ccagcttcaa	acattttcac	tcaagtctcc	cataccaaac	tgtctgttga	ggccccagat	480
tcaaaaattct	ccccggatga	tatggatctt	aaactctctg	cccagagccc	tgaatccaaa	540
ttttctgcag	agacccactc	agctgcaagc	tttccccacgc	aggtgggggg	cccaactcgct	600
gtgctgttgg	ggaccacat	ccggctcccc	ctagttccaa	tccccaaccc	tggggccccc	660
acctctctgg	tggctctggcg	ccggggctca	aagggtctgg	cagctggggg	cctggggcca	720
ggggcacctc	tgatcaggct	ggaccctgtct	caccgagacc	acctgcgatt	tgaccaggcc	780
cgggggggttc	tggagctcgc	ctctgcccag	ctggacgatg	caggggtcta	cacggctgag	840
gtcatccggg	caggggtctc	ccagcagact	cacgagtta	cggtgggtgt	gtatgagccc	900
ctaccccagc	tgtcggttca	gccccaggct	ccagagacag	aggagggggc	ggccgagctc	960
cggctgcgt	gcctgggggt	ggggccaggt	cgcggggagc	tgagctggag	ccgggacgga	1020
cgcgcctgg	aggcggcgga	atcggaggga	gccgagacgc	cccggtatgc	ctcagagggc	1080
gaccagctgc	tcatctgtcg	ccctgtgcgc	agcgaccacg	cccggtacac	ttggccgcgtc	1140
cgcagccccct	tcggccacag	ggaggctgccc	gccgacgtca	gcgtttcta	cggcccccggac	1200
ccggccgacca	tcacggtctc	ctcgaccgc	gacgcccgcgc	ctgcccgtt	tgtcaccgcg	1260
ggcagtaacg	tgaccttgcg	ctgcccggcc	gcctcgcggc	cgcccccggcga	catcacgtgg	1320
agcctggcg	accggccgga	ggcccggtgt	cccgcggggt	cgcccttctt	gctgcccggcg	1380
gtccgaccgg	gccacgcagg	cacccacgccc	tgcctgggg	cgaaccccg	taccggccgc	1440
cgcggccgct	cgctgtctaa	ccttacagtg	gcccacgtgc	ccccccggggc	cccacagtgc	1500
tcagttgaag	ggggtcccg	ggacccgcgc	ctccgcttcc	gctgtctgt	gccccggcg	1560
gccccctgt	cctccctgca	gttccagggt	ctcccccgaag	gcatccgcgc	cggggccagt	1620
tcctctgtgc	tgcctggggc	cgtccccggc	caccccccggc	tcagcggcgt	ccccatcacc	1680
tgccttgc	gcccacgtgt	ggccacgcgt	acctgcacag	tcacccggga	ggccccccga	1740
gagggtctgc	tgcacccgt	gggtgcagag	acacgggtgg	gggaggcaga	ggtggcactg	1800
gaggcctctg	gttgtccccc	accctcacgg	gcacccctgg	cccgggaaagg	gaggccccctg	1860
gctccaggag	gccccggatcg	cctgcggctc	agtcaagatg	ggcggaaaact	ccacatcgcc	1920
aacttcagcc	tggattggga	cctggggaaat	tactccgtgc	tgtcagttgt	ggcgctgggt	1980
gctggcggtg	accagatcac	cctcattggc	cccacgttga	gccatggggc	catcgctggc	2040
atcgctctgg	gtccctgtct	gggcctggcg	ctgctagccg	tacttctct	cctttgcac	2100
tgctgcctgt	gcccgttctg	tggaaaagact	cctgagaaaa	agaagcatcc	ttctaccttg	2160
gtccccgtgg	tcaccccttc	agaaaaagaag	atgcatagtg	tgacccagt	ggagattca	2220
tggcctctgg	acctcaaaat	ccctctggag	gaccacagct	caactaggc	ctaccaagcc	2280
acagacccca	gttcagttgt	ctctgttaggc	ggaggctcaa	agactgtcg	cgcagccaca	2340
	cagggtgtga					2349

<210> 19
 <211> 789
 <212> DNA
 <213> Homo sapiens

<400> 19

atggactctc	ttgttacacgc	aaacacccaaa	ttttgctttt	atcttttca	agagataggc	60
aaagatgatc	gtcataaaaaaa	cataattttc	tctcccttga	gcctctcagc	tgcccttgg	120
atggtaacgt	tgggtgtctag	aagtgcacgt	gcacatcaga	ttgatgaggc	tgggtcctt	180
aacaatgaga	gccccggatgt	cagctgtac	tttggggcagc	ttctctccaa	attagacagg	240
atcaagactg	attacacact	gagtattgcc	aacaggcttt	atggagagca	ggaattccca	300

atctgtcagg aatacttaga tggtgtgatt	caattttacc acacgacgat	tgaaagtgtt	360
gatttccaaa aaaacccctga aaaatccaga	caagagatta acttctgggt	tgaatgtcaa	420
tcccaaggta aaatcaagga actcttcagc	aaggacgcta ttaatgctga	gactgtgctg	480
gtactggtga atgctgttta cttcaaggcc	aatggggaaa catacttga	ccatgaaaac	540
acgggtggatg cacccttctg tctaaatgcg	aatgaaaaca agagtgtgaa	gatgtatgacg	600
caaaaaggcc tctacagaat tggcttcata	gaggaggtga aggcacagat	cctggaaatg	660
aggtacacca agggaaagct cagcatgttc	gtgctgctgc catctcactc	taaagataac	720
ctgaagggtc tggaaagaggt aaatcttcat	ttccacatct ctacaaaata	tttaatgata	780
gatctttag			789

<210> 20

<211> 1185

<212> DNA

<213> Homo sapiens

<400> 20

atggactctc ttgttacagc aaacacccaa ttttgctttg atcttttca	agagataggc	60
aaagatgatc gtcataaaaaa catattttc tctccctga gcctctcagc	tgcccttggt	120
atggtacgtctgggtgct tagtgcacgt gcacatcaga ttgatgaggt	actacactc	180
aacaaaacga cagaggctct ggtcagcag gctgggtcct taaacaatga	gagcggactg	240
gtcagctgtcttttgc gttctctcc aaattagaca ggatcaagac	tgattacaca	300
ctgagtttgc ccaacaggct ttatggagag caggaattcc caatctgtca	ggaataactta	360
gatgggtgtatcaatttta ccacacgacg attgaaatgt ttgatttcca	aaaaaaccct	420
aaaaaaatcca gacaagagat taacttctgg gttgaatgtc aatcccaagg	taaaatcaag	480
gaactcttca gcaaggacgc tattaatgtc gagactgtgc	ttgtactgggt gaatgctgtt	540
tacttcaagg ccaaattggaa aacataactt gaccatgaaa acacgggtgg	tgacacccccc	600
tgtctaaatgcg aatggggaaa caagagtgtg aagatgtga	cgcaaaaagg cctctacaga	660
attggcttcata tagaggaggt gaaggcacag atccctggaaa tgaggtacac	caaggggaag	720
ctcagcatgt tcgtgtctgc gccatctcactc tctaaagata acctgaaggg	tctggagag	780
cttggaaaggaa aaatcaccta tgaaaaatg gtggccttgg gcagctcaga	aaacatgtca	840
gaagaatcgg tggccttgc cttccccccgg ttcaccctgg aagacagcta	tgatctcaat	900
tccattttac aagacatggg cattacggat atctttgtatc aacaggggc	tgatcttact	960
ggaatctctc caagtccaa ttgttacttg tcaaaaaatc tccacaaaac	ttttgtggag	1020
gtggatgaaa acggtaccca ggcagctgca gccactgggg ctgtgtctc	ggaaagggtca	1080
ctacgatctt ggggtggagtt taatgccaac cacccttttc tcttttcat	tagacacaac	1140
aaaacccaaa ccattctctt ttatggcagg gtctgtctc cttaa		1185

<210> 21

<211> 1416

<212> DNA

<213> Homo sapiens

<400> 21

atgtcgggtgc cgctgctcaa gatcggggtc gtgctgagca ccatggccat	gatcactaac	60
tggatgtccc agacgctgcc ctcgctgggt ggcctcaaca ccaccaagct	ctcggcggcc	120
ggccggggca cgctggaccg cagcaccggc gtgctgccc ccaaccctga	ggagagctgg	180
caggtgtaca gctctgcaca ggacagcggag ggcaggtgtc tctgcacagt	gtcgctcca	240
cagcagacca tgggttcacg ggatgcccgc acaaaaacagc tgaggcagct	actggagaag	300
gtgcagaaca tggctcaatc catagaggc ttggacaggg ggaccaggag	agacttgcag	360
tacgtggaga agatggagaa ccaaattgaaa ggactggagt ccaagttcaa	acaggcgata	420
aaagcgaaaa tggatgaact taggccttg atacctgtt tggagagta	caaggccgat	480
gccaaaattgg tattgcagtt taaagaggag gtccagaatc tgacgtcagt	gtttaacagag	540
ctgcaagagg aaattggcgc ctatgactac gatgaacttc agacgaggt	gttcaatctt	600
gaagaaaaggc tccgtgcattt catgaaaaa ctagcttgcg ggaagttgac	ggcatcagt	660
gaccggcgtga ctgtcaagac ctccggctcg aggttcggat cctggatgac	agaccctctc	720
gcccctgaag gcgataaccg ggtgtggtac atggacggct atcacaacaa	ccgcttcgt	780
cgtgagtaca agtccatgggt tgacttcatg aacacggaca atttccac	ccaccgtctc	840
ccccacccct ggtcgggcac gggcaggtg gtctacaacg gttctatcta	cttcaacaag	900
ttccagagcc acatcatcat caggtttgac ctgaagacag agaccatct	caagaccgc	960

agcctggact atgccggta caacaacatg taccactacg cctggggtgg ccactcgac	1020
atcgaccta tgggtggacga gagcgggctg tggccgtgt acgccacca ccagaacgct	1080
ggcaacatcg tggtcagtag gctggacccc gtgtccctgc agaccctgca gacctggAAC	1140
acgagctacc ccaagcgcag cgccggggag gccttcatca tctgcggcac gctgtacgtc	1200
accaacggct actcaggggg taccagggtc cactatgcat accagacca aacccctacc	1260
tatgaataca tcgacatccc attccagaac aaatactccc acatctccat gctggactac	1320
aaccccaagg accggggccct gtatgcctgg aacaacggcc accagatcttccatcaacgtg	1380
acccttcc acgtcatccg ctccgacgag ttgttag	1416

<210> 22
 <211> 1458
 <212> DNA
 <213> Homo sapiens

<400> 22	
atgtcggtgc cgctgctcaa gatcggggtc gtgctgagca ccatggccat gatcaactac	60
tggatgtccc agacgctgccc ctgcgtgggt ggcctcaaca ccaccaagct ctcggcgccc	120
ggcgccggga cgctggaccg cagcaccggc gtgctgccc ccaaccctga ggagagctgg	180
cagggttaca gctctgccc ggacagcggag ggcagggtta tctgcacagt ggtcgctcca	240
cagcagacca tgggttacg ggatgcccgc aaaaaacagc tgaggcagct actggagaag	300
gtgcagaaca tggctcaatc catagagggtc ttggacaggc ggacccagag agacttgcag	360
tacgtggaga agatggagaa ccaaatacgaa ggactggagt ccaagttcaa acaggtggag	420
gagattataa gctacacccgt gcccaggcag tttaaggcga taaaagcga aatggatgaa	480
ctttaggcctt tgataccctgt gttggaaagag tacaaggccg atgccaattt ggtattgcag	540
tttaaagagg aggtccagaa tctgacgtca gtgcttaacg agctgcaaga gggaaattggc	600
gcctatgact acgatgaact tcagagcaga gtgtccaaat ttgaagaaag gctccgtca	660
tgcattgaaa aactagcttgcggaaatgggttgc acgggcatca gtgaccctgt gactgtcaag	720
acctccggct cgagggttgcg atccgttgc acagaccctc tcgcccgtga aggcgataac	780
cgggtgtggt acatggacgg ctatcacaac aaccgcttcg tacgtgagta caagtccatg	840
gttgacttca tgaacacgga caatttcacc tcccaccgtc tccccccaccc ctggcgggc	900
acggggcagg tggcttacaa cgggttctatc tacttcaaca agtcccagag ccacatcatc	960
atcagggttgc acctgaagac agagaccatc ctcggatccgc acggccatccgc atatggcgtt	1020
tacaacaaca tggatccacta cgcctgggtt ggccacttcg acatcgacccatc catgggtggac	1080
gagagcgggc tggggccgt gtacgcccacc aaccagaacg ctggcaacat cgtggctagt	1140
aggctggacc cccgttccct gcagaccctg cagacctgga acacgagctt ccccaagcgc	1200
agcggccgggg aggccttcat catctgcggc acgctgtacg tcaccaacgg ctactcaggg	1260
ggtaccaagg tccactatgc ataccagacc aatgcctcca cctatgaata catcgacatc	1320
ccattccaga acaaatactc ccacatctcc atgctggact acaaccccaa ggaccggcc	1380
ctgtatgcct ggaacaacgg ccaccagatc ctctacaacg tgaccctt ccacgtcatc	1440
cgctccgacg agttgttag	1458

<210> 23
 <211> 861
 <212> DNA
 <213> Homo sapiens

<400> 23	
atgctgcattc tgctggcgct cttcctgcac tgcctccctc tggcctctgg ggactatgac	60
atctgcaat cctgggtgac cacagatgag ggccccaccc gggagggtcta cgcctgccc	120
cccaaggtga tgcgcctgaa ggactacgtc aagggtgaagg tggagccctc aggcattcaca	180
tgtggagacc cccctgagag gttctgtcc catgagaatc cctacctatg cagcaacgag	240
tgtgacgcctt ccaacccggc cctggccac ccggccaggc tcatgttgcga caaggaggag	300
gaggccctgg ccacctactg gcagagcatac acctggagcc gctacccag cccgctggaa	360
cccaacatca cccttctgtt gaacaagacc gtggagctga ccgcacgt ggtgatgacc	420
ttcagatcgtc gccggccac ggtcatggtc ctggagaatg ccctggacaa cggggcgacc	480
tggcagccctt accagttcta cgccgaggac tgcattggagg ccttcggat tgcattgggg	540
cgggcccgcg acatgtcatc ctccagcgcg caccgcgtgc tctgcaccga ggagactcg	600
cgctggcgag gtcctaaagaa ggagaaggac gtgcgttgc aggtgcggga ccgcattcgcc	660
atcttgcctt gccccgaccc gtcacatcg gacaacccatc acacgcggct ggagagcgcc	720

aagggcctca aggagttctt caccctcacc gacctgcgca tgccgctgct ggcggccggcg	780
ctgggcggca cctatgtgca gcgggagaac ctctacaagt acttctacgc catctccaac	840
atcgaggtca tcggcaggta a	861

<210> 24
 <211> 1602
 <212> DNA
 <213> Homo sapiens

<400> 24

atgtgcacatc tgctggcgct cttcctgcac tgcctccctc tggcctctgg ggactatgac	60
atctgcaaat cctgggtgac cacagatgag ggccccacac gggagttcta cgcctgcag	120
cccaagggtga tgcgcctgaa ggactacgtc aaggtaagg tggagccctc aggcatacaca	180
tgtggagacc cccctgagag gttctgtcc catgagaatc cctacctatg cagcaacagag	240
tgtgacgcct ccaaccggc cctggccac ccgcccaggc tcatgttcga caaggaggag	300
gagggcctgg ccacactactg gcagagacatc acctggagcc gctaccccg cccgctggaa	360
gccaacatca cccttcgtg gaacaagacc gtggagctga ccgacgacgt ggtgatgacc	420
ttcgagttacg gccggccac ggtcatggtc ctggagaagt ccctggacaa cgggcgcacc	480
tggcagccct accagtctta cgccgaggac tgcatggagg ccttcggat gtccgcccgc	540
cgggcccgcg acatgtcatac ctccagcgcg caccgcgtgc tctgcaccga ggagtactcg	600
cgtgggcag gctccaagaa ggagaagcac gtgcgttcg aggtgcggga ccgcgtcgcc	660
atctttccg gccccgacatc gcgaacatcg gacaacctct acacgcggct ggagagcgc	720
aagggcctca aggagttctt caccctcacc gacctgcga tgccgctgct ggcggccggc	780
ctgggcggca cctatgtgca gcgggagaac ctctacaagt acttctacgc catctccaac	840
atcgaggtca tcggcagggtg caagtgcac ctgcacgcac acctgtgtc catgcgcgag	900
ggcagcctgc agtgcgagtg cgagcacaac accaccgc ccgactgcgg caagtgcag	960
aagaatttcc gcacccggc ctggcgggccc ggctcctacc tgccgctgccc ccatggctct	1020
cccaacgcct gtacgcctcc ctccccaagg gagctggag cagactgcga atgcgtacgtt	1080
cactccaaacc gctgcagtc cattgacttc ctgaatgtgg tgacctgcgt cagctgcag	1140
cacaacacgc gaggtcagca ctgcccagcac tgccggctgg gctactaccg caacggctcg	1200
gcagagctgg atgatgagaa cgtctgcatt gagttaact gcaaccagat aggctccgt	1260
cacgaccggc gcaacgcgac cggcttctgc gagtgcgcg agggcgcggc gggcccccag	1320
tgccgactgc gctcccccac gcactactgg cgccagggtc gctaccccaa cgtgtgcgac	1380
gacgaccagc tgctgtgcca gaacggaggc acctgcctgc agaaccagcg ctgcgcctgc	1440
ccgcgcggct acacccggcgt gcgctgcgag cagcccccgt gcgaccccccgc cgacgatgac	1500
ggcggtctgg actgcgaccc cgcccccggg gccgccccgc gccccccac cctgcgtcg	1560
tgctgtgc tgctggggt ggcaccccccgt ctggccgcgt ctggccgcgt ga	1602

<210> 25
 <211> 1488
 <212> DNA
 <213> Homo sapiens

<400> 25

atgtttgcga acagtccagg gtgcctcaac atgcttcatt atgtttactg tgcctgtggc	60
catggttgc agctggtag aagtgtgtca agctctgtgg atgaaggagg cacatgccat	120
tgtatggttc acctacccaa caaccccatc cccctggagc agctgaaaca gctacaaagt	180
acagctcagg agtcatttg caagtatgag cagaagctgt ctagatgtgc acgcgcatt	240
gaagataaaag acaatgaggt tctgaaatg agtcacatgc tgaagtcctg gaatcccagt	300
gcccttgctt ctccttatga gaacccaggc ttcaacctgc tgcctggc gctggaggga	360
gcacaggagt tggtgactca acttaaaagcc atgggagggtg ttagtgtggc tggggacctc	420
ctccaccaac ttccagggca ggtgactaac gccagtctca cactcaaact tttggctgac	480
tctgaccagt gcagctttgg tgcttcag caggagggtgg atgtccttga gagtcaacta	540
agtgaatgtg agagagaaaa ggagaaaagaa ggcctttgga caccctggac caccctccc	600
cccgcttctt gtgcctcatgg aggctccag gaagtttagca aatcccttgt ggtgcagctc	660
actcggagag gcttctcata taaggcagggt ccctggggcc gagactcagc acccaatcca	720
gcctcttccc tttactgggt tgctctctca cgtacagatg gcaggactt tgactactat	780
cggctgcggcc catcctataa tgacccgcga ctgtatggaaa actatgaaga gaggaagatg	840
ggctatggtg atggcagtgg aaacgttgtg tacaagaact ttatgtactt taactactgt	900

ggcacaaggta	acatggccaa	aatggacctt	tcctccaaaca	cactgggtct	gtggcgcttg	960
ctgcctggtg	ccacctataa	caaccgcttt	tcctgtgtct	gtgtgccttg	gaaggactta	1020
gattttgtgt	gtgatgagaa	ggggctgtgg	gttctgtatg	ccactgagga	gagcaagggc	1080
aacctgggtt	tgagtcgtct	caacgctagc	accctagaag	tggagaaaac	ctggcgtaacc	1140
agccagtaca	agccagccct	gtcaggggcc	ttcatggct	gtgggggtct	ctatgcctta	1200
cactcaactg	acacccacca	agaggagatc	ttctatgttt	ttgacacacc	caccgggcag	1260
gagcggccgc	tcagcatct	gttggacaag	atgctggaaa	agctgcaggg	catcaactac	1320
tgccccttag	accacaagcc	gtatgtctc	agtgtatggtt	acctgataaa	ttatgacctc	1380
actttcctga	caatgaagac	caggctacca	agaccacca	ccaggaggcc	ctctggggct	1440
catgctccac	caaaacctgt	caaaccctaa	gaggcttcca	gaccctga		1488

<210> 26
 <211> 1053
 <212> DNA
 <213> Homo sapiens

<400> 26						
atgagaaatc	ataagaaggt	gactaacgccc	agtctcacac	tcaaactttt	ggctgactct	60
gaccagtgc	gttttggtc	tctccagcag	gaggtggatg	tccttgagag	tcaactaagt	120
gaatcttctt	gtgcccattgg	aggcctccag	gaagtttagca	aatcccttgc	ggtcagctc	180
actcggagag	gcttctcata	taaggcaggt	ccctggggcc	gagactcagc	acccaatcca	240
gcctcttccc	tttactgggt	tgctcctcta	cgtacagatg	gcagttatgg	ctgtcaccctt	300
ataattctga	atgcagggac	ttggcctagg	tactttgact	actatcggt	gtgcaaattcc	360
tataatgacc	tcgcactgct	gaaaaactat	gaagagagga	agatggctt	ttggatggc	420
agtggaaacg	ttgtgtacaa	gaactttatg	tacttaact	actgtggcac	aagtgcacatg	480
gcacaaatgg	acctttcttc	caacacactg	gtgctgtggc	gtctgtgc	ttggccacc	540
tataacaacc	gtctttcttg	tgctgggtgt	ccctggaaagg	acttagattt	tgctgggtat	600
gagaaggggc	tgtgggtct	gtatgcccact	gaggagagca	agggcaacct	gtttgtgagt	660
cgtctcaacg	ctagcacccct	agaagtggag	aaaacctggc	gtaccagcca	gtacaagcc	720
gccctgtcag	gggccttcat	ggcctgtggg	gtgctctatg	ccttacactc	actgaacacc	780
caccaagagg	agatcttcta	tgcttttgac	accaccaccc	ggcaggagcg	ccgcctcagc	840
atctgttgg	acaagatgct	gaaaaagctg	caggccatca	actactgccc	ctcagaccac	900
aaggcgtatg	tcttcagtg	tggttacctg	ataaaattatg	acctcacctt	cctgacaatg	960
aagaccaggc	taccaagacc	acccaccagg	aggccctctg	gggctcatgc	tccaccaaaa	1020
cctgtcaaac	ctaaacgaggc	ttccagaccc	tga			1053

<210> 27
 <211> 1860
 <212> DNA
 <213> Homo sapiens

<400> 27						
atggccgtg	gtcgagccct	tcttcccatt	gagatgctgc	aactgtcctt	acgggaagaa	60
agtacacgg	caaggatggg	ggcccaggag	cagattggtc	tgcaggatga	gataacaagct	120
gcaaatgcag	gaatttagtgg	gtccccagga	gtggacgggg	tagtggacgg	tggatcttcc	180
aggggtgacc	cggccctgac	agtgtctgt	tgtgaagttc	ctcctgtgag	gtcaccgttc	240
agaacccacc	cccaacttcc	tgtgcggctt	cctcgaaatc	ttgagttctc	agttcctgag	300
agaagaaccc	tgaggaacag	acttaccta	gcaaccctgg	cacccaaac	ccgacacatg	360
ctactgctgc	tgctactgct	gccacccctg	ctctgtggg	gagtgggggc	taaggaacag	420
aaggattacc	tgctgacaat	gcagaagtcc	tgacgggtc	aggagggct	gtgtgtctct	480
gtgtttgtct	ccttctctta	ccccccaaaat	ggctggactg	cctccgatcc	agttcatggc	540
tactgttcc	gggcaggggg	ccatgttaagc	cgaaacatic	cagtggccac	aaacaaccca	600
gctcgagcag	tgcaggagga	gactcgggac	cgattccacc	tcctgggg	cccacagaac	660
aaggattgt	ccctgagcat	cagagacacc	agagagatg	atgcaggggac	atacgtctt	720
tgttagaga	gaggaaatat	gaaatggat	tataaatatg	accagcttc	tgtaatgtg	780
acagccctga	ctcacatgcc	cacccctctc	atcccccggg	ccctggagtc	tggccacccc	840
aggaacctga	cctgctctgt	gcccctggcc	tgtgaacagg	ggacgcccc	cacgatcacc	900
tggatgggg	cctccgtgtc	ctccctggac	cccactatca	ctcgctctc	gatgctcagc	960
ctcatccac	agccccagga	ccatggcacc	agccctcacct	gtcaggtgac	tttgcctggg	1020

gccggcggtga	ccatgaccag	ggctgtccga	ctcaacatat	cctatcctcc	tcagaacttg	1080
accatgactg	tcttccaagg	agatggcaca	gcatccacaa	ccttggagaa	tggctggcc	1140
ctttcagttcc	tggaggggcca	gtccctgcac	cttgcgtgt	ctgtcgacag	caatccccct	1200
gccaggcggtga	gctggacctg	ggggagcctg	accctgagcc	cctcacagtc	ctcgaaacctt	1260
gggggtgtgg	agctgcctcg	agtgcgtgt	aaggatgaag	gggaattcac	ctgcccagct	1320
cagaaccctc	taggcctcca	gcacatttcc	ctgagcctct	cctgcacaaa	cgagttacaca	1380
ggcaaaatga	ggcctataatc	aggagtgacg	ctaggggcat	tcgggggagc	tggagccaca	1440
gccctggctct	tcctgtactt	ctgcacatc	ttcggtttag	ttaggtcctg	caggaagaaa	1500
tcggcaaggc	cagcagtggg	cgtggggat	acaggcatgg	aggacgcaaa	cgctgtcagg	1560
ggctcagcc	ctcagatgga	ggaaggaaact	cctggggctc	cttcctggat	gctctctgg	1620
gcatgctggc	cccactgctc	tgcactgact	cccttcttct	cctccattca	gggaccctg	1680
attgaatccc	cggcagatga	cagcccccca	caccatgctc	cgccagccct	ggccacccccc	1740
tccccagagg	aaggagagat	ccagtatgca	tccctcagct	tccacaaagc	gaggcctcag	1800
tacccacagg	aacaggaggc	catcggttat	gagtactccg	agatcaacat	ccccaaagtga	1860

<210> 28

<211> 1473

<212> DNA

<213> Homo sapiens

<400> 28

atgctactgc	tgctgtact	gctgccaccc	ctgctctgt	ggagagtggt	ggctaaggaa	60
cagaaggatt	acctgtgtac	aatgcagaag	tcctgtacgg	tgcaaggaggg	cctgtgtgtc	120
tctgtgtttt	gtcccttctc	ctaccccaa	aatggcttgg	ctgcctccga	tccagttcat	180
ggctactgtt	tccgggcagg	ggaccatgt	agccggaaaca	ttccagtggtc	cacaacaaac	240
ccagctcgag	cagtgcagga	ggagactcg	gaccgattcc	accccttgg	ggacccacag	300
aacaaggatt	gtacccttgc	catcagagac	accagagaga	gtgtatgcagg	gacatacg	360
ttttgtgttag	agagaggaaa	tatggaaatgg	aattataaaat	atgaccagct	ctctgtgaat	420
gtgacagcc	tgactcacat	gcccaccc	tccatcccg	ggacccttgg	gtctggccac	480
cccaaggaa	tgacctgtc	tgtgccc	gcctgtgaac	aggggaccc	ccccacgatc	540
acctggatgg	gggcctccgt	gtccccc	gacc	tcactcg	ctcgatgtc	600
agccatcc	cacagcccc	ggaccatggc	accagctca	cctgtcaggt	gaccttgc	660
ggggccggcg	tgaccatgac	caggcgtgtc	cgactcaaca	tatccatcc	tcctcagaac	720
ttgaccatg	ctgtcttcca	aggagatggc	acagcatca	caaccttgg	aatggctcg	780
gccttttgc	tcctggaggg	ccagttcc	caccc	gtgtgtc	cagcaatccc	840
cctgccc	tgagctggac	ctgggggagc	ctgacc	gccc	tcaca	900
cttgggggtgc	tggagctg	tcgagtgc	gtgaaggat	aaaggaaat	cac	960
gctcagaacc	ctcttaggtc	ccagcacatt	tcc	ctc	ctc	1020
acaggcaaaa	tgaggcc	atcaggagt	acg	ctt	ctt	1080
acagccctgg	tcttctgt	cttctgc	atcttc	gtt	gtt	1140
aaatcgccaa	ggccagc	ggcgtgggg	gatacagg	tggaggac	aaacg	1200
aggggc	cctctc	agg	acc	ttt	ttt	1260
aagccccc	cagctgttgc	ccc	ctc	gtt	gtt	1320
ctcagcttcc	ataaa	gtt	ca	cc	cc	1380
tactcg	ggaga	tca	aa	cc	cc	1440
cacaaccc	ccagcaaa	agg	cc	gg	gg	1473

<210> 29

<211> 1389

<212> DNA

<213> Homo sapiens

<400> 29

atgctccac	tttggactt	ttcactgt	ctgggagc	tagcaggaaa	agaagtttgc	60
tacaaagac	tcggctgtt	cagtgtat	gac	tccc	catgt	120
ctccatata	tgc	ccaa	at	ttt	ttt	180
gagaacccaa	acaacttca	agatgt	ca	ttt	ttt	240
tat	tttggaa	cagaca	acc	ttt	ttt	300
tggc	agag	at	cc	ttt	ttt	360
acatgt	gttgc	ca	cc	ttt	ttt	

gattggatca acggttcacg ggaataacatc catgctgtaa acaatctccg	420
gctgaggtgg cttattttat tgatgttctc atgaaaaaaat ttgaatattc	480
gtgcacttga ttggccacag cttggggagca cacctggctg gggaaagctgg	540
ccaggccttgc aagaataac tggtaagcat gcccgcagt tggccttga	600
gagggctacc tggtatctgc tactctggct aacaatgtca acttcgtaga	660
tacaaatcac atggatcaa ctcccataat cccccagtgg atgaggggca	720
cttcctgtta cttccttctc gtgcttatgg ttggctgatc ttggctcggt	780
ctcactcgta tggaaatggc ttcccttctt gactgttaacc atgcccgaag	840
ttatcaattt tatgctgaaa gcatttttaa ttctgatgca tttattgttt	900
atccttgcata atccttgcata cttctttgt tccaaagaag gttgcccac	960
aatgggtcat tttgtgtata gatttcactt caaaaatatg aagactaatg	1020
gatcacatta ttttttaaac acagggtccc ttccccatt tgcccggttgg	1080
aggcacaat tttttttttt tgcttgcata cttacacaaa attaatcgat	1140
actcagtgga agcgaagtca ctcaggaaac tgctttctt cgtgtaggcg	1200
ggggcgttag gggcgttag aaaaactttag ccaggcatga ttgtttttttt	1260
ttttttttttt gcaatgttta acgttgaaaaa cattacaagt ttgtttttttt	1320
ttttttttttt gaaagattctc agaataagtt gggagcagaa atggtgatata	1380
atcatctgg gttttttttt tataaatcta ctttctgttag ccaagacatt	1389
atggacacttca atggacacttca gttttttttt atttctccca	
gaaatatggaa ccatgtttttt cttttttttt gaaatctgaaa	

<210> 30

<211> 768

<212> DNA

<213> Homo sapiens

<400> 30

atgggtctgc tgctgggtat cctcatcccg gtgctggta gctggccgg	60
cacgtcgccg cactacgaga tgctggcac ctggccatg gtctgcgacc	120
cctacacggg caccaaggcg cccagcaccc ctggccacgccc	180
cgaccggccg ctcatgcagt ccctgcccac cttcatccag	240
ggccccaat gcgaggccgg cagggccggg aaggcggtc cgccggggcc	300
ccccggggcc acggcccat gggggccccc ggcgagaagg gcgagccgg	360
ccggccaccc ctggccggcc cgccggcctg aacgcggccg gggccatcg	420
cgccggccacc tacagcacgg ggcccaagat cgcttctac	480
gcccgcctca agcggcagca tgaaggctac	540
gaggtctca agttcgacga cgtgttcacc aacctcgaa accactacga	600
ccccaccacc ggcgatgttca cctgctccat cccggcattc	660
tacttctca cctaccacgt cctgatgcgc	720
ggaggggacg gcaccagcat gtggctgtat ctctgaaaaa	780
acaaccaggt gctgtctgt gcaattgccc aagatgttca	768
tcagaattac gactatgcca gtaacagtgt ttctggattt	
attattttatg ctgactga aacaacaaat acagcacgtt	

<210> 31

<211> 2355

<212> DNA

<213> Homo sapiens

<400> 31

atggagggcg acggcgccg cccatgggccc ctggcgctgc tgccacatt	60
cgacgcggc gaggtcacgg gctggagaa ggtggctcg ggcggcttcg	120
ggcagggtgtt caagggtgcgc catgtccact ggaagacctg	180
gtctgcgacc gtcggccatc aagtgtctgc ccagctgc	240
cgtcgacac agggagcgca tggagctttt ggaagaagcc aagaagatgg	300
atcttcgttgc tggatggcat ctggcgaa cctgtcgcc tggatggatgg	360
gtacatggag acgggctccc tggaaaagct gctggcttcg gagccattgc	420
catggatct ccgggttccga atcatccacg agacggcggt gggcatgaac	480
ttcctgcact gcatggcccc cccactctg tcaagccgc	540
actaccacgt caagatttctt gatggatgttccga	600
ttcctgcact gatggatgttccga gacaccaagc acgatgtata	660
ttcctgcact gatggatgttccga aagccgtttt cagatgagaa	720
ttcctgcact gatggatgttccga gacaccaagc acgatgtata	780
ttcctgcact gatggatgttccga aagccgtttt cagatgagaa	840
ttcctgcact gatggatgttccga gacaccaagc acgatgtata	

tctgaaacccg	aggacctgtg	tgaaaagcct	gatgacgaag	tgaaaagaaaac	tgctcatgat	900
ctggacgtga	aaagcccccc	ggagcccagg	agcgagggtgg	tgcctgcag	gctcaagcgg	960
gcctctgccc	ccacccctcga	taacgactac	agcctctccg	agctgctctc	acagctggac	1020
tctggagttt	cccagggctgt	cgagggcccc	gaggagctca	gcccgcagctc	ctctgagtcc	1080
aagctccat	cgtccggcag	tgggaaagagg	ctctcggggg	tgcctcgggt	ggactccgccc	1140
ttctcttcca	gaggatcaact	gtcgctgtcc	tttgagcggg	aaccttcaac	cagcgatctg	1200
ggcaccacag	acgtccagaa	gaagaagctt	gtggatgcca	tgcgtgtccgg	ggacaccaggc	1260
aaactgtatga	agatccctgca	gcccgcaggac	gtggacactgg	cactggacag	cgggtgcagc	1320
ctgctgcacc	tggcggtgga	ggccgggcaa	gaggagtgcg	ccaagtggct	gctgctcaac	1380
aatgccaacc	ccaaacctgag	caaccgtagg	ggctccaccc	cgttgcacat	ggccgtggag	1440
aggaggggtgc	gggggtgtcg	ggagctcctg	ctggcgccga	agatcagtgt	caacgccaag	1500
gatgaggacc	agtggacagc	cctccacttt	gcagcccaaga	acggggacga	gtctagacaca	1560
cggctgtgt	tggagaagaa	cgcctcggtc	aacgagggtgg	actttgaggg	ccggacgccc	1620
atgcacgtgg	cctgcagca	cggggcaggag	aatatcggtc	gcatcctgct	gcgcccggc	1680
gtggacgtga	gcctgcaggg	caaggatgcc	tggctgccac	tgcactacgc	tgcctggcag	1740
ggccacactgc	ccatcgtaa	gctgctggcc	aagcagccgg	gggtgagtgt	gaacgcccag	1800
acgctggatg	ggaggacgccc	attgcacctg	gccgcacagc	gcgggcacta	ccgcgtggcc	1860
cgcatccctca	tgcacccgtg	ctccgacgtc	aacgtctgca	gcctgctggc	acagacaccc	1920
ctgcacgtgg	ccgcggagac	ggggcacacg	agcactgcca	ggctgctct	gcatcgggc	1980
gctggcaagg	aggccatgac	ctcagacggc	tacaccgtc	tgcacctggc	tgcccgcac	2040
ggacacactgg	ccactgtcaa	gctgcttgcc	gaggagaagg	ccgatgtgt	ggcccgggga	2100
cccctgaacc	agacggcgct	gcacctggct	gcccccacg	ggcaactcgga	gttggtgag	2160
gagttggtca	gcccggatgt	cattgacactg	ttcgacagac	aggggctcag	cgcgctgcac	2220
ctggccggccc	aggggccggca	cgcacagacg	gtggagactc	tgctcaggca	tggggcccac	2280
atcaacactgc	agagcctcaa	gttccagggc	ggccatggcc	ccggcccccac	gctcctgcgg	2340
cgaagcaaga	cctag					2355

<210> 32

<211> 759

<212> DNA

<213> Homo sapiens

<400> 32

atggcagccc	ccgcctgct	gctcctagca	ctgctgctgc	ccgtgggggc	ctggcccgccc	60
ctgcccagga	ggccctgtgt	gactgctgc	cgcccgccct	ggccccctgg	accctatgcc	120
cgggtgagtg	acagggacct	gtggaggggg	gacctgtgga	gggggctgccc	tcgagtaacgg	180
cccaactatacg	acatcgaaat	cctcaaagggt	gagaagggtg	aggccggcgt	ccgaggtcgg	240
gccggcagga	gcgggaaaaga	ggggccgcca	ggcgcccggg	gcctgcaggg	ccgcagaggc	300
cagaaggggc	aggtggggcc	gccccggcgc	gcgtgcccac	gtgcctacgc	cgcccttctcc	360
gtgggcccgc	gcgagggcct	gcacagctcc	gaccacttcc	aggccgtgccc	cttcgacacag	420
gagctggtga	acctggacgg	cgccttgcac	ctggccgcgg	gccgccttct	ctgcacgggt	480
cccgccgtct	acttcctcag	cctcaacgtg	cacacctgga	actacaagga	gacctacccgt	540
cacatcatgc	tgaaccggcg	gccccggccc	gtgcctctacg	cgcaagccac	cgagcgcagc	600
gtcatgcagg	cccagagcct	gatgtgtcg	ctggccggcgg	gcaacgcgt	ctgggtgcgc	660
atgttccaggc	gcgaccggga	caacgcctac	tacggccgagc	acggagacct	ctacatcacc	720
ttcagcggcc	acctggtcaa	gccccggccc	gagctgttag			759

<210> 33

<211> 1782

<212> DNA

<213> Homo sapiens

<400> 33

atccccagct	cgctgttcgc	agacctggag	cgcaacggca	gcggccggcgg	cgccggcggc	60
agcagcggag	ggggagagac	cctggatgac	caaagagccc	tgcagtcgc	gctcgaccag	120
ctctccctgc	tggggctgga	cagtgcacgg	ggcgcctctc	tgtacacag	cgagccgcgc	180
aagaagagcg	tgaacatgac	cgagtgcgtg	ccagtaccca	gttctgagca	tgtcgcccag	240
atcggtgggc	ggcaaggtag	gtcgaggagg	gatggggagc	tggatcccag	cgcatctcc	300
ccagatgact	tttctggat	tctcggttt	ggttcgggac	gactgcagtc	actggggag	360

ggccaggcag	ccaatgggct	gttcctcgag	cgccctcgccg	gtgggatccg	ctgcccagcc	420
cgtggcgcgg	cccggagggtt	taaaatcaaa	gcgctgcggg	cgaagaccaa	tacttacatc	480
aagaccccaag	ttcgcgggga	ggagcctgtc	tttgggtgtga	cgggcaggaa	ggaggatgtg	540
gccatggctc	ggagggagat	catctctgt	gccgagact	tctccatgt	ccgcgcctcc	600
cggaaaaga	acacggca	caacggcgcg	gtgcctggc	cggccaaacct	gcccggcag	660
accaccatcc	aagtgcgggt	accctaccgc	gtgggtgggc	tcgtgggtgg	gccccaaaggc	720
gccacaatca	agcgcatcca	gcagcagacg	cacacgtaca	tcgtgacgccc	cagccggat	780
aaggagccgg	tgttcgaggt	gaccggcatg	ccagagaacg	tggatcgcgc	tcgagagggag	840
attgaggcgc	acattgtct	gctgaccggc	ggcatcattt	agctcacaga	cgagaacgac	900
ttcacgcaca	acggcaccga	tgtgggcttc	gatctgcata	atgggtccgg	cggtgcttcc	960
acagacttt	atttcggcgg	cgggaccacgc	agcagcgcag	cggctaccca	gcccctggcg	1020
gactacagcc	ccccatggcc	cgccttgagc	tttgcgcaca	acggaaacaa	taacaataac	1080
ggcaatgggt	acacctacac	agcggggggga	gaagcctcag	tgccatcccc	cgacggctgc	1140
cccgagctgc	agcccactt	tgacccggct	cccgcctcccc	cacctggggc	accacttata	1200
tggggccagt	tcgagcggtc	cccgggaggg	ggacctgcag	ctccggatc	tttttcctgc	1260
tcttcttctg	catcttcgtc	tgcttcttcc	tcctccgtgg	tcttccccgg	gggtggcgcc	1320
agtgcgcct	ccaacgcaca	cctggggcta	ttgggtgcacc	gccggctgca	ccctggcacc	1380
agctgcccgc	gcctgtctcc	acccttgcac	atggcccccgg	gggggggaga	gcaccacctg	1440
gctgcgggg	tgcgcagcga	ccccgggtgg	ggaggcctgg	cctacgccc	ttatgccaac	1500
gggctgggg	cacagctgcc	tgggttgcag	ccgtcgga	cgtcgccgc	ctccctttcg	1560
tccagctcct	cctccagtc	ttcatcctct	tcctccgggc	ttcgcgtaa	aggcagccgc	1620
gactgctccg	tgtgcttcga	gagcgaagtg	attgcccgc	tggtccctg	tggccacaac	1680
ctcttctgca	tggagtgcgc	caatcgcatc	tgtgagaaga	gcaagcccg	gtgcccggc	1740
tgccacacccg	cggtaactca	ggccatccgc	atctttctt	aa		1782

<210> 34
 <211> 1419
 <212> DNA
 <213> Homo sapiens

<400> 34

atgcccagct	cgctgttcgc	agacctggag	cgcaacggca	gcggcggcgg	cggcggcggc	60
agcagcggag	ggggagagac	cctggatgac	caaagagccc	tgcagctcgc	gctcgaccag	120
ctctccctgc	tggggctgga	cagtgacgag	ggcgcctctc	tgtacgacag	cgagccgcgc	180
aagaagagcg	tgaacatgac	cgagtgcgt	ccagttacca	gttctgagca	tgtcgccgag	240
atcggtgggc	ggcaagggtt	taaaatcaaa	gctgctgcggg	cgaagaccaa	tacttacatc	300
aagaccccaag	ttcgcgggga	ggagcctgtc	tttgggtgtga	cgggcaggaa	ggaggatgtg	360
gccatggctc	ggagggagat	catctctgt	gccgagact	tctccatgt	ccgcgcctcc	420
cggaaaaga	acacggca	caacggcgcg	gtgcctggc	cggccaaacct	gcccggcag	480
accaccatcc	aagtgcgggt	accctaccgc	gtgggtgggc	tcgtgggtgg	gccccaaaggc	540
gccacaatca	agcgcatcca	gcagcagacg	cacacgtaca	tcgtgacgccc	cagccggat	600
aaggagccgg	tgttcgaggt	gaccggcatg	ccagagaacg	tggatcgcgc	tcgagagggag	660
attgaggcgc	acattgtct	gctgaccggc	ggcatcattt	agctcacaga	cgagaacgac	720
ttcacgcaca	acggcaccga	tgtgggcttc	gatctgcata	atgggtccgg	cgggtccggc	780
ccaggcagcc	tctggagcaa	gccccccccc	agcatcacgc	ccaccccccgg	ccgcaagcct	840
ttctctagct	accgcaacga	cagctccagc	tcgcttggca	gtgtttccac	agactttat	900
ttcgcggcgc	ggaccagcag	cagcgcagcg	gctacccagc	gcctggcga	ctacagccct	960
gcgcctcca	acgccaacct	ggggctattt	gtgcaccgc	ggctgcaccc	tggcaccagc	1020
tgcccgcc	tgtctccacc	tttgacatg	gccccggggg	cgggagagca	ccacctggct	1080
cgcgggggtgc	gcagcgaccc	gggtggagga	ggcctggcct	acgccccta	tgccaacggg	1140
ctgggggcac	agctgcctgg	tttgacccgc	tcggacacgt	cgggtccctc	ctcttcgtcc	1200
agctcttcct	ccagcttttc	atcctttcc	tccggcttc	ggcgtaaagg	cagccgcac	1260
tgctccgtgt	gcttcgagag	cgaagtgtt	gccgcgtgg	tgcctgtgg	ccacaacctc	1320
ttctgcattgg	agtgcgcaca	tcgcattgt	gagaagagcg	agcccgagtg	cccggtctgc	1380
cacaccgcgg	tcactcaggc	catccgcata	ttttcttaa			1419

<210> 35
 <211> 1824
 <212> DNA

<213> Homo sapiens

<400> 35

atgtggggcc	tggtggaggct	cctgctggcc	tggctgggtg	gctggggctg	catggggcgt	60
ctggcagccc	cagcccccggc	ctggggcagggg	tcccggaac	acccaggggcc	tgctctgctg	120
cggactcgaa	ggagctgggt	ctggAAC	ttctttgtca	ttgaggaata	tgctggtcca	180
gagcctgttc	tcattggcaa	gctgactcg	gatgttgacc	ggggagaggg	ccgcaccaag	240
tacctgttga	ccggggaggg	gcaaggcacc	gtattttgtga	ttgatgaggc	cacaggcaat	300
attcatgtta	ccaagagcct	tgaccggggag	aaaaaggcgc	aatatgtgt	actggcccaa	360
gcccgtggacc	gagcctccaa	ccggccctgt	gagccccat	cagagttcat	catcaaagt	420
caagacatca	acgacaatcc	accatTTT	ccccttggc	cctaccatgc	caccgtgcc	480
gagatgttca	atgtcgggac	atcagtgatc	caggtactg	ctcacgatgc	tgtgacccc	540
agctatggga	acagtgc当地	gctgggttac	actgttctgg	atggactgac	tttcttctct	600
gtggacccccc	agactggagt	ggtgcgtaca	gccatcccc	acatggaccg	ggagacacag	660
gaggagttct	ttgtgtgtat	ccaggc当地	gacatggcg	gccacatggg	ggggctgtca	720
ggcagcacta	cggtactgt	cacgctcagc	gatgtcaacg	acaacccccc	caagttccca	780
cagagcttat	accaggatc	cgtgggtggag	acagctggac	ctggcacact	ggtggccgg	840
ctccggggccc	aggaccaga	cctgggggac	aacgc当地	tggcatacag	catcctggat	900
ggggaggggt	ctgaggcctt	cagcatcagc	acagacttgc	agggtcgaga	cgggctctc	960
actgtccgc当地	agcccttaga	cttgagagc	cagcgctcct	actccttccg	tgtcgaggcc	1020
accaacacgc当地	tcattgaccc	agcctatctg	cggcgagggg	ccttcaagga	tgtggccctct	1080
gtgcgtgtgg	cagtgc当地	tgccccc当地	ccacctgtc	tcacccaggc	tgccttaccac	1140
ctgacagtgc当地	ctgagaacaa	ggccccc当地	accctggtag	gccagatctc	cgcggctgac	1200
ctggactccc当地	ctgccc当地	aatcagatac	ccatcctcc	ccactcaga	tccggagcgt	1260
tgcttctcta当地	tccagccccg	ggaaggcacc	atccatacag	cagcaccct	ggatcgc当地	1320
gctcgc当地	ggcacaaccc	cactgtgt	gctacagagc	tcgtccctta	tacccctgt	1380
tatgc当地	gggctctcc	accctttt	tttc当地	catatgaaaa	ctgccc当地	1440
atatgtggat当地	atctgaaatgt	gtcagtgt	gcctatata	atgtgc当地	gtggccatg	1500
gtcttagtct当地	ttgc当地	caaaggagga	gggagaggac	cagggaggc	ggctgtt当地	1560
ggacagaagc当地	agtcaactag	gtgggagctg	agccagaact	gcaattatct	cccaaagtcc	1620
agagaagggg当地	tccaccagg	aaccaggatg	agagctcagg	cctctcaact	ccagggctcc	1680
agaggcacac当地	acaggaactg	cacacgc当地	gcctgccc当地	ctcggtgaa	tccc当地	1740
tatcactcac当地	ctacacctgg	gcacagaact	acatacacct	gtggacatga	atatgcaccc	1800
tcttatgccc当地	agtcaaacac	ctg				1824

<210> 36

<211> 2346

<212> DNA

<213> Homo sapiens

<400> 36

atgtggggcc	tggtggaggct	cctgctggcc	tggctgggtg	gctggggctg	catggggcgt	60
ctggcagccc	cagcccccggc	ctggggcagggg	tcccggaac	acccaggggcc	tgctctgctg	120
cggactcgaa	ggagctgggt	ctggAAC	ttctttgtca	ttgaggaata	tgctggtcca	180
gagcctgttc	tcattggcaa	gctgactcg	gatgttgacc	ggggagaggg	ccgcaccaag	240
tacctgttga	ccggggaggg	ggcaggcacc	gtattttgtga	ttgatgaggc	cacaggcaat	300
attcatgtta	ccaagagcct	tgaccggggag	aaaaaggcgc	aatatgtgt	actggcccaa	360
gccgtggacc	gagcctccaa	ccggccctgt	gagccccat	cagagttcat	catcaaagt	420
caagacatca	acgacaatcc	accatTTT	ccccttggc	cctaccatgc	caccgtgcc	480
gagatgtcca	atgtcgggac	atcagtgatc	caggtactg	ctcacgatgc	tgtgacccc	540
agctatggga	acagtgc当地	gctgggttac	actgttctgg	atggactgac	tttcttctct	600
gtggacccccc当地	agactggagt	ggtgcgtaca	gccatcccc	acatggaccg	ggagacacag	660
gaggagttct当地	ttgtgtgtat	ccaggc当地	gacatggggc	gccacatggg	ggggctgtca	720
ggcagcacta当地	cggtactgt	cacgctcagc	gatgtcaacg	acaacccccc	caagttccca	780
cagagcttat当地	accaggatc	cgtgggtggag	acagctggac	ctggcacact	ggtggccgg	840
ctccggggccc当地	aggaccaga	cctgggggac	aacgc当地	tggcatacag	catcctggat	900
ggggaggggt当地	ctgaggcctt	cagcatcagc	acagacttgc	agggtcgaga	cgggctctc	960
actgtccgc当地	agcccttaga	cttgagagc	cagcgctcct	actccttccg	tgtcgaggcc	1020
accaacacgc当地	tcattgaccc	agcctatctg	cggcgagggg	ccttcaagga	tgtggccctct	1080

gtgcgtgtgg cagtgcaga	tgccccagag ccacccgc	tcacccaggc tgcctaccac	1140
ctgacagtgc ctgagaacaa	ggcccccggg accctggtag	gccagatctc cgccggctgac	1200
ctggactccc ctgccagccc	aatcagatac tccatcctcc	cccactcaga tccggagcgt	1260
tgcttctcta tccagcccga	gaaaggcacc atccatacag	cagcaccctt ggatcgcgag	1320
gctcgcgcct ggcacaaac	cactgtgctg gctacagagc	tcgacagttc tgcacaggcc	1380
tcgcgcgtgc aagtggccat	ccagaccctg gatgagaatg	acaatgctcc ccagctggct	1440
gagccctacg atactttgt	gtgtactct gcagctcctg	gccagctgtat tcaggtcattc	1500
cggccctgg acagagatga	agttggcaac agtagccatg	tctccttca aggtcctctg	1560
ggccctgtatg ccaacttac	tgtccaggac aaccgagatg	gctccgcctg cctgctgctg	1620
ccctcccgcc ctgctcacc	ccgccccatgcc ccctacttgg	ttcccataga actgtgggac	1680
tggggcagc cggcgctgag	cagcactgac acagtgactg	ttagtgtgt cgcgtccag	1740
cctgacggct ctgtggcatc	ctgctggcct gaggctcacc	tctcagctgc tggcgtcagc	1800
accggcggcc tgcttgcatt	catcacctgt gtgggtgc	tgcttgcctt ggtgggtgctc	1860
ttcgtggccc tgccggcga	gaagcaagaa gcaactgatgg	tactggagga ggaggacgtc	1920
cgagagaaca tcatcaccta	cgacgacgag ggcggcggcg	aggaggacac cgaggccctc	1980
gacatcacgg cttgcagaa	cccggacggg gcgccccccc	cgccgccccgg ccctcccg	2040
cggcgagacg tggccccc	ggcccggggtg tcgcgcagc	ccagacccccc cggccccc	2100
gacgtggcgc agctcctggc	gctgcggctc cgcgaggcgg	acgaggaccc cggcgtaccc	2160
ccgtacgact cggtgccagg	gtacggctac gaggcccg	gctccttgc cggctccctc	2220
agctccctgg gtcggccag	cgaagccggc ggcggccccgg	gcccgcggaa gcccgtggac	2280
gactgggtc cgcttcccg	caccctggcc gagctgtatg	ggcccaagga gccccggcc	2340
ccctga			2346

<210> 37

<211> 1923

<212> DNA

<213> Homo sapiens

<400> 37

atggccagag gccattacat ttatgtggat	acccctttt gcaagcaggg	ggagaaaagct	60
gtgctgctaa gtcctgactt acaggctgag	aatggagct gcctccgttt	ggtctaccag	120
ataaaccacat cttcggagtc tctgtcagat	cccagccagc tgaacctcta	catgagattt	180
gaagatgaaa gcttgcattcg cttgcattgg	tcaagcttca aacccctt	cagctggctc	240
atagccagct tggatttgca aaacagttcc	aagaaattca agattttaat	agaagggtgt	300
ctaggacagg gaaacacagc cagcatcgca	ctatggaaa tcaagatgac	aaccggctac	360
tgtattgaat gtgactttga agaaaatcat	ctctgtggct ttgtgaaccg	ctggaaatccc	420
aatgtgaact gtttgcattgg aggaggaatg	attccggaaatg tccactccat	tctccacag	480
gatcacacat tcaagagtga actggccac	tacatgtacg tggactcagt	ttatgtgaag	540
cacttccagg aggtggcaca gctcatctcc	ccgttgcacca cggccccat	ggctggctgc	600
ctgtcatttt attaccagat ccagcagggg	aatgacaatg tctttccct	ttacactcgg	660
gatgtggctg gccttacga gaaatctgg	aaagcagaca ggcaggaa	tgctgcctgg	720
aaccttgcgg aggtcgagtt cacaatccat	tttcctctgc aggttatttt	tgaagttgt	780
ttcaatggtc ccaagggagg ttatgttgc	ctggatgata ttcattctc	tcctgttac	840
tgccagaatc agacagaact tctgttca	gcccgttgc	ttttgagcaa	900
gatctctgca acttttacca agataaaagaa	ggtccaggtt ggacccgagt	gaaagtaaaa	960
ccaaacatgt atcgggctgg agaccacact	acaggcttag ggtattacct	gctagccaaac	1020
acaaaagtca catctcagcc tggctacatt	ggaaggctct atggccctc	cctaccagga	1080
aacttgcagt attgtctgcg ttttattat	gcccattatg gattttaaa	aatgagtgac	1140
acccttagcag ttacatctt tgaagagaac	catgtggttc aagagaagat	ctggctgtg	1200
ttggagtccc caaggggtgt ttggatgc	gctgaaatca cctttaagaa	gcccattgc	1260
accaagggtgg ttttcatgag cctatgcaaa	agtttctggg actgtggct	tgtggccctg	1320
gatgacatta caatacaatt ggaaagctgc	tcatcttcag agaaacttcc	acccctccac	1380
ggagagtgtt ctttcgagca agatgaatgt	acatttactc aggagaaaag	aaaccggagc	1440
agctggcaca ggaggagggg agaaactccc	acttcctaca caggacaaa	gggagatcac	1500
actactgggg taggctacta catgtacatt	gaggccctccc atatgtgt	tggacaaaaa	1560
gcacgcctct tggccaggcc tctgcgagga	gtctctggaa aacactgctt	gaccttttc	1620
taccacatgt atgggggggg cactggctc	ctgagtgttt atctgaaaaa	ggaagaagac	1680
agtgaagagt ccctctttag gaggagaaga	ggtgaacaga gcatttcctg	gctacgagca	1740
ctgattgaat acagctgtga gaggcaacac	cagataattt ttgaagccat	tcgaggagta	1800

tcaataagaa gtgatattgc cattgtatgtat gttaaatttc aggcaggacc ctgtggagaa 1860
atggaaagata caactcaaca atcatcagga tattctgagg acttaaatga aattgagttat 1920
taa

<210> 38

<211> 2061

<212> DNA

<213> Homo sapiens

<400> 38

atgctgttaa	ggggcgtcct	cctggcgttg	caagccctgc	agctcggccgg	tgccctcgac	60
ctgcccgt	ggtcgtgc	cttgaagag	agcaacttgcg	gctttgactc	cgtgttggcc	120
tctctccgt	ggatttaaa	tgaggaaggc	cattacattt	atgtggatac	ctccttggc	180
aagcaggggg	agaaaagctgt	gctgctaagt	cctgacttac	aggctgagga	atggagctgc	240
ctccgttgg	tcaccatgt	aaccacatct	tcggagtctc	tgtcagatcc	cagccagctg	300
aaccctaca	ttagatttg	agatgaaagc	tttgcgtct	tgctttggtc	agctaaggaa	360
ccttcagaca	gctggctcat	agccagctt	gatttgcaaa	acagttccaa	gaaattcaag	420
attttaatag	aagggtgtact	aggacaggg	aacacagcc	gcacatgcact	atttgcattc	480
aagatgacaa	ccggctactg	tattgaatgt	gactttgaag	aaaatcatct	ctgtggcttt	540
gtgaaccgct	ggaatcccaa	tgtgaactgg	tttgcgtgg	gaggaagtat	tcggaatgtc	600
caactccattc	tcccacagga	tcacaccc	aagagtgaac	tgcccacta	catgtacgt	660
gactcagttt	atgtgaagca	cttccaggag	gtggcacagc	tcatctcccc	gttgaccacag	720
gccccatgg	ctggctgcct	gtcattttat	taccagatcc	agcaggggaa	tgacaatgtc	780
ttttccctt	acactcggg	tgtggctggc	cttacaggg	aatatctggaa	agcagacagg	840
ccagggaaatg	ctgcctggaa	ccttgccggag	gtcgagttca	catgccattt	tcctctgcag	900
gttatttttg	aagtgcctt	caatggtccc	aagggaggtt	atgttgcct	ggatgatatt	960
tcattcttc	ctgttcactg	ccagaatcag	acagaacttc	tgttcagtc	cgtgaaagcc	1020
agctgcattt	tttagcaaga	tctctgcaac	tttaccaag	ataaaagaagg	tccaggttgg	1080
acccgagtga	aagtaaaaacc	aaacatgtat	cgggctggag	accacactac	aggcttaggg	1140
tattacctgc	tagccaacac	aaagtccaca	tctcagccctg	gctacattgg	aaggctctat	1200
ggccccc	taccagggaa	cttgcagtt	tgtctgcgtt	ttcattatgc	catctatgg	1260
tttttaaaaa	tgagtgcac	cctagcgtt	tacatcttt	aagagaacca	tgtggttcaa	1320
gagaagatct	ggtctgttt	ggatcccc	agggtgttt	ggatgcacgc	tgaaatcacc	1380
tttaagaagc	ccatgcctac	caaggtgtt	ttcatgagcc	tatgcaaaag	tttctggac	1440
tgtgggttt	tagccctgg	tgacattaca	atacaattgg	gaagctgc	atcttcagag	1500
aaacttccac	ctccacctgg	agagtgtact	ttcgcagcaag	atgaatgtac	atttactcag	1560
gagaaaaagaa	accggagcag	ctggcacagg	aggagggggag	aaactccac	ttcctacaca	1620
ggaccaaaagg	gagatcacac	tactgggta	ggctactaca	tgtacattga	ggcctcccat	1680
atggtgtatg	gacaaaaaagc	acgccttctt	tccaggcctc	tgcgaggagt	ctctggaaaa	1740
cactgcttg	ccttttctt	ccacatgtat	ggagggggca	ctggcctgt	gagtgtttat	1800
ctgaaaaaagg	aagaagacag	tgaagagttc	ctcttattgg	ggagaagagg	tgaacagac	1860
atttccctggc	tacgagact	gattgaatac	agctgtgaga	ggcaacacca	gataatttt	1920
gaagccattc	gaggagtatc	aataagaagt	gatattgcca	ttgatgtatgt	taaatttcag	1980
gcaggaccct	gtggagaaat	ggaagataca	actcaacaat	catcaggata	ttctgaggac	2040
ttaaatgaaa	ttgagtatta	a				2061

<210> 39

<211> 465

<212> DNA

<213> *Homo sapiens*

<400> 39

atgacacctgt	ccccaaacaca	gcccacccctgt	tttccacctgc	cttacgtccca	gaaatgc	60
atccctactg	tggagcagct	gactctgggg	atcccatgcc	agaatcatgg	ggagatagac	120
catggccagg	atataattcc	agcagagaag	ctctgtcatc	tgcaggattg	caaggtgaac	180
cttcacagag	ctgcctgcgg	tgagtgtatt	gttgacccca	agacttccag	cttcccttac	240
tgtcagggga	cctgcctgac	cctcaacagt	gagttcatc	aatccaactt	tgcactcaaa	300
gtttgcacta	taagagggga	gtgcctattg	atctgttcc	ggctctttca	gacctgttagt	360
cccaccaagg	tcattcttt	ctccctaacc	gtccaggat	acgaacgtaa	gatgagcgtt	420

cactgtgtga acgcattcctt gatagagaag tgtggctgct cttga

465

<210> 40
 <211> 277
 <212> PRT
 <213> Homo sapiens

<400> 40
 Met Arg Gly Leu Val Met Ala Pro Leu Leu Ile Leu Val Gly Gly
 1 5 10 15
 Thr Glu Ala Phe Arg Ile Cys Ala Phe Asn Ala His Arg Leu Thr Leu
 20 25 30
 Ala Lys Leu Thr Lys Glu Ser Val Met Asp Thr Leu Val Gln Ile Leu
 35 40 45
 Ala Arg Cys Asp Ile Met Val Leu Gln Glu Val Val Asp Ser Ser Gln
 50 55 60
 Asn Thr Val Pro Phe Leu Leu Gln Lys Leu Lys Ser Ser Arg Ser Tyr
 65 70 75 80
 Ser Phe Leu Asn Ser Ser Leu Leu Gly Arg Ser Thr Tyr Lys Glu Lys
 85 90 95
 Tyr Val Tyr Ile Tyr Arg Ser Asp Lys Thr Gln Val Leu Asn Phe Tyr
 100 105 110
 Gln Tyr Asn Asp Thr Asp Asp Ile Phe Ala Arg Glu Pro Phe Val Ala
 115 120 125
 His Phe Thr Leu Pro Ser Lys Thr Leu Pro Ser Val Val Leu Val Pro
 130 135 140
 Leu His Thr Thr Pro Lys Asp Val Glu Lys Glu Leu Asn Ala Leu Tyr
 145 150 155 160
 Asp Val Phe Leu Asp Val Tyr Gln Arg Trp Gln Asn Glu Asn Val Ile
 165 170 175
 Leu Leu Gly Asp Phe Asn Ala Asp Cys Ala Ser Leu Thr Lys Lys Arg
 180 185 190
 Leu Lys Ser Leu Leu Leu Arg Thr Lys Ala Gly Phe His Trp Val Ile
 195 200 205
 Pro Asp Gly Glu Asp Thr Thr Val Arg Ala Ser Thr Asn Cys Thr Tyr
 210 215 220
 Asp Arg Ile Val Val His Gly Gln Gly Cys Gln Met Leu Leu Lys Ala
 225 230 235 240
 Ala Ala Thr Phe Asp Phe Pro Lys Arg Phe Gln Leu Thr Glu Glu
 245 250 255
 Ala Leu Arg Ile Ser Asp His Tyr Pro Val Glu Val Glu Leu Ser Gln
 260 265 270
 Ala Thr Pro Leu Ser
 275

<210> 41
 <211> 480
 <212> PRT
 <213> Homo sapiens

<400> 41
 Met Leu Gly Arg Phe Gln Pro Phe Ser Leu Val Arg Ser Phe Arg Leu
 1 5 10 15
 Gly Phe Gly Ala Cys Cys Tyr Pro Asn Gln Lys Cys Ala Thr Gln Thr
 20 25 30
 Ile Arg Pro Pro Asp Ser Arg Cys Leu Val Gln Ala Val Ser Gln Asn
 35 40 45
 Phe Asn Phe Ala Lys Asp Val Leu Asp Gln Trp Ser Gln Leu Glu Lys
 50 55 60

Asp Gly Leu Arg Gly Pro Tyr Pro Ala Leu Trp Lys Val Ser Ala Lys
 65 70 75 80
 Gly Glu Glu Asp Lys Trp Ser Phe Glu Arg Met Thr Gln Leu Ser Lys
 85 90 95
 Lys Ala Ala Ser Ile Leu Ser Asp Thr Cys Ala Leu Ser His Gly Asp
 100 105 110
 Arg Leu Met Ile Ile Leu Pro Pro Thr Pro Glu Ala Tyr Trp Ile Cys
 115 120 125
 Leu Ala Cys Val Arg Leu Gly Ile Thr Phe Val Pro Gly Ser Pro Gln
 130 135 140
 Leu Thr Ala Lys Lys Ile Arg Tyr Gln Leu Arg Met Ser Lys Ala Gln
 145 150 155 160
 Cys Ile Val Ala Asn Glu Ala Met Ala Pro Val Val Asn Ser Ala Val
 165 170 175
 Ser Asp Cys Pro Thr Leu Lys Thr Lys Leu Leu Val Ser Asp Lys Ser
 180 185 190
 Tyr Asp Gly Trp Leu Asp Phe Lys Lys Leu Ile Gln Val Ala Pro Pro
 195 200 205
 Lys Gln Thr Tyr Met Arg Thr Lys Ser Gln Asp Pro Met Ala Ile Phe
 210 215 220
 Phe Thr Lys Gly Thr Thr Gly Ala Pro Lys Met Val Glu Tyr Ser Gln
 225 230 235 240
 Tyr Gly Leu Gly Met Gly Phe Ser Gln Ala Ser Arg Arg Trp Met Asp
 245 250 255
 Leu Gln Pro Thr Asp Val Leu Trp Ser Leu Gly Asp Ala Phe Gly Gly
 260 265 270
 Ser Leu Ser Leu Ser Ala Val Leu Gly Thr Trp Phe Gln Gly Ala Cys
 275 280 285
 Val Phe Leu Cys His Met Pro Thr Phe Cys Pro Glu Thr Val Leu Asn
 290 295 300
 Val Leu Ser Arg Phe Pro Ile Thr Thr Leu Ser Ala Asn Pro Glu Met
 305 310 315 320
 Tyr Gln Glu Leu Leu Gln His Lys Cys Phe Thr Ser Tyr Arg Phe Lys
 325 330 335
 Ser Leu Lys Gln Cys Val Ala Ala Gly Gly Pro Ile Ser Pro Gly Val
 340 345 350
 Ile Glu Asp Trp Lys Arg Ile Thr Lys Leu Asp Ile Tyr Glu Gly Tyr
 355 360 365
 Gly Gln Thr Glu Thr Gly Leu Leu Cys Ala Thr Ser Lys Thr Ile Lys
 370 375 380
 Leu Lys Pro Ser Ser Leu Gly Lys Pro Leu Pro Pro Tyr Ile Val Gln
 385 390 395 400
 Ile Val Asp Glu Asn Ser Asn Leu Leu Pro Pro Gly Glu Glu Gly Asn
 405 410 415
 Ile Ala Ile Arg Ile Lys Leu Asn Gln Pro Ala Ser Leu Tyr Cys Pro
 420 425 430
 His Met Val Ser Trp Glu Glu Tyr Ala Ser Ala Arg Gly His Met Leu
 435 440 445
 Tyr Leu Thr Gly Asp Arg Gly Ile Met Asp Glu Asp Gly Tyr Phe Trp
 450 455 460
 Trp Ser Gly Arg Val Asp Asp Val Ala Asn Ala Leu Gly Gln Arg Leu
 465 470 475 480

<210> 42

<211> 583

<212> PRT

<213> Homo sapiens

<400> 42

Met Leu Gly Arg Phe Gln Pro Phe Ser Leu Val Arg Ser Phe Arg Leu
 1 5 10 15
 Gly Phe Gly Ala Cys Cys Tyr Pro Asn Gln Lys Cys Ala Thr Gln Thr
 20 25 30
 Ile Arg Pro Pro Asp Ser Arg Cys Leu Val Gln Ala Val Ser Gln Asn
 35 40 45
 Phe Asn Phe Ala Lys Asp Val Leu Asp Gln Trp Ser Gln Leu Glu Lys
 50 55 60
 Asp Gly Leu Arg Gly Pro Tyr Pro Ala Leu Trp Lys Val Ser Ala Lys
 65 70 75 80
 Gly Glu Glu Asp Lys Trp Ser Phe Glu Arg Met Thr Gln Leu Ser Lys
 85 90 95
 Lys Ala Ala Ser Ile Leu Ser Asp Thr Cys Ala Leu Ser His Gly Asp
 100 105 110
 Arg Leu Met Ile Ile Leu Pro Pro Thr Pro Glu Ala Tyr Trp Ile Cys
 115 120 125
 Leu Ala Cys Val Arg Leu Gly Ile Thr Phe Val Pro Gly Ser Pro Gln
 130 135 140
 Leu Thr Ala Lys Lys Ile Arg Tyr Gln Leu Arg Met Ser Lys Ala Gln
 145 150 155 160
 Cys Ile Val Ala Asn Glu Ala Met Ala Pro Val Val Asn Ser Ala Val
 165 170 175
 Ser Asp Cys Pro Thr Leu Lys Thr Lys Leu Leu Val Ser Asp Lys Ser
 180 185 190
 Tyr Asp Gly Trp Leu Asp Phe Lys Lys Leu Ile Gln Val Ala Pro Pro
 195 200 205
 Lys Gln Thr Tyr Met Arg Thr Lys Ser Gln Asp Pro Met Ala Ile Phe
 210 215 220
 Phe Thr Lys Gly Thr Thr Gly Ala Pro Lys Met Val Glu Tyr Ser Gln
 225 230 235 240
 Tyr Gly Leu Gly Met Gly Phe Ser Gln Ala Ser Arg Arg Trp Met Asp
 245 250 255
 Leu Gln Pro Thr Asp Val Leu Trp Ser Leu Gly Asp Ala Phe Gly
 260 265 270
 Ser Leu Ser Leu Ser Ala Val Leu Gly Thr Trp Phe Gln Gly Ala Cys
 275 280 285
 Val Phe Leu Cys His Met Pro Thr Phe Cys Pro Glu Thr Val Leu Asn
 290 295 300
 Val Leu Ser Arg Phe Pro Ile Thr Thr Leu Ser Ala Asn Pro Glu Met
 305 310 315 320
 Tyr Gln Glu Leu Leu Gln His Lys Cys Phe Thr Ser Tyr Arg Phe Lys
 325 330 335
 Ser Leu Lys Gln Cys Val Ala Ala Gly Gly Pro Ile Ser Pro Gly Val
 340 345 350
 Ile Glu Asp Trp Lys Arg Ile Thr Lys Leu Asp Ile Tyr Glu Gly Tyr
 355 360 365
 Gly Gln Thr Glu Thr Gly Leu Leu Cys Ala Thr Ser Lys Thr Ile Lys
 370 375 380
 Leu Lys Pro Ser Ser Leu Gly Lys Pro Leu Pro Pro Tyr Ile Val Gln
 385 390 395 400
 Ile Val Asp Glu Asn Ser Asn Leu Leu Pro Pro Gly Glu Glu Gly Asn
 405 410 415
 Ile Ala Ile Arg Ile Lys Leu Asn Gln Pro Ala Ser Leu Tyr Cys Pro
 420 425 430
 His Met Val Ser Trp Glu Glu Tyr Ala Ser Ala Arg Gly His Met Leu
 435 440 445
 Tyr Leu Thr Gly Asp Arg Gly Ile Met Asp Glu Asp Gly Tyr Phe Trp
 450 455 460
 Trp Ser Gly Arg Val Asp Asp Val Ala Asn Ala Leu Gly Gln Arg Phe

465	470	475	480
Ser Arg Pro Gly Ala Ala Ala Ala Ala Ser Ala Val Gly Ala Pro Pro			
485	490	495	
Gly Gly Trp His Ser Leu Cys Ala Ser Val Pro Ile Leu Gln Val Val			
500	505	510	
Lys Pro Pro Asn Val Leu Thr Pro Gln Phe Leu Ser His Asp Gln Gly			
515	520	525	
Gln Leu Thr Lys Glu Leu Gln Gln His Ile Lys Ser Val Thr Gly Pro			
530	535	540	
Cys Lys Tyr Gln Arg Lys Val Glu Phe Val Pro Glu Leu Pro Lys Thr			
545	550	555	560
Val Thr Gly Lys Ile Lys Arg Glu Leu Gln Val Trp Ser Asp Val Val			
565	570	575	
Ser Ser Glu Leu Arg Asn Asp			
580			

<210> 43
 <211> 581
 <212> PRT
 <213> Homo sapiens

<400> 43			
Met Pro Leu Lys His Tyr Leu Leu Leu Leu Val Gly Cys Gln Ala Trp			
1	5	10	15
Gly Ala Gly Leu Ala Tyr His Gly Cys Pro Ser Glu Cys Thr Cys Ser			
20	25	30	
Arg Ala Ser Gln Val Glu Cys Thr Gly Ala Arg Ile Val Ala Val Pro			
35	40	45	
Thr Pro Leu Pro Trp Asn Ala Met Ser Leu Gln Ile Leu Asn Thr His			
50	55	60	
Ile Thr Glu Leu Asn Glu Ser Pro Phe Leu Asn Ile Ser Ala Leu Ile			
65	70	75	80
Ala Leu Arg Ile Glu Lys Asn Glu Leu Ser Arg Ile Thr Pro Gly Ala			
85	90	95	
Phe Arg Asn Leu Gly Ser Leu Arg Tyr Leu Ser Leu Ala Asn Asn Lys			
100	105	110	
Leu Gln Val Leu Pro Ile Gly Leu Phe Gln Gly Leu Asp Ser Leu Glu			
115	120	125	
Ser Leu Leu Leu Ser Ser Asn Gln Leu Leu Gln Ile Gln Pro Ala His			
130	135	140	
Phe Ser Gln Cys Ser Asn Leu Lys Glu Leu Gln Leu His Gly Asn His			
145	150	155	160
Leu Glu Tyr Ile Pro Asp Gly Ala Phe Asp His Leu Val Gly Leu Thr			
165	170	175	
Lys Leu Asn Leu Gly Lys Asn Ser Leu Thr His Ile Ser Pro Arg Val			
180	185	190	
Phe Gln His Leu Gly Asn Leu Gln Val Leu Arg Leu Tyr Glu Asn Arg			
195	200	205	
Leu Thr Asp Ile Pro Met Gly Thr Phe Asp Gly Leu Val Asn Leu Gln			
210	215	220	
Glu Leu Ala Leu Gln Gln Asn Gln Ile Gly Leu Leu Ser Pro Gly Leu			
225	230	235	240
Phe His Asn Asn His Asn Leu Gln Arg Leu Tyr Leu Ser Asn Asn His			
245	250	255	
Ile Ser Gln Leu Pro Pro Ser Ile Phe Met Gln Leu Pro Gln Leu Asn			
260	265	270	
Arg Leu Thr Leu Phe Gly Asn Ser Leu Lys Glu Leu Ser Leu Gly Ile			
275	280	285	
Phe Gly Pro Met Pro Asn Leu Arg Glu Leu Trp Leu Tyr Asp Asn His			

290	295	300
Ile Ser Ser Leu Pro Asp Asn Val Phe Ser Asn Leu Arg Gln Leu Gln		
305	310	315
Val Leu Ile Leu Ser Arg Asn Gln Ile Ser Phe Ile Ser Pro Gly Ala		320
325	330	335
Phe Asn Gly Leu Thr Glu Leu Arg Glu Leu Ser Leu His Thr Asn Ala		
340	345	350
Leu Gln Asp Leu Asp Gly Asn Val Phe Arg Met Leu Ala Asn Leu Gln		
355	360	365
Asn Ile Ser Leu Gln Asn Asn Arg Leu Arg Gln Leu Pro Gly Asn Ile		
370	375	380
Phe Ala Asn Val Asn Gly Leu Met Ala Ile Gln Leu Gln Asn Asn Gln		
385	390	395
Leu Glu Asn Leu Pro Leu Gly Ile Phe Asp His Leu Gly Lys Leu Cys		400
405	410	415
Glu Leu Arg Leu Tyr Asp Asn Pro Trp Arg Cys Asp Ser Asp Ile Leu		
420	425	430
Pro Leu Arg Asn Trp Leu Leu Leu Asn Gln Pro Arg Leu Gly Thr Asp		
435	440	445
Thr Val Pro Val Cys Phe Ser Pro Ala Asn Val Arg Gly Gln Ser Leu		
450	455	460
Ile Ile Ile Asn Val Asn Val Ala Val Pro Ser Val His Val Pro Glu		
465	470	475
Val Pro Ser Tyr Pro Glu Thr Pro Trp Tyr Pro Asp Thr Pro Ser Tyr		
485	490	495
Pro Asp Thr Thr Ser Val Ser Ser Thr Thr Glu Leu Thr Ser Pro Val		
500	505	510
Glu Asp Tyr Thr Asp Leu Thr Thr Ile Gln Val Thr Asp Asp Arg Ser		
515	520	525
Val Trp Gly Met Thr His Ala His Ser Gly Leu Ala Ile Ala Ala Ile		
530	535	540
Val Ile Gly Ile Val Ala Leu Ala Cys Ser Leu Ala Ala Cys Val Gly		
545	550	555
Cys Cys Cys Lys Lys Arg Ser Gln Ala Val Leu Met Gln Met Lys		560
565	570	575
Ala Pro Asn Glu Cys		
580		

<210> 44
 <211> 628
 <212> PRT
 <213> Homo sapiens

<400> 44		
Met Pro Gly Ala Pro Asp Trp Ser Leu Asn Ser Ser Arg Asn Ala Arg		
1	5	10
Ser Leu Glu Gly Leu Pro Leu Cys Pro Trp Trp Ala Leu Phe Val Pro		
20	25	30
Arg Ala Ala Ala Leu Val Gly Leu Gln Arg Lys Gln Glu Asn Ser Ser		
35	40	45
Asp Ile Phe Phe Ser Ser Pro Phe Thr Val Thr Pro Asp Ala Leu Pro		
50	55	60
Thr Ala Ile Thr Trp Glu His Ile Pro Phe Ala Lys Leu Ala Gly Leu		
65	70	75
Ile Ala Gly Pro Leu Val Glu Met Cys Arg Gln Arg Leu Ser Lys Glu		80
85	90	95
Phe Glu Ala Leu Lys Gly Glu Phe Arg Asp Leu Gly His Cys Leu Pro		
100	105	110
Gly Ala Gln Arg Gly Asn Arg Ile Thr Lys Arg Asn Lys Cys Gly Gln		

115	120	125
Ser Arg Gln Ala Leu Ile Gly Gln Arg Gln Glu Asp Ala Gly Ser Ala		
130	135	140
Pro Leu Gln Met His Pro Ser Val Ala Ala Leu Gly Ala Gly Ala Ala		
145	150	155
Leu Arg Glu Ile Gln Pro Leu Gln Arg Glu Pro Glu Leu Ser Ser Gly		160
165	170	175
Pro Arg Asn Ser Arg Leu Leu Cys Trp Gly Ser Pro Ala Thr Trp Asn		
180	185	190
Pro Thr Tyr Leu Ser Arg Val Leu Gly Gln Gln Val Ala Val Thr Val		
195	200	205
Thr Glu Ala Gly Leu Gln Ala Val Pro Trp Gly Pro Ser Arg Glu Phe		
210	215	220
Asn Ala Lys Gly Ser Ser Ala Ser Ile Arg Val Gly Gln Pro Gln		
225	230	235
Lys Leu Arg Leu Arg Val Gln Arg Ser Arg Arg Gln Cys Pro Pro Val		240
245	250	255
Gln Ser Ser Gln Asp Leu Pro Pro Gly Gly Ser Gln Asp Gly Asp Leu		
260	265	270
Lys Glu Pro Thr Glu Arg Val Thr Arg Asp Leu Ser Ser Gly Ala Pro		
275	280	285
Arg Gly Arg Asn Leu Pro Ala Pro Asp Gln Pro Gln Pro Pro Leu Gln		
290	295	300
Arg Gly Thr Arg Leu Arg Leu Arg Gln Arg Arg Arg Arg Leu Leu Ile		
305	310	315
Lys Lys Met Pro Ala Ala Ala Thr Ile Pro Ala Asn Ser Ser Asp Ala		320
325	330	335
Pro Phe Ile Arg Pro Gly Pro Gly Thr Leu Asp Gly Arg Trp Val Ser		
340	345	350
Leu His Arg Ser Gln Gln Glu Arg Lys Arg Val Met Gln Glu Ala Cys		
355	360	365
Ala Lys Tyr Arg Ala Ser Ser Arg Arg Ala Val Thr Pro Arg His		
370	375	380
Val Ser Arg Ile Phe Val Glu Asp Arg His Arg Val Leu Tyr Cys Glu		
385	390	395
Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Val Leu Met Val Leu		400
405	410	415
Ala Gly Leu Ala Ser Ser Thr Ala Asp Ile Gln His Asn Thr Val His		
420	425	430
Tyr Gly Ser Ala Leu Lys Arg Leu Asp Thr Phe Asp Arg Gln Gly Ile		
435	440	445
Leu His Arg Leu Ser Thr Tyr Thr Lys Met Leu Phe Val Arg Glu Pro		
450	455	460
Phe Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe Glu His Pro Asn		
465	470	475
Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Leu Ala Arg Tyr Arg		480
485	490	495
Ala Asn Ala Ser Arg Glu Ala Leu Arg Thr Gly Ser Gly Val Arg Phe		
500	505	510
Pro Glu Phe Val Gln Tyr Leu Leu Asp Val His Arg Pro Val Gly Met		
515	520	525
Asp Ile His Trp Asp His Val Ser Arg Leu Cys Ser Pro Cys Leu Ile		
530	535	540
Asp Tyr Asp Phe Val Gly Lys Phe Glu Ser Met Glu Asp Asp Ala Asn		
545	550	555
Phe Phe Leu Ser Leu Ile Arg Ala Pro Arg Asn Leu Thr Phe Pro Arg		560
565	570	575
Phe Lys Asp Arg His Ser Gln Glu Ala Arg Thr Thr Ala Arg Ile Ala		
580	585	590

His Gln Tyr Phe Ala Gln Leu Ser Ala Leu Gln Arg Gln Arg Thr Tyr
 595 600 605
 Asp Phe Tyr Tyr Met Asp Tyr Leu Met Phe Asn Tyr Ser Lys Pro Phe
 610 615 620
 Ala Asp Leu Tyr
 625

<210> 45
 <211> 424
 <212> PRT
 <213> Homo sapiens

<400> 45
 Met Thr Leu Arg Pro Gly Thr Met Arg Leu Ala Cys Met Phe Ser Ser
 1 5 10 15
 Ile Leu Leu Phe Gly Ala Ala Gly Leu Leu Leu Phe Ile Ser Leu Gln
 20 25 30
 Asp Pro Thr Glu Leu Ala Pro Gln Gln Val Pro Gly Ile Lys Phe Asn
 35 40 45
 Ile Arg Pro Arg Gln Pro His His Asp Leu Pro Pro Gly Gly Ser Gln
 50 55 60
 Asp Gly Asp Leu Lys Glu Pro Thr Glu Arg Val Thr Arg Asp Leu Ser
 65 70 75 80
 Ser Gly Ala Pro Arg Gly Arg Asn Leu Pro Ala Pro Asp Gln Pro Gln
 85 90 95
 Pro Pro Leu Gln Arg Gly Thr Arg Leu Arg Leu Arg Gln Arg Arg Arg
 100 105 110
 Arg Leu Leu Ile Lys Lys Met Pro Ala Ala Ala Thr Ile Pro Ala Asn
 115 120 125
 Ser Ser Asp Ala Pro Phe Ile Arg Pro Gly Pro Gly Thr Leu Asp Gly
 130 135 140
 Arg Trp Val Ser Leu His Arg Ser Gln Gln Glu Arg Lys Arg Val Met
 145 150 155 160
 Gln Glu Ala Cys Ala Lys Tyr Arg Ala Ser Ser Ser Arg Arg Ala Val
 165 170 175
 Thr Pro Arg His Val Ser Arg Ile Phe Val Glu Asp Arg His Arg Val
 180 185 190
 Leu Tyr Cys Glu Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Val
 195 200 205
 Leu Met Val Leu Ala Gly Leu Ala Ser Ser Thr Ala Asp Ile Gln His
 210 215 220
 Asn Thr Val His Tyr Gly Ser Ala Leu Lys Arg Leu Asp Thr Phe Asp
 225 230 235 240
 Arg Gln Gly Ile Leu His Arg Leu Ser Thr Tyr Thr Lys Met Leu Phe
 245 250 255
 Val Arg Glu Pro Phe Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe
 260 265 270
 Glu His Pro Asn Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Leu
 275 280 285
 Ala Arg Tyr Arg Ala Asn Ala Ser Arg Glu Ala Leu Arg Thr Gly Ser
 290 295 300
 Gly Val Arg Phe Pro Glu Phe Val Gln Tyr Leu Leu Asp Val His Arg
 305 310 315 320
 Pro Val Gly Met Asp Ile His Trp Asp His Val Ser Arg Leu Cys Ser
 325 330 335
 Pro Cys Leu Ile Asp Tyr Asp Phe Val Gly Lys Phe Glu Ser Met Glu
 340 345 350
 Asp Asp Ala Asn Phe Phe Leu Ser Leu Ile Arg Ala Pro Arg Asn Leu
 355 360 365

Thr Phe Pro Arg Phe Lys Asp Arg His Ser Gln Glu Ala Arg Thr Thr
 370 375 380
 Ala Arg Ile Ala His Gln Tyr Phe Ala Gln Leu Ser Ala Leu Gln Arg
 385 390 395 400
 Gln Arg Thr Tyr Asp Phe Tyr Tyr Met Asp Tyr Leu Met Phe Asn Tyr
 405 410 415
 Ser Lys Pro Phe Ala Asp Leu Tyr
 420

<210> 46
 <211> 638
 <212> PRT
 <213> Homo sapiens

<400> 46
 Met Ala Gly Gly Ser Ala Thr Thr Trp Gly Tyr Pro Val Ala Leu Leu
 1 5 10 15
 Leu Leu Val Ala Thr Leu Gly Leu Gly Arg Trp Leu Gln Pro Asp Pro
 20 25 30
 Gly Leu Pro Gly Leu Arg His Ser Tyr Asp Cys Gly Ile Lys Gly Met
 35 40 45
 Gln Leu Leu Val Phe Pro Arg Pro Gly Gln Thr Leu Arg Phe Lys Val
 50 55 60
 Val Asp Glu Phe Gly Asn Arg Phe Asp Val Asn Asn Cys Ser Ile Cys
 65 70 75 80
 Tyr His Trp Val Thr Ser Arg Pro Gln Glu Pro Ala Val Phe Ser Ala
 85 90 95
 Asp Tyr Arg Gly Cys His Val Leu Glu Lys Asp Gly Arg Phe His Leu
 100 105 110
 Arg Val Phe Met Glu Ala Val Leu Pro Asn Gly Arg Val Asp Val Ala
 115 120 125
 Gln Asp Ala Thr Leu Ile Cys Pro Lys Pro Asp Pro Ser Arg Thr Leu
 130 135 140
 Asp Ser Gln Leu Ala Pro Pro Ala Met Phe Ser Val Ser Thr Pro Gln
 145 150 155 160
 Thr Leu Ser Phe Leu Pro Thr Ser Gly His Thr Ser Gln Gly Ser Gly
 165 170 175
 His Ala Phe Pro Ser Pro Leu Asp Pro Gly His Ser Ser Val His Pro
 180 185 190
 Thr Pro Ala Leu Pro Ser Pro Gly Pro Gly Pro Thr Leu Ala Thr Leu
 195 200 205
 Ala Gln Pro His Trp Gly Thr Leu Glu His Trp Asp Val Asn Lys Arg
 210 215 220
 Asp Tyr Ile Gly Thr His Leu Ser Gln Glu Gln Cys Gln Val Ala Ser
 225 230 235 240
 Gly His Leu Pro Cys Ile Val Arg Arg Thr Ser Lys Glu Ala Cys Gln
 245 250 255
 Gln Ala Gly Cys Cys Tyr Asp Asn Thr Arg Glu Val Pro Cys Tyr Tyr
 260 265 270
 Gly Asn Thr Ala Thr Val Gln Cys Phe Arg Asp Gly Tyr Phe Val Leu
 275 280 285
 Val Val Ser Gln Glu Met Ala Leu Thr His Arg Ile Thr Leu Ala Asn
 290 295 300
 Ile His Leu Ala Tyr Ala Pro Thr Ser Cys Ser Pro Thr Gln His Thr
 305 310 315 320
 Glu Ala Phe Val Val Phe Tyr Phe Pro Leu Thr His Cys Gly Thr Thr
 325 330 335
 Met Gln Val Ala Gly Asp Gln Leu Ile Tyr Glu Asn Trp Leu Val Ser
 340 345 350

Gly Ile His Ile Gln Lys Gly Pro Gln Gly Ser Ile Thr Arg Asp Ser
 355 360 365
 Thr Phe Gln Leu His Val Arg Cys Val Phe Asn Ala Ser Asp Phe Leu
 370 375 380
 Pro Ile Gln Ala Ser Ile Phe Pro Pro Pro Ser Pro Ala Pro Met Thr
 385 390 395 400
 Gln Pro Gly Pro Leu Arg Leu Glu Leu Arg Ile Ala Lys Asp Glu Thr
 405 410 415
 Phe Ser Ser Tyr Tyr Gly Glu Asp Asp Tyr Pro Ile Val Arg Leu Leu
 420 425 430
 Arg Glu Pro Val His Val Glu Val Arg Leu Leu Gln Arg Thr Asp Pro
 435 440 445
 Asn Leu Val Leu Leu His Gln Cys Trp Gly Ala Pro Ser Ala Asn
 450 455 460
 Pro Phe Gln Gln Pro Gln Trp Pro Ile Leu Ser Asp Gly Cys Pro Phe
 465 470 475 480
 Lys Gly Asp Ser Tyr Arg Thr Gln Met Val Ala Leu Asp Gly Ala Thr
 485 490 495
 Pro Phe Gln Ser His Tyr Gln Arg Phe Thr Val Ala Thr Phe Ala Leu
 500 505 510
 Leu Asp Ser Gly Ser Gln Arg Ala Leu Arg Gly Leu Val Tyr Leu Phe
 515 520 525
 Cys Ser Thr Ser Ala Cys His Thr Ser Gly Leu Glu Thr Cys Ser Thr
 530 535 540
 Ala Cys Ser Thr Gly Thr Arg Gln Arg Arg Ser Ser Gly His Arg
 545 550 555 560
 Asn Asp Thr Ala Arg Pro Gln Asp Ile Val Ser Ser Pro Gly Pro Val
 565 570 575
 Gly Phe Glu Asp Ser Tyr Gly Gln Glu Pro Thr Leu Gly Pro Thr Asp
 580 585 590
 Ser Asn Gly Asn Ser Ser Leu Arg Pro Leu Leu Trp Ala Val Leu Leu
 595 600 605
 Leu Pro Ala Val Ala Leu Val Leu Gly Phe Gly Val Phe Val Gly Leu
 610 615 620
 Ser Gln Thr Trp Ala Gln Lys Leu Trp Glu Ser Asn Arg Gln
 625 630 635

<210> 47
 <211> 229
 <212> PRT
 <213> Homo sapiens

<400> 47

Met Lys Pro Leu Ala Gln Leu Leu Leu Phe Leu Leu Gln Phe Gln Lys
 1 5 10 15
 Gly Asn Leu Val Ser Gln Ser Ser Ser Thr Pro Leu Met Val Asn Gly
 20 25 30
 Val Leu Gly Glu Ser Val Thr Leu Pro Leu Glu Phe Pro Ala Gly Glu
 35 40 45
 Arg Ile Gln Phe Ile Thr Trp Leu Cys Asn Gly Thr Ser Phe Ala Phe
 50 55 60
 Leu Glu Pro Tyr Glu Gly Lys Ser Pro Lys Ile Tyr Val Thr His Pro
 65 70 75 80
 Lys Trp Gln Lys Arg Leu Ser Phe Thr Gln Ser Tyr Ser Pro Gln Leu
 85 90 95
 Ser Asn Leu Glu Met Glu Asn Ile Gly Phe Tyr Ser Ala Gln Ile Ala
 100 105 110
 Thr Glu Thr Ser Ala Lys Leu Ser Ser Tyr Thr Leu Arg Ile Phe Lys
 115 120 125

Gln Leu Pro Arg Pro Gln Val Arg Val Asp Ser Ile Ile Ser Glu Asn
 130 135 140
 Gly Ile Cys Asn Ala Ile Leu Arg Cys Ser Val Glu Glu Gly Gly Glu
 145 150 155 160
 Thr Ile Thr Tyr Glu Trp Thr Ser Met Gly Pro Gly Ala Ala Val Ser
 165 170 175
 His Val Gly Leu His Asp Leu Asp Trp Ile Tyr Thr Cys Thr Ala Leu
 180 185 190
 Asn Pro Val Ser Tyr Ser Asn Ser Thr Leu Thr Leu Ala Ala Gln Leu
 195 200 205
 Cys Ala Ser Lys Ser Pro Leu Leu Val Ser Leu Ala Pro Leu Gly Asn
 210 215 220
 Val Leu Ser Gly Leu
 225

<210> 48
 <211> 310
 <212> PRT
 <213> Homo sapiens

<400> 48

Met Lys Pro Leu Ala Gln Leu Leu Leu Phe Leu Leu Gln Phe Gln Lys
 1 5 10 15
 Gly Asn Leu Val Ser Gln Ser Ser Ser Thr Pro Leu Met Val Asn Gly
 20 25 30
 Val Leu Gly Glu Ser Val Thr Leu Pro Leu Glu Phe Pro Ala Gly Glu
 35 40 45
 Arg Ile Gln Phe Ile Thr Trp Leu Cys Asn Gly Thr Ser Phe Ala Phe
 50 55 60
 Leu Glu Pro Tyr Glu Gly Lys Ser Pro Lys Ile Tyr Val Thr His Pro
 65 70 75 80
 Lys Trp Gln Lys Arg Leu Ser Phe Thr Gln Ser Tyr Ser Pro Gln Leu
 85 90 95
 Ser Asn Leu Glu Met Glu Asn Ile Gly Phe Tyr Ser Ala Gln Ile Ala
 100 105 110
 Thr Glu Thr Ser Ala Lys Leu Ser Ser Tyr Thr Leu Arg Ile Phe Lys
 115 120 125
 Gln Leu Pro Arg Pro Gln Val Arg Val Asp Ser Ile Ile Ser Glu Asn
 130 135 140
 Gly Ile Cys Asn Ala Ile Leu Arg Cys Ser Val Glu Glu Gly Gly Glu
 145 150 155 160
 Thr Ile Thr Tyr Glu Trp Thr Ser Met Gly Pro Gly Ala Ala Val Ser
 165 170 175
 His Val Gly Leu His Asp Leu Asp Trp Ile Tyr Thr Cys Thr Ala Leu
 180 185 190
 Asn Pro Val Ser Tyr Ser Asn Ser Thr Leu Thr Leu Ala Ala Gln Leu
 195 200 205
 Cys Ala Ser Ser Lys Ala Ala Glu Gly Thr Tyr Cys Pro Val Lys Trp
 210 215 220
 Ile Phe Leu Gly Asn Arg Leu Leu Leu Val Phe Leu Gly Val Leu
 225 230 235 240
 Arg Thr Trp His Ile Gln Ala Gln Val Leu Ser Lys Pro Leu Arg Pro
 245 250 255
 Asn Ser Gly Glu Leu Val Asn Leu Ser Ser Ile Pro Tyr Pro Trp Glu
 260 265 270
 Pro Ser His Thr Ala Asp Ala Thr Trp Leu Gly Lys Trp Gly Gly Ser
 275 280 285
 Glu Gly Glu Arg Lys Ser Thr Trp Asn Ile Ser Thr Thr Lys Arg His
 290 295 300

Trp Lys Ser Phe Tyr Lys
305 310

<210> 49
<211> 841
<212> PRT
<213> Homo sapiens

<400> 49
Met Lys Leu Trp Ile His Leu Phe Tyr Ser Ser Leu Leu Ala Cys Ile
1 5 10 15
Ser Leu His Ser Gln Thr Pro Val Leu Ser Ser Arg Gly Ser Cys Asp
20 25 30
Ser Leu Cys Asn Cys Glu Glu Lys Asp Gly Thr Met Leu Ile Asn Cys
35 40 45
Glu Ala Lys Gly Ile Lys Met Val Ser Glu Ile Ser Val Pro Pro Ser
50 55 60
Arg Pro Phe Gln Leu Ser Leu Leu Asn Asn Gly Leu Thr Met Leu His
65 70 75 80
Thr Asn Asp Phe Ser Gly Leu Thr Asn Ala Ile Ser Ile His Leu Gly
85 90 95
Phe Asn Asn Ile Ala Asp Ile Glu Ile Gly Ala Phe Asn Gly Leu Gly
100 105 110
Leu Leu Lys Gln Leu His Ile Asn His Asn Ser Leu Glu Ile Leu Lys
115 120 125
Glu Asp Thr Phe His Gly Leu Glu Asn Leu Glu Phe Leu Gln Ala Asp
130 135 140
Asn Asn Phe Ile Thr Val Ile Glu Pro Ser Ala Phe Ser Lys Leu Asn
145 150 155 160
Arg Leu Lys Val Leu Ile Leu Asn Asp Asn Ala Ile Glu Ser Leu Pro
165 170 175
Pro Asn Ile Phe Arg Phe Val Pro Leu Thr His Leu Asp Leu Arg Gly
180 185 190
Asn Gln Leu Gln Thr Leu Pro Tyr Val Gly Phe Leu Glu His Ile Gly
195 200 205
Arg Ile Leu Asp Leu Gln Leu Glu Asp Asn Lys Trp Ala Cys Asn Cys
210 215 220
Asp Leu Leu Gln Leu Lys Thr Trp Leu Glu Asn Met Pro Pro Gln Ser
225 230 235 240
Ile Ile Gly Asp Val Val Cys Asn Ser Pro Pro Phe Phe Lys Gly Ser
245 250 255
Ile Leu Ser Arg Leu Lys Lys Glu Ser Ile Cys Pro Thr Pro Pro Val
260 265 270
Tyr Glu Glu His Glu Asp Pro Ser Gly Ser Leu His Leu Ala Ala Thr
275 280 285
Ser Ser Ile Asn Asp Ser Arg Met Ser Thr Lys Thr Thr Ser Ile Leu
290 295 300
Lys Leu Pro Thr Lys Ala Pro Gly Leu Ile Pro Tyr Ile Thr Lys Pro
305 310 315 320
Ser Thr Gln Leu Pro Gly Pro Tyr Cys Pro Ile Pro Cys Asn Cys Lys
325 330 335
Val Leu Ser Pro Ser Gly Leu Leu Ile His Cys Gln Glu Arg Asn Ile
340 345 350
Glu Ser Leu Ser Asp Leu Arg Pro Pro Pro Gln Asn Pro Arg Lys Leu
355 360 365
Ile Leu Ala Gly Asn Ile Ile His Ser Leu Met Lys Ser Asp Leu Val
370 375 380
Glu Tyr Phe Thr Leu Glu Met Leu His Leu Gly Asn Asn Arg Ile Glu
385 390 395 400

Val Leu Glu Glu Gly Ser Phe Met Asn Leu Thr Arg Leu Gln Lys Leu
 405 410 415
 Tyr Leu Asn Gly Asn His Leu Thr Lys Leu Ser Lys Gly Met Phe Leu
 420 425 430
 Gly Leu His Asn Leu Glu Tyr Leu Tyr Leu Glu Tyr Asn Ala Ile Lys
 435 440 445
 Glu Ile Leu Pro Gly Thr Phe Asn Pro Met Pro Lys Leu Lys Val Leu
 450 455 460
 Tyr Leu Asn Asn Asn Leu Leu Gln Val Leu Pro Pro His Ile Phe Ser
 465 470 475 480
 Gly Val Pro Leu Thr Lys Val Asn Leu Lys Thr Asn Gln Phe Thr His
 485 490 495
 Leu Pro Val Ser Asn Ile Leu Asp Asp Leu Asp Leu Leu Thr Gln Ile
 500 505 510
 Asp Leu Glu Asp Asn Pro Trp Asp Cys Ser Cys Asp Leu Val Gly Leu
 515 520 525
 Gln Gln Trp Ile Gln Lys Leu Ser Lys Asn Thr Val Thr Asp Asp Ile
 530 535 540
 Leu Cys Thr Ser Pro Gly His Leu Asp Lys Lys Glu Leu Lys Ala Leu
 545 550 555 560
 Asn Ser Glu Ile Leu Cys Pro Gly Leu Val Asn Asn Pro Ser Met Pro
 565 570 575
 Thr Gln Thr Ser Tyr Leu Met Val Thr Thr Pro Ala Thr Thr Thr Asn
 580 585 590
 Thr Ala Asp Thr Ile Leu Arg Ser Leu Thr Asp Ala Val Pro Leu Ser
 595 600 605
 Val Leu Ile Leu Gly Leu Leu Ile Met Phe Ile Thr Ile Val Phe Cys
 610 615 620
 Ala Ala Gly Ile Val Val Leu Val Leu His Arg Arg Arg Arg Tyr Lys
 625 630 635 640
 Lys Lys Gln Val Asp Glu Gln Met Arg Asp Asn Ser Pro Val His Leu
 645 650 655
 Gln Tyr Ser Met Tyr Gly His Lys Thr Thr His His Thr Thr Glu Arg
 660 665 670
 Pro Ser Ala Ser Leu Tyr Glu Gln His Met Val Ser Pro Met Val His
 675 680 685
 Val Tyr Arg Ser Pro Ser Phe Gly Pro Lys His Leu Glu Glu Glu
 690 695 700
 Glu Arg Asn Glu Lys Glu Gly Ser Asp Ala Lys His Leu Gln Arg Ser
 705 710 715 720
 Leu Leu Glu Gln Glu Asn His Ser Pro Leu Thr Gly Ser Asn Met Lys
 725 730 735
 Tyr Lys Thr Thr Asn Gln Ser Thr Glu Phe Leu Ser Phe Gln Asp Ala
 740 745 750
 Ser Ser Leu Tyr Arg Asn Ile Leu Glu Lys Glu Arg Glu Leu Gln Gln
 755 760 765
 Leu Gly Ile Thr Glu Tyr Leu Arg Lys Asn Ile Ala Gln Leu Gln Pro
 770 775 780
 Asp Met Glu Ala His Tyr Pro Gly Ala His Glu Glu Leu Lys Leu Met
 785 790 795 800
 Glu Thr Leu Met Tyr Ser Arg Pro Arg Lys Val Leu Val Glu Gln Thr
 805 810 815
 Lys Asn Glu Tyr Phe Glu Leu Lys Ala Asn Leu His Ala Glu Pro Asp
 820 825 830
 Tyr Leu Glu Val Leu Glu Gln Gln Thr
 835 840

<210> 50
 <211> 241

<212> PRT
 <213> Homo sapiens

<400> 50
 Met Gly Asn Pro Gly Leu Ala Trp Leu Val Leu Leu Gly Leu Val Leu
 1 5 10 15
 Leu Leu Ser Ser Phe Met Glu Arg Gly Gly His Ser Pro Ser Pro Ala
 20 25 30
 Ala Leu Ser Ala Met Glu Asn Leu Ile Thr Tyr Ala Val Gln Lys Gly
 35 40 45
 His Leu Ser Ser Ser Tyr Val Gln Pro Leu Leu Val Lys Gly Glu Asn
 50 55 60
 Cys Leu Ala Pro Arg Gln Lys Thr Ser Leu Lys Lys Ala Cys Pro Gly
 65 70 75 80
 Val Val Pro Arg Ser Val Trp Gly Ala Arg Glu Thr His Cys Pro Arg
 85 90 95
 Met Thr Leu Pro Ala Lys Tyr Gly Ile Ile His Thr Ala Gly Arg
 100 105 110
 Thr Cys Asn Ile Ser Asp Glu Cys Arg Leu Leu Val Arg Asp Ile Gln
 115 120 125
 Ser Phe Tyr Ile Asp Arg Leu Lys Ser Cys Asp Ile Gly Tyr Asn Phe
 130 135 140
 Leu Val Gly Gln Asp Gly Ala Ile Tyr Glu Gly Val Gly Trp Asn Val
 145 150 155 160
 Gln Gly Ser Ser Thr Pro Gly Tyr Asp Asp Ile Ala Leu Gly Ile Thr
 165 170 175
 Phe Met Gly Thr Phe Thr Gly Ile Pro Pro Asn Ala Ala Leu Glu
 180 185 190
 Ala Ala Gln Asp Leu Ile Gln Cys Ala Met Val Lys Gly Tyr Leu Thr
 195 200 205
 Pro Asn Tyr Leu Leu Val Gly His Ser Asp Val Ala Arg Thr Leu Ser
 210 215 220
 Pro Gly Gln Ala Leu Tyr Asn Ile Ile Ser Thr Trp Pro His Phe Lys
 225 230 235 240
 His

<210> 51
 <211> 369
 <212> PRT
 <213> Homo sapiens

<400> 51
 Met Leu Pro Trp Leu Leu Val Phe Ser Ala Leu Gly Leu Gln Ala Trp
 1 5 10 15
 Gly Asp Ser Ser Trp Asn Lys Thr Gln Ala Lys Gln Val Ser Glu Gly
 20 25 30
 Leu Gln Tyr Leu Phe Glu Asn Ile Ser Gln Leu Thr Glu Lys Asp Val
 35 40 45
 Ser Thr Thr Val Ser Arg Lys Ala Trp Gly Ala Glu Ala Val Gly Cys
 50 55 60
 Ser Ile Gln Leu Thr Thr Pro Val Asn Val Leu Val Ile His His Val
 65 70 75 80
 Pro Gly Leu Glu Cys His Asp Arg Thr Val Cys Ser Gln Arg Leu Arg
 85 90 95
 Glu Leu Gln Ala His His Val His Asn Asn Ser Gly Cys Asp Val Ala
 100 105 110
 Tyr Asn Phe Leu Val Gly Asp Asp Gly Arg Val Tyr Glu Gly Val Gly
 115 120 125

Trp Asn Ile Gln Gly Val His Thr Gln Gly Tyr Asn Asn Ile Ser Leu
 130 135 140
 Gly Phe Ala Phe Phe Gly Thr Lys Lys Gly His Ser Pro Ser Pro Ala
 145 150 155 160
 Ala Leu Ser Ala Met Glu Asn Leu Ile Thr Tyr Ala Val Gln Lys Gly
 165 170 175
 His Leu Ser Ser Ser Tyr Val Gln Pro Leu Leu Val Lys Gly Glu Asn
 180 185 190
 Cys Leu Ala Pro Arg Gln Lys Thr Ser Leu Lys Lys Ala Cys Pro Gly
 195 200 205
 Val Val Pro Arg Ser Val Trp Gly Ala Arg Glu Thr His Cys Pro Arg
 210 215 220
 Met Thr Leu Pro Ala Lys Tyr Gly Ile Ile His Thr Ala Gly Arg
 225 230 235 240
 Thr Cys Asn Ile Ser Asp Glu Cys Arg Leu Leu Val Arg Asp Ile Gln
 245 250 255
 Ser Phe Tyr Ile Asp Arg Leu Lys Ser Cys Asp Ile Gly Tyr Asn Phe
 260 265 270
 Leu Val Gly Gln Asp Gly Ala Ile Tyr Glu Gly Val Gly Trp Asn Val
 275 280 285
 Gln Gly Ser Ser Thr Pro Gly Tyr Asp Asp Ile Ala Leu Gly Ile Thr
 290 295 300
 Phe Met Gly Thr Phe Thr Gly Ile Pro Pro Asn Ala Ala Leu Glu
 305 310 315 320
 Ala Ala Gln Asp Leu Ile Gln Cys Ala Met Val Lys Gly Tyr Leu Thr
 325 330 335
 Pro Asn Tyr Leu Leu Val Gly His Ser Asp Val Ala Arg Thr Leu Ser
 340 345 350
 Pro Gly Gln Ala Leu Tyr Asn Ile Ile Ser Thr Trp Pro His Phe Lys
 355 360 365
 His

<210> 52
 <211> 382
 <212> PRT
 <213> Homo sapiens

<400> 52

Met Ala Pro Arg Ala Gly Gln Pro Gly Leu Gln Gly Leu Leu Leu Val
 1 5 10 15
 Ala Ala Ala Leu Ser Gln Pro Ala Ala Pro Cys Pro Phe Gln Cys Tyr
 20 25 30
 Cys Phe Gly Gly Pro Lys Leu Leu Leu Arg Cys Ala Ser Gly Ala Glu
 35 40 45
 Leu Arg Gln Pro Pro Arg Asp Val Pro Pro Asp Ala Arg Asn Leu Thr
 50 55 60
 Ile Val Gly Ala Asn Leu Thr Val Leu Arg Ala Ala Ala Phe Ala Gly
 65 70 75 80
 Gly Asp Gly Asp Gly Asp Gln Ala Ala Gly Val Arg Leu Pro Leu Leu
 85 90 95
 Ser Ala Leu Arg Leu Thr His Asn His Ile Glu Val Val Glu Asp Gly
 100 105 110
 Ala Phe Asp Gly Leu Pro Ser Leu Ala Ala Leu Asp Leu Ser His Asn
 115 120 125
 Pro Leu Arg Ala Leu Gly Gly Ala Phe Arg Gly Leu Pro Ala Leu
 130 135 140
 Arg Ser Leu Gln Leu Asn His Ala Leu Val Arg Gly Gly Pro Ala Leu
 145 150 155 160

Leu Ala Ala Leu Asp Ala Ala Leu Ala Pro Leu Ala Glu Leu Arg Leu
 165 170 175
 Leu Gly Leu Ala Gly Asn Ala Leu Ser Arg Leu Pro Pro Ala Ala Leu
 180 185 190
 Arg Leu Ala Arg Leu Glu Gln Leu Asp Val Arg Leu Asn Ala Leu Ala
 195 200 205
 Gly Leu Asp Pro Asp Glu Leu Arg Ala Leu Glu Arg Asp Gly Gly Leu
 210 215 220
 Pro Gly Pro Arg Leu Leu Ala Asp Asn Pro Leu Arg Cys Gly Cys
 225 230 235 240
 Ala Ala Arg Pro Leu Leu Ala Trp Leu Arg Asn Ala Thr Glu Arg Val
 245 250 255
 Pro Asp Ser Arg Arg Leu Arg Cys Ala Ala Pro Arg Ala Leu Leu Asp
 260 265 270
 Arg Pro Leu Leu Asp Leu Asp Gly Ala Arg Leu Arg Cys Ala Asp Ser
 275 280 285
 Gly Ala Asp Ala Arg Gly Glu Glu Ala Glu Ala Ala Gly Pro Glu Leu
 290 295 300
 Glu Ala Ser Tyr Val Phe Phe Gly Leu Val Leu Ala Leu Ile Gly Leu
 305 310 315 320
 Ile Phe Leu Met Val Leu Tyr Leu Asn Arg Arg Gly Ile Gln Arg Trp
 325 330 335
 Met Arg Asn Leu Arg Glu Ala Cys Arg Asp Gln Met Glu Gly Tyr His
 340 345 350
 Tyr Arg Tyr Glu Gln Asp Ala Asp Pro Arg Arg Ala Pro Ala Pro Ala
 355 360 365
 Ala Pro Ala Gly Ser Arg Ala Thr Ser Pro Gly Ser Gly Leu
 370 375 380

<210> 53
 <211> 185
 <212> PRT
 <213> Homo sapiens

<400> 53

Met Met Leu Leu Leu Cys Leu Gly Leu Thr Leu Val Cys Ala Gln
 1 5 10 15
 Glu Glu Glu Asn Asn Asp Ala Val Thr Ser Asn Phe Asp Leu Ser Lys
 20 25 30
 Ile Ser Gly Glu Trp Tyr Ser Val Leu Leu Ala Ser Asp Cys Arg Glu
 35 40 45
 Lys Ile Glu Glu Asp Gly Ser Met Arg Val Phe Val Lys His Ile Asp
 50 55 60
 Tyr Leu Gly Asn Ser Ser Leu Thr Phe Lys Leu His Glu Ile Glu Asn
 65 70 75 80
 Gly Asn Cys Thr Glu Ile Asn Leu Ala Cys Lys Pro Thr Glu Lys Asn
 85 90 95
 Ala Ile Cys Ser Thr Asp Tyr Asn Gly Leu Asn Val Ile Asp Ile Leu
 100 105 110
 Glu Thr Asp Tyr Asp Asn Tyr Ile Tyr Phe Tyr Asn Lys Asn Ile Lys
 115 120 125
 Asn Gly Glu Thr Phe Leu Met Leu Glu Leu Tyr Val Arg Thr Pro Asp
 130 135 140
 Val Ser Ser Gln Leu Lys Glu Arg Phe Val Lys Tyr Cys Glu Glu His
 145 150 155 160
 Gly Ile Asp Lys Glu Asn Ile Phe Asp Leu Thr Lys Val Asp Arg Cys
 165 170 175
 Leu Gln Ala Arg Asp Glu Gly Ala Ala
 180 185

<210> 54
 <211> 586
 <212> PRT
 <213> Homo sapiens

<400> 54
 Met His Tyr Asn Leu Gln Gly Pro Thr Arg Arg Ile Arg Ile Ser Leu
 1 5 10 15
 Leu Asn Asp Gly Gly Leu Lys Ile Ala Asn Val Thr Lys Ala Asp Ala
 20 25 30
 Gly Thr Tyr Thr Cys Met Ala Glu Asn Gln Phe Gly Lys Ala Asn Gly
 35 40 45
 Thr Thr His Leu Val Val Thr Glu Pro Thr Arg Ile Thr Leu Ala Pro
 50 55 60
 Ser Asn Met Asp Val Ser Val Gly Glu Ser Val Ile Leu Pro Cys Gln
 65 70 75 80
 Val Gln His Asp Pro Leu Leu Asp Ile Ile Phe Thr Trp Tyr Phe Asn
 85 90 95
 Gly Ala Leu Ala Asp Phe Lys Lys Asp Gly Ser His Phe Glu Lys Val
 100 105 110
 Gly Gly Ser Ser Ser Gly Asp Leu Met Ile Arg Asn Ile Gln Leu Lys
 115 120 125
 His Ser Gly Lys Tyr Val Cys Met Val Gln Thr Gly Val Asp Ser Val
 130 135 140
 Ser Ser Ala Ala Asp Leu Ile Val Arg Gly Ser Pro Gly Pro Pro Glu
 145 150 155 160
 Asn Val Lys Val Asp Glu Ile Thr Asp Thr Thr Ala Gln Leu Ser Trp
 165 170 175
 Lys Glu Gly Lys Asp Asn His Ser Pro Val Ile Ser Tyr Ser Ile Gln
 180 185 190
 Ala Arg Thr Pro Phe Ser Val Gly Trp Gln Thr Val Thr Thr Val Pro
 195 200 205
 Glu Val Ile Asp Gly Lys Thr His Thr Ala Thr Val Val Glu Leu Asn
 210 215 220
 Pro Trp Val Glu Tyr Glu Phe Arg Val Val Ala Ser Asn Lys Ile Gly
 225 230 235 240
 Gly Gly Glu Pro Ser Leu Pro Ser Glu Lys Val Arg Thr Glu Glu Ala
 245 250 255
 Val Pro Glu Val Pro Pro Ser Glu Val Asn Gly Gly Gly Ser Arg
 260 265 270
 Ser Glu Leu Val Ile Thr Trp Asp Pro Val Pro Glu Glu Leu Gln Asn
 275 280 285
 Gly Glu Gly Phe Gly Tyr Val Val Ala Phe Arg Pro Leu Gly Val Thr
 290 295 300
 Thr Trp Ile Gln Thr Val Val Thr Ser Pro Asp Thr Pro Arg Tyr Val
 305 310 315 320
 Phe Arg Asn Glu Ser Ile Val Pro Tyr Ser Pro Tyr Glu Val Lys Val
 325 330 335
 Gly Val Tyr Asn Asn Lys Gly Glu Gly Pro Phe Ser Pro Val Thr Thr
 340 345 350
 Val Phe Ser Ala Glu Glu Glu Pro Thr Val Ala Pro Ser Gln Val Ser
 355 360 365
 Ala Asn Ser Leu Ser Ser Ser Glu Ile Glu Val Ser Trp Asn Thr Ile
 370 375 380
 Pro Trp Lys Leu Ser Asn Gly His Leu Leu Gly Tyr Glu Val Arg Tyr
 385 390 395 400
 Trp Asn Gly Gly Lys Glu Glu Ser Ser Ser Lys Met Lys Val Ala
 405 410 415

Gly Asn Glu Thr Ser Ala Arg Leu Arg Gly Leu Lys Ser Asn Leu Ala
 420 425 430
 Tyr Tyr Thr Ala Val Arg Ala Tyr Asn Ser Ala Gly Ala Gly Pro Phe
 435 440 445
 Ser Ala Thr Val Asn Val Thr Thr Lys Lys Thr Pro Pro Ser Gln Pro
 450 455 460
 Pro Gly Asn Val Val Trp Asn Ala Thr Asp Thr Lys Val Leu Leu Asn
 465 470 475 480
 Trp Glu Gln Val Lys Ala Met Glu Asn Glu Ser Glu Val Thr Gly Tyr
 485 490 495
 Lys Val Phe Tyr Arg Thr Ser Ser Gln Asn Asn Val Gln Val Leu Asn
 500 505 510
 Thr Asn Lys Thr Ser Ala Glu Leu Val Leu Pro Ile Lys Glu Asp Tyr
 515 520 525
 Ile Ile Glu Val Lys Ala Thr Thr Asp Gly Gly Asp Gly Thr Ser Ser
 530 535 540
 Glu Gln Ile Arg Ile Pro Arg Ile Thr Ser Met Asp Ala Arg Gly Ser
 545 550 555 560
 Thr Ser Ala Ile Ser Asn Val His Pro Met Ser Ser Tyr Met Pro Ile
 565 570 575
 Val Leu Phe Leu Ile Val Tyr Val Leu Trp
 580 585

<210> 55
 <211> 1026
 <212> PRT
 <213> Homo sapiens

<400> 55
 Met Leu Val Val Glu Arg Val Met Val Leu Pro Ile Gly Phe Pro Leu
 1 5 10 15
 Gly Val Ser Asp Asp Ser Thr Leu His Gly Pro Ile Phe Ile Gln Glu
 20 25 30
 Pro Ser Pro Val Met Phe Pro Leu Asp Ser Glu Glu Lys Lys Val Lys
 35 40 45
 Leu Asn Cys Glu Val Lys Gly Asn Pro Lys Pro His Ile Arg Trp Lys
 50 55 60
 Leu Asn Gly Thr Asp Val Asp Thr Gly Met Asp Phe Arg Tyr Ser Val
 65 70 75 80
 Val Glu Gly Ser Leu Leu Ile Asn Asn Pro Asn Lys Thr Gln Asp Ala
 85 90 95
 Gly Thr Tyr Gln Cys Thr Ala Thr Asn Ser Phe Gly Thr Ile Val Ser
 100 105 110
 Arg Glu Ala Lys Leu Gln Phe Ala Tyr Leu Asp Asn Phe Lys Thr Arg
 115 120 125
 Thr Arg Ser Thr Val Ser Val Arg Arg Gly Gln Gly Met Val Leu Leu
 130 135 140
 Cys Gly Pro Pro Pro His Ser Gly Glu Leu Ser Tyr Ala Trp Ile Phe
 145 150 155 160
 Asn Glu Tyr Pro Ser Tyr Gln Asp Asn Arg Arg Phe Val Ser Gln Glu
 165 170 175
 Thr Gly Asn Leu Tyr Ile Ala Lys Val Glu Lys Ser Asp Val Gly Asn
 180 185 190
 Tyr Thr Cys Val Val Thr Asn Thr Val Thr Asn His Lys Val Leu Gly
 195 200 205
 Pro Pro Thr Pro Leu Ile Leu Arg Asn Asp Gly Val Met Gly Glu Tyr
 210 215 220
 Glu Pro Lys Ile Glu Val Gln Phe Pro Glu Thr Val Pro Thr Ala Lys
 225 230 235 240

Gly Ala Thr Val Lys Leu Glu Cys Phe Ala Leu Gly Asn Pro Val Pro
 245 250 255
 Thr Ile Ile Trp Arg Arg Ala Asp Gly Lys Pro Ile Ala Arg Lys Ala
 260 265 270
 Arg Arg His Lys Ser Asn Gly Ile Leu Glu Ile Pro Asn Phe Gln Gln
 275 280 285
 Glu Asp Ala Gly Leu Tyr Glu Cys Val Ala Glu Asn Ser Arg Gly Lys
 290 295 300
 Asn Val Ala Arg Gly Gln Leu Thr Phe Tyr Ala Gln Pro Asn Trp Ile
 305 310 315 320
 Gln Lys Ile Asn Asp Ile His Val Ala Met Glu Glu Asn Val Phe Trp
 325 330 335
 Glu Cys Lys Ala Asn Gly Arg Pro Lys Pro Thr Tyr Lys Trp Leu Lys
 340 345 350
 Asn Gly Glu Pro Leu Leu Thr Arg Asp Arg Ile Gln Ile Glu Gln Gly
 355 360 365
 Thr Leu Asn Ile Thr Ile Val Asn Leu Ser Asp Ala Gly Met Tyr Gln
 370 375 380
 Cys Leu Ala Glu Asn Lys His Gly Val Ile Phe Ser Asn Ala Glu Leu
 385 390 395 400
 Ser Val Ile Ala Val Gly Pro Asp Phe Ser Arg Thr Leu Leu Lys Arg
 405 410 415
 Val Thr Leu Val Lys Val Gly Glu Val Val Ile Glu Cys Lys Pro
 420 425 430
 Lys Ala Ser Pro Lys Pro Val Tyr Thr Trp Lys Lys Gly Arg Asp Ile
 435 440 445
 Leu Lys Glu Asn Glu Arg Ile Thr Ile Ser Glu Asp Gly Asn Leu Arg
 450 455 460
 Ile Ile Asn Val Thr Lys Ser Asp Ala Gly Ser Tyr Thr Cys Ile Ala
 465 470 475 480
 Thr Asn His Phe Gly Thr Ala Ser Ser Thr Gly Asn Leu Val Val Lys
 485 490 495
 Asp Pro Thr Arg Val Met Val Pro Pro Ser Ser Met Asp Val Thr Val
 500 505 510
 Gly Glu Ser Ile Val Leu Pro Cys Gln Val Thr His Asp His Ser Leu
 515 520 525
 Asp Ile Val Phe Thr Trp Ser Phe Asn Gly His Leu Ile Asp Phe Asp
 530 535 540
 Arg Asp Gly Asp His Phe Glu Arg Val Gly Gly Asp Ser Ala Gly Asp
 545 550 555 560
 Leu Met Ile Arg Asn Ile Gln Leu Lys His Ala Gly Lys Tyr Val Cys
 565 570 575
 Met Val Gln Thr Ser Val Asp Arg Leu Ser Ala Ala Ala Asp Leu Ile
 580 585 590
 Val Arg Gly Pro Pro Gly Pro Pro Glu Ala Val Thr Ile Asp Glu Ile
 595 600 605
 Thr Asp Thr Thr Ala Gln Leu Ser Trp Arg Pro Gly Pro Asp Asn His
 610 615 620
 Ser Pro Ile Thr Met Tyr Val Ile Gln Ala Arg Thr Pro Phe Ser Val
 625 630 635 640
 Gly Trp Gln Ala Val Ser Thr Val Pro Glu Leu Ile Asp Gly Lys Thr
 645 650 655
 Phe Thr Ala Thr Val Val Gly Leu Asn Pro Trp Val Glu Tyr Glu Phe
 660 665 670
 Arg Thr Val Ala Ala Asn Val Ile Gly Ile Gly Glu Pro Ser Arg Pro
 675 680 685
 Ser Glu Lys Arg Arg Thr Glu Glu Ala Leu Pro Glu Val Thr Pro Ala
 690 695 700
 Asn Val Ser Gly Gly Ser Lys Ser Glu Leu Val Ile Thr Trp

705	710	715	720												
Glu	Thr	Val	Pro	Glu	Glu	Leu	Gln	Asn	Gly	Arg	Gly	Phe	Gly	Tyr	Val
				725				730							735
Val	Ala	Phe	Arg	Pro	Tyr	Gly	Lys	Met	Ile	Trp	Met	Leu	Thr	Val	Leu
				740				745				750			
Ala	Ser	Ala	Asp	Ala	Ser	Arg	Tyr	Val	Phe	Arg	Asn	Glu	Ser	Val	His
				755				760				765			
Pro	Phe	Ser	Pro	Phe	Glu	Val	Lys	Val	Gly	Val	Phe	Asn	Asn	Lys	Gly
				770				775				780			
Glu	Gly	Pro	Phe	Ser	Pro	Thr	Thr	Val	Val	Tyr	Ser	Ala	Glu	Glu	
				785				790				795			800
Pro	Thr	Lys	Pro	Pro	Ala	Ser	Ile	Phe	Ala	Arg	Ser	Leu	Ser	Ala	Thr
				805				810				815			
Asp	Ile	Glu	Val	Phe	Trp	Ala	Ser	Pro	Leu	Glu	Lys	Asn	Arg	Gly	Arg
				820				825				830			
Ile	Gln	Gly	Tyr	Glu	Val	Lys	Tyr	Trp	Arg	His	Glu	Asp	Lys	Glu	Glu
				835				840				845			
Asn	Ala	Arg	Lys	Ile	Arg	Thr	Val	Gly	Asn	Gln	Thr	Ser	Thr	Lys	Ile
				850				855				860			
Thr	Asn	Leu	Lys	Gly	Ser	Val	Leu	Tyr	His	Leu	Ala	Val	Lys	Ala	Tyr
				865				870				875			880
Asn	Ser	Ala	Gly	Thr	Gly	Pro	Ser	Ser	Ala	Thr	Val	Asn	Val	Thr	Thr
				885				890				895			
Arg	Lys	Pro	Pro	Ser	Gln	Pro	Pro	Gly	Asn	Ile	Ile	Trp	Asn	Ser	
				900				905				910			
Ser	Asp	Ser	Lys	Ile	Ile	Leu	Asn	Trp	Asp	Gln	Val	Lys	Ala	Leu	Asp
				915				920				925			
Asn	Glu	Ser	Glu	Val	Lys	Gly	Tyr	Lys	Val	Leu	Tyr	Arg	Trp	Asn	Arg
				930				935				940			
Gln	Ser	Ser	Thr	Ser	Val	Ile	Glu	Thr	Asn	Lys	Thr	Ser	Val	Glu	Leu
				945				950				955			960
Ser	Leu	Pro	Phe	Asp	Glu	Asp	Tyr	Ile	Ile	Glu	Ile	Lys	Pro	Phe	Ser
				965				970				975			
Asp	Gly	Gly	Asp	Gly	Ser	Ser	Ser	Glu	Gln	Ile	Arg	Ile	Pro	Lys	Ile
				980				985				990			
Ser	Asn	Ala	Tyr	Ala	Arg	Gly	Ser	Gly	Ala	Ser	Thr	Ser	Asn	Ala	Cys
				995				1000				1005			
Thr	Leu	Ser	Ala	Ile	Ser	Thr	Ile	Met	Ile	Ser	Leu	Thr	Ala	Arg	Ser
				1010				1015				1020			
Ser	Leu														
	1025														

<210> 56
 <211> 844
 <212> PRT
 <213> Homo sapiens

<400>	56														
Met	Asp	Asn	Pro	Gln	Ala	Leu	Pro	Leu	Phe	Leu	Leu	Ala	Ser	Leu	
1				5				10				15			
Val	Gly	Ile	Leu	Thr	Leu	Arg	Ala	Ser	Ser	Gly	Leu	Gln	Gln	Thr	Asn
				20				25				30			
Phe	Ser	Ser	Ala	Phe	Ser	Ser	Asp	Ser	Lys	Ser	Ser	Ser	Gln	Gly	Leu
				35				40				45			
Gly	Val	Glu	Val	Pro	Ser	Ile	Lys	Pro	Pro	Ser	Trp	Lys	Val	Pro	Asp
				50				55				60			
Gln	Phe	Leu	Asp	Ser	Lys	Ala	Ser	Ala	Gly	Ile	Ser	Asp	Ser	Ser	Trp
				65				70				75			80
Phe	Pro	Glu	Ala	Leu	Ser	Ser	Asn	Met	Ser	Gly	Ser	Phe	Trp	Ser	Asn

Val	Ser	Ala	Glu	Gly	Gln	Asp	Leu	Ser	Pro	Val	Ser	Pro	Phe	Ser	Glu
100								105						110	
Thr	Pro	Gly	Ser	Glu	Val	Phe	Pro	Asp	Ile	Ser	Asp	Pro	Gln	Val	Pro
115								120					125		
Ala	Lys	Asp	Pro	Lys	Pro	Ser	Phe	Thr	Val	Lys	Thr	Pro	Ala	Ser	Asn
130						135				140					
Ile	Ser	Thr	Gln	Val	Ser	His	Thr	Lys	Leu	Ser	Val	Glu	Ala	Pro	Asp
145						150				155			160		
Ser	Lys	Phe	Ser	Pro	Asp	Asp	Met	Asp	Leu	Lys	Leu	Ser	Ala	Gln	Ser
165									170				175		
Pro	Glu	Ser	Lys	Phe	Ser	Ala	Glu	Thr	His	Ser	Ala	Ala	Ser	Phe	Pro
180							185				190				
Gln	Gln	Val	Gly	Gly	Pro	Leu	Ala	Val	Leu	Val	Gly	Thr	Thr	Ile	Arg
195						200				205					
Leu	Pro	Leu	Val	Pro	Ile	Pro	Asn	Pro	Gly	Pro	Pro	Thr	Ser	Leu	Val
210						215				220					
Val	Trp	Arg	Arg	Gly	Ser	Lys	Val	Leu	Ala	Ala	Gly	Gly	Leu	Gly	Pro
225						230				235			240		
Gly	Ala	Pro	Leu	Ile	Ser	Leu	Asp	Pro	Ala	His	Arg	Asp	His	Leu	Arg
245							250				255				
Phe	Asp	Gln	Ala	Arg	Gly	Val	Leu	Glu	Leu	Ala	Ser	Ala	Gln	Leu	Asp
260						265				270					
Asp	Ala	Gly	Val	Tyr	Thr	Ala	Glu	Val	Ile	Arg	Ala	Gly	Val	Ser	Gln
275						280				285					
Gln	Thr	His	Glu	Phe	Thr	Val	Gly	Val	Tyr	Glu	Pro	Leu	Pro	Gln	Leu
290						295				300					
Ser	Val	Gln	Pro	Lys	Ala	Pro	Glu	Thr	Glu	Gly	Ala	Ala	Glu	Leu	
305						310				315			320		
Arg	Leu	Arg	Cys	Leu	Gly	Trp	Gly	Pro	Gly	Arg	Gly	Glu	Leu	Ser	Trp
325							330				335				
Ser	Arg	Asp	Gly	Arg	Ala	Leu	Glu	Ala	Ala	Glu	Ser	Glu	Gly	Ala	Glu
340							345				350				
Thr	Pro	Arg	Met	Arg	Ser	Glu	Gly	Asp	Gln	Leu	Leu	Ile	Val	Arg	Pro
355							360				365				
Val	Arg	Ser	Asp	His	Ala	Arg	Tyr	Thr	Cys	Arg	Val	Arg	Ser	Pro	Phe
370							375				380				
Gly	His	Arg	Glu	Ala	Ala	Ala	Asp	Val	Ser	Val	Phe	Tyr	Gly	Pro	Asp
385							390				395			400	
Pro	Pro	Thr	Ile	Thr	Val	Ser	Ser	Asp	Arg	Asp	Ala	Ala	Pro	Ala	Arg
405							410				415				
Phe	Val	Thr	Ala	Gly	Ser	Asn	Val	Thr	Leu	Arg	Cys	Ala	Ala	Ala	Ser
420							425				430				
Arg	Pro	Pro	Ala	Asp	Ile	Thr	Trp	Ser	Leu	Ala	Asp	Pro	Ala	Glu	Ala
435							440				445				
Ala	Val	Pro	Ala	Gly	Ser	Arg	Leu	Leu	Leu	Pro	Ala	Val	Gly	Pro	Gly
450							455				460				
His	Ala	Gly	Thr	Tyr	Ala	Cys	Leu	Ala	Ala	Asn	Pro	Arg	Thr	Gly	Arg
465							470				475			480	
Arg	Arg	Arg	Ser	Leu	Leu	Asn	Leu	Thr	Val	Ala	Asp	Leu	Pro	Pro	Gly
485							490				495				
Ala	Pro	Gln	Cys	Ser	Val	Glu	Gly	Gly	Pro	Gly	Asp	Arg	Ser	Leu	Arg
500							505				510				
Phe	Arg	Cys	Ser	Trp	Pro	Gly	Gly	Ala	Pro	Ala	Ala	Ser	Leu	Gln	Phe
515							520				525				
Gln	Gly	Leu	Pro	Glu	Gly	Ile	Arg	Ala	Gly	Pro	Val	Ser	Ser	Val	Leu
530							535				540				
Leu	Ala	Ala	Val	Pro	Ala	His	Pro	Arg	Leu	Ser	Gly	Val	Pro	Ile	Thr
545							550				555			560	

Cys Leu Ala Arg His Leu Val Ala Thr Arg Thr Cys Thr Val Thr Pro
 565 570 575
 Glu Ala Pro Arg Glu Val Leu Leu His Pro Leu Val Ala Glu Thr Arg
 580 585 590
 Leu Gly Ala Glu Val Ala Leu Glu Ala Ser Gly Cys Pro Pro Pro
 595 600 605
 Ser Arg Ala Ser Trp Ala Arg Glu Gly Arg Pro Leu Ala Pro Gly Gly
 610 615 620
 Gly Ser Arg Leu Arg Leu Ser Gln Asp Gly Arg Lys Leu His Ile Gly
 625 630 635 640
 Asn Phe Ser Leu Asp Trp Asp Leu Gly Asn Tyr Ser Val Leu Cys Ser
 645 650 655
 Gly Ala Leu Gly Ala Gly Asp Gln Ile Thr Leu Ile Asp Gly Pro
 660 665 670
 Ala Leu Gly Arg Thr Ser Thr Tyr Arg Asp Trp Val Ser Leu Leu Ile
 675 680 685
 Leu Gly Pro Gln Glu Arg Ser Ala Val Val Pro Leu Pro Pro Arg Asn
 690 695 700
 Pro Gly Thr Trp Thr Phe Arg Ile Leu Pro Ile Leu Gly Gly Gln Pro
 705 710 715 720
 Gly Thr Pro Ser Gln Ser Arg Val Tyr Arg Ala Gly Pro Thr Leu Ser
 725 730 735
 His Gly Ala Ile Ala Gly Ile Val Leu Gly Ser Leu Leu Gly Leu Ala
 740 745 750
 Leu Leu Ala Val Leu Leu Leu Cys Ile Cys Cys Leu Cys Arg Phe
 755 760 765
 Arg Gly Lys Thr Pro Glu Lys Lys Lys His Pro Ser Thr Leu Val Pro
 770 775 780
 Val Val Thr Pro Ser Glu Lys Lys Met His Ser Val Thr Pro Val Glu
 785 790 795 800
 Ile Ser Trp Pro Leu Asp Leu Lys Val Pro Leu Glu Asp His Ser Ser
 805 810 815
 Thr Arg Ala Tyr Gln Ala Thr Asp Pro Ser Ser Val Val Ser Val Gly
 820 825 830
 Gly Gly Ser Lys Thr Val Arg Ala Ala Thr Gln Val
 835 840

<210> 57
 <211> 782
 <212> PRT
 <213> Homo sapiens

<400> 57

Met Asp Asn Pro Gln Ala Leu Pro Leu Phe Leu Leu Leu Ala Ser Leu
 1 5 10 15
 Val Gly Ile Leu Thr Leu Arg Ala Ser Ser Gly Leu Gln Gln Thr Asn
 20 25 30
 Phe Ser Ser Ala Phe Ser Ser Asp Ser Lys Ser Ser Ser Gln Gly Leu
 35 40 45
 Gly Val Glu Val Pro Ser Ile Lys Pro Pro Ser Trp Lys Val Pro Asp
 50 55 60
 Gln Phe Leu Asp Ser Lys Ala Ser Ala Gly Ile Ser Asp Ser Ser Trp
 65 70 75 80
 Phe Pro Glu Ala Leu Ser Ser Asn Met Ser Gly Ser Phe Trp Ser Asn
 85 90 95
 Val Ser Ala Glu Gly Gln Asp Leu Ser Pro Val Ser Pro Phe Ser Glu
 100 105 110
 Thr Pro Gly Ser Glu Val Phe Pro Asp Ile Ser Asp Pro Gln Val Pro
 115 120 125

Ala Lys Asp Pro Lys Pro Ser Phe Thr Val Lys Thr Pro Ala Ser Asn
 130 135 140
 Ile Ser Thr Gln Val Ser His Thr Lys Leu Ser Val Glu Ala Pro Asp
 145 150 155 160
 Ser Lys Phe Ser Pro Asp Asp Met Asp Leu Lys Leu Ser Ala Gln Ser
 165 170 175
 Pro Glu Ser Lys Phe Ser Ala Glu Thr His Ser Ala Ala Ser Phe Pro
 180 185 190
 Gln Gln Val Gly Gly Pro Leu Ala Val Leu Val Gly Thr Thr Ile Arg
 195 200 205
 Leu Pro Leu Val Pro Ile Pro Asn Pro Gly Pro Pro Thr Ser Leu Val
 210 215 220
 Val Trp Arg Arg Gly Ser Lys Val Leu Ala Ala Gly Gly Leu Gly Pro
 225 230 235 240
 Gly Ala Pro Leu Ile Ser Leu Asp Pro Ala His Arg Asp His Leu Arg
 245 250 255
 Phe Asp Gln Ala Arg Gly Val Leu Glu Leu Ala Ser Ala Gln Leu Asp
 260 265 270
 Asp Ala Gly Val Tyr Thr Ala Glu Val Ile Arg Ala Gly Val Ser Gln
 275 280 285
 Gln Thr His Glu Phe Thr Val Gly Val Tyr Glu Pro Leu Pro Gln Leu
 290 295 300
 Ser Val Gln Pro Lys Ala Pro Glu Thr Glu Gly Ala Ala Glu Leu
 305 310 315 320
 Arg Leu Arg Cys Leu Gly Trp Gly Pro Gly Arg Gly Glu Leu Ser Trp
 325 330 335
 Ser Arg Asp Gly Arg Ala Leu Glu Ala Ala Glu Ser Glu Gly Ala Glu
 340 345 350
 Thr Pro Arg Met Arg Ser Glu Gly Asp Gln Leu Leu Ile Val Arg Pro
 355 360 365
 Val Arg Ser Asp His Ala Arg Tyr Thr Cys Arg Val Arg Ser Pro Phe
 370 375 380
 Gly His Arg Glu Ala Ala Ala Asp Val Ser Val Phe Tyr Gly Pro Asp
 385 390 395 400
 Pro Pro Thr Ile Thr Val Ser Ser Asp Arg Asp Ala Ala Pro Ala Arg
 405 410 415
 Phe Val Thr Ala Gly Ser Asn Val Thr Leu Arg Cys Ala Ala Ala Ser
 420 425 430
 Arg Pro Pro Ala Asp Ile Thr Trp Ser Leu Ala Asp Pro Ala Glu Ala
 435 440 445
 Ala Val Pro Ala Gly Ser Arg Leu Leu Leu Pro Ala Val Gly Pro Gly
 450 455 460
 His Ala Gly Thr Tyr Ala Cys Leu Ala Ala Asn Pro Arg Thr Gly Arg
 465 470 475 480
 Arg Arg Arg Ser Leu Leu Asn Leu Thr Val Ala Asp Leu Pro Pro Gly
 485 490 495
 Ala Pro Gln Cys Ser Val Glu Gly Gly Pro Gly Asp Arg Ser Leu Arg
 500 505 510
 Phe Arg Cys Ser Trp Pro Gly Gly Ala Pro Ala Ala Ser Leu Gln Phe
 515 520 525
 Gln Gly Leu Pro Glu Gly Ile Arg Ala Gly Pro Val Ser Ser Val Leu
 530 535 540
 Leu Ala Ala Val Pro Ala His Pro Arg Leu Ser Gly Val Pro Ile Thr
 545 550 555 560
 Cys Leu Ala Arg His Leu Val Ala Thr Arg Thr Cys Thr Val Thr Pro
 565 570 575
 Glu Ala Pro Arg Glu Val Leu Leu His Pro Leu Val Ala Glu Thr Arg
 580 585 590
 Leu Gly Glu Ala Glu Val Ala Leu Glu Ala Ser Gly Cys Pro Pro Pro

595	600	605
Ser Arg Ala Ser Trp Ala Arg Glu Gly Arg Pro Leu Ala Pro Gly Gly		
610	615	620
Gly Ser Arg Leu Arg Leu Ser Gln Asp Gly Arg Lys Leu His Ile Gly		
625	630	635
Asn Phe Ser Leu Asp Trp Asp Leu Gly Asn Tyr Ser Val Leu Cys Ser		
645	650	655
Gly Ala Leu Gly Ala Gly Asp Gln Ile Thr Leu Ile Gly Pro Thr		
660	665	670
Leu Ser His Gly Ala Ile Ala Gly Ile Val Leu Gly Ser Leu Leu Gly		
675	680	685
Leu Ala Leu Ala Val Leu Leu Leu Cys Ile Cys Cys Leu Cys		
690	695	700
Arg Phe Arg Gly Lys Thr Pro Glu Lys Lys His Pro Ser Thr Leu		
705	710	715
Val Pro Val Val Thr Pro Ser Glu Lys Lys Met His Ser Val Thr Pro		
725	730	735
Val Glu Ile Ser Trp Pro Leu Asp Leu Lys Val Pro Leu Glu Asp His		
740	745	750
Ser Ser Thr Arg Ala Tyr Gln Ala Thr Asp Pro Ser Ser Val Val Ser		
755	760	765
Val Gly Gly Ser Lys Thr Val Arg Ala Ala Thr Gln Val		
770	775	780

<210> 58

<211> 262

<212> PRT

<213> Homo sapiens

<400> 58

Met Asp Ser Leu Val Thr Ala Asn Thr Lys Phe Cys Phe Asp Leu Phe		
1	5	10
Gln Glu Ile Gly Lys Asp Asp Arg His Lys Asn Ile Phe Phe Ser Pro		
20	25	30
Leu Ser Leu Ser Ala Ala Leu Gly Met Val Arg Leu Gly Ala Arg Ser		
35	40	45
Asp Ser Ala His Gln Ile Asp Glu Ala Gly Ser Leu Asn Asn Glu Ser		
50	55	60
Gly Leu Val Ser Cys Tyr Phe Gly Gln Leu Leu Ser Lys Leu Asp Arg		
65	70	75
Ile Lys Thr Asp Tyr Thr Leu Ser Ile Ala Asn Arg Leu Tyr Gly Glu		
85	90	95
Gln Glu Phe Pro Ile Cys Gln Glu Tyr Leu Asp Gly Val Ile Gln Phe		
100	105	110
Tyr His Thr Thr Ile Glu Ser Val Asp Phe Gln Lys Asn Pro Glu Lys		
115	120	125
Ser Arg Gln Glu Ile Asn Phe Trp Val Glu Cys Gln Ser Gln Gly Lys		
130	135	140
Ile Lys Glu Leu Phe Ser Lys Asp Ala Ile Asn Ala Glu Thr Val Leu		
145	150	155
Val Leu Val Asn Ala Val Tyr Phe Lys Ala Lys Trp Glu Thr Tyr Phe		
165	170	175
Asp His Glu Asn Thr Val Asp Ala Pro Phe Cys Leu Asn Ala Asn Glu		
180	185	190
Asn Lys Ser Val Lys Met Met Thr Gln Lys Gly Leu Tyr Arg Ile Gly		
195	200	205
Phe Ile Glu Glu Val Lys Ala Gln Ile Leu Glu Met Arg Tyr Thr Lys		
210	215	220
Gly Lys Leu Ser Met Phe Val Leu Leu Pro Ser His Ser Lys Asp Asn		

225	230	235	240
Leu Lys Gly Leu Glu Glu Val Asn Leu His Phe His Ile Ser Thr Lys			
245	250		255
Tyr Leu Met Ile Asp Leu			
260			
<210> 59			
<211> 394			
<212> PRT			
<213> Homo sapiens			
<400> 59			
Met Asp Ser Leu Val Thr Ala Asn Thr Lys Phe Cys Phe Asp Leu Phe			
1 5 10 15			
Gln Glu Ile Gly Lys Asp Asp Arg His Lys Asn Ile Phe Phe Ser Pro			
20 25 30			
Leu Ser Leu Ser Ala Ala Leu Gly Met Val Arg Leu Gly Ala Arg Ser			
35 40 45			
Asp Ser Ala His Gln Ile Asp Glu Val Leu His Phe Asn Lys Thr Thr			
50 55 60			
Glu Pro Leu Asp Gln Gln Ala Gly Ser Leu Asn Asn Glu Ser Gly Leu			
65 70 75 80			
Val Ser Cys Tyr Phe Gly Gln Leu Leu Ser Lys Leu Asp Arg Ile Lys			
85 90 95			
Thr Asp Tyr Thr Leu Ser Ile Ala Asn Arg Leu Tyr Gly Glu Gln Glu			
100 105 110			
Phe Pro Ile Cys Gln Glu Tyr Leu Asp Gly Val Ile Gln Phe Tyr His			
115 120 125			
Thr Thr Ile Glu Ser Val Asp Phe Gln Lys Asn Pro Glu Lys Ser Arg			
130 135 140			
Gln Glu Ile Asn Phe Trp Val Glu Cys Gln Ser Gln Gly Lys Ile Lys			
145 150 155 160			
Glu Leu Phe Ser Lys Asp Ala Ile Asn Ala Glu Thr Val Leu Val Leu			
165 170 175			
Val Asn Ala Val Tyr Phe Lys Ala Lys Trp Glu Thr Tyr Phe Asp His			
180 185 190			
Glu Asn Thr Val Asp Ala Pro Phe Cys Leu Asn Ala Asn Glu Asn Lys			
195 200 205			
Ser Val Lys Met Met Thr Gln Lys Gly Leu Tyr Arg Ile Gly Phe Ile			
210 215 220			
Glu Glu Val Lys Ala Gln Ile Leu Glu Met Arg Tyr Thr Lys Gly Lys			
225 230 235 240			
Leu Ser Met Phe Val Leu Leu Pro Ser His Ser Lys Asp Asn Leu Lys			
245 250 255			
Gly Leu Glu Glu Leu Glu Arg Lys Ile Thr Tyr Glu Lys Met Val Ala			
260 265 270			
Trp Ser Ser Glu Asn Met Ser Glu Glu Ser Val Val Leu Ser Phe			
275 280 285			
Pro Arg Phe Thr Leu Glu Asp Ser Tyr Asp Leu Asn Ser Ile Leu Gln			
290 295 300			
Asp Met Gly Ile Thr Asp Ile Phe Asp Glu Thr Arg Ala Asp Leu Thr			
305 310 315 320			
Gly Ile Ser Pro Ser Pro Asn Leu Tyr Leu Ser Lys Ile Ile His Lys			
325 330 335			
Thr Phe Val Glu Val Asp Glu Asn Gly Thr Gln Ala Ala Ala Thr			
340 345 350			
Gly Ala Val Val Ser Glu Arg Ser Leu Arg Ser Trp Val Glu Phe Asn			
355 360 365			
Ala Asn His Pro Phe Leu Phe Phe Ile Arg His Asn Lys Thr Gln Thr			

370	375	380
Ile Leu Phe Tyr Gly Arg Val Cys Ser Pro		
385	390	
<210> 60		
<211> 471		
<212> PRT		
<213> Homo sapiens		
<400> 60		
Met Ser Val Pro Leu Leu Lys Ile Gly Val Val Leu Ser Thr Met Ala		
1	5	10
15		
Met Ile Thr Asn Trp Met Ser Gln Thr Leu Pro Ser Leu Val Gly Leu		
20	25	30
30		
Asn Thr Thr Lys Leu Ser Ala Ala Gly Gly Gly Thr Leu Asp Arg Ser		
35	40	45
45		
Thr Gly Val Leu Pro Thr Asn Pro Glu Glu Ser Trp Gln Val Tyr Ser		
50	55	60
60		
Ser Ala Gln Asp Ser Glu Gly Arg Cys Ile Cys Thr Val Val Ala Pro		
65	70	75
80		
Gln Gln Thr Met Cys Ser Arg Asp Ala Arg Thr Lys Gln Leu Arg Gln		
85	90	95
95		
Leu Leu Glu Lys Val Gln Asn Met Ser Gln Ser Ile Glu Val Leu Asp		
100	105	110
110		
Arg Arg Thr Gln Arg Asp Leu Gln Tyr Val Glu Lys Met Glu Asn Gln		
115	120	125
125		
Met Lys Gly Leu Glu Ser Lys Phe Lys Gln Ala Ile Lys Ala Lys Met		
130	135	140
140		
Asp Glu Leu Arg Pro Leu Ile Pro Val Leu Glu Glu Tyr Lys Ala Asp		
145	150	155
160		
Ala Lys Leu Val Leu Gln Phe Lys Glu Glu Val Gln Asn Leu Thr Ser		
165	170	175
175		
Val Leu Asn Glu Leu Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Asp Glu		
180	185	190
190		
Leu Gln Ser Arg Val Ser Asn Leu Glu Glu Arg Leu Arg Ala Cys Met		
195	200	205
205		
Gln Lys Leu Ala Cys Gly Lys Leu Thr Gly Ile Ser Asp Pro Val Thr		
210	215	220
220		
Val Lys Thr Ser Gly Ser Arg Phe Gly Ser Trp Met Thr Asp Pro Leu		
225	230	235
240		
Ala Pro Glu Gly Asp Asn Arg Val Trp Tyr Met Asp Gly Tyr His Asn		
245	250	255
255		
Asn Arg Phe Val Arg Glu Tyr Lys Ser Met Val Asp Phe Met Asn Thr		
260	265	270
270		
Asp Asn Phe Thr Ser His Arg Leu Pro His Pro Trp Ser Gly Thr Gly		
275	280	285
285		
Gln Val Val Tyr Asn Gly Ser Ile Tyr Phe Asn Lys Phe Gln Ser His		
290	295	300
300		
Ile Ile Ile Arg Phe Asp Leu Lys Thr Glu Thr Ile Leu Lys Thr Arg		
305	310	315
320		
Ser Leu Asp Tyr Ala Gly Tyr Asn Asn Met Tyr His Tyr Ala Trp Gly		
325	330	335
335		
Gly His Ser Asp Ile Asp Leu Met Val Asp Glu Ser Gly Leu Trp Ala		
340	345	350
350		
Val Tyr Ala Thr Asn Gln Asn Ala Gly Asn Ile Val Val Ser Arg Leu		
355	360	365
365		
Asp Pro Val Ser Leu Gln Thr Leu Gln Thr Trp Asn Thr Ser Tyr Pro		
370	375	380
380		
Lys Arg Ser Ala Gly Glu Ala Phe Ile Ile Cys Gly Thr Leu Tyr Val		

385	390	395	400
Thr Asn Gly Tyr Ser Gly Gly Thr Lys Val His Tyr Ala Tyr Gln Thr			
405	410	415	
Asn Ala Ser Thr Tyr Glu Tyr Ile Asp Ile Pro Phe Gln Asn Lys Tyr			
420	425	430	
Ser His Ile Ser Met Leu Asp Tyr Asn Pro Lys Asp Arg Ala Leu Tyr			
435	440	445	
Ala Trp Asn Asn Gly His Gln Ile Leu Tyr Asn Val Thr Leu Phe His			
450	455	460	
Val Ile Arg Ser Asp Glu Leu			
465	470		
<210> 61			
<211> 485			
<212> PRT			
<213> Homo sapiens			
<400> 61			
Met Ser Val Pro Leu Leu Lys Ile Gly Val Val Leu Ser Thr Met Ala			
1	5	10	15
Met Ile Thr Asn Trp Met Ser Gln Thr Leu Pro Ser Leu Val Gly Leu			
20	25	30	
Asn Thr Thr Lys Leu Ser Ala Ala Gly Gly Thr Leu Asp Arg Ser			
35	40	45	
Thr Gly Val Leu Pro Thr Asn Pro Glu Glu Ser Trp Gln Val Tyr Ser			
50	55	60	
Ser Ala Gln Asp Ser Glu Gly Arg Cys Ile Cys Thr Val Val Ala Pro			
65	70	75	80
Gln Gln Thr Met Cys Ser Arg Asp Ala Arg Thr Lys Gln Leu Arg Gln			
85	90	95	
Leu Leu Glu Lys Val Gln Asn Met Ser Gln Ser Ile Glu Val Leu Asp			
100	105	110	
Arg Arg Thr Gln Arg Asp Leu Gln Tyr Val Glu Lys Met Glu Asn Gln			
115	120	125	
Met Lys Gly Leu Glu Ser Lys Phe Lys Gln Val Glu Glu Ile Ile Ser			
130	135	140	
Tyr Thr Trp Pro Arg Gln Phe Lys Ala Ile Lys Ala Lys Met Asp Glu			
145	150	155	160
Leu Arg Pro Leu Ile Pro Val Leu Glu Glu Tyr Lys Ala Asp Ala Lys			
165	170	175	
Leu Val Leu Gln Phe Lys Glu Glu Val Gln Asn Leu Thr Ser Val Leu			
180	185	190	
Asn Glu Leu Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Asp Glu Leu Gln			
195	200	205	
Ser Arg Val Ser Asn Leu Glu Glu Arg Leu Arg Ala Cys Met Gln Lys			
210	215	220	
Leu Ala Cys Gly Lys Leu Thr Gly Ile Ser Asp Pro Val Thr Val Lys			
225	230	235	240
Thr Ser Gly Ser Arg Phe Gly Ser Trp Met Thr Asp Pro Leu Ala Pro			
245	250	255	
Glu Gly Asp Asn Arg Val Trp Tyr Met Asp Gly Tyr His Asn Asn Arg			
260	265	270	
Phe Val Arg Glu Tyr Lys Ser Met Val Asp Phe Met Asn Thr Asp Asn			
275	280	285	
Phe Thr Ser His Arg Leu Pro His Pro Trp Ser Gly Thr Gly Gln Val			
290	295	300	
Val Tyr Asn Gly Ser Ile Tyr Phe Asn Lys Phe Gln Ser His Ile Ile			
305	310	315	320
Ile Arg Phe Asp Leu Lys Thr Glu Thr Ile Leu Lys Thr Arg Ser Leu			

325	330	335
Asp Tyr Ala Gly Tyr Asn Asn Met	Tyr His	Tyr Ala Trp Gly Gly His
340	345	350
Ser Asp Ile Asp Leu Met Val Asp	Glu Ser Gly	Leu Trp Ala Val Tyr
355	360	365
Ala Thr Asn Gln Asn	Gly Asn Ile Val Val	Ser Arg Leu Asp Pro
370	375	380
Val Ser Leu Gln Thr Leu Gln Thr	Trp Asn Thr	Ser Tyr Pro Lys Arg
385	390	395
Ser Ala Gly Glu Ala Phe Ile Ile	Cys Gly Thr	Leu Tyr Val Thr Asn
405	410	415
Gly Tyr Ser Gly Gly Thr Lys Val	His Tyr Ala Tyr Gln Thr	Asn Ala
420	425	430
Ser Thr Tyr Glu Tyr Ile Asp Ile	Pro Phe Gln Asn Lys	Tyr Ser His
435	440	445
Ile Ser Met Leu Asp Tyr Asn Pro	Lys Asp Arg	Ala Leu Tyr Ala Trp
450	455	460
Asn Asn Gly His Gln Ile Leu Tyr	Asn Val Thr	Leu Phe His Val Ile
465	470	475
Arg Ser Asp Glu Leu		480
	485	

<210> 62
 <211> 286
 <212> PRT
 <213> Homo sapiens

<400> 62		
Met Leu His Leu Leu Ala Leu Phe Leu His	Cys Leu Pro Leu Ala Ser	
1	5	10
		15
Gly Asp Tyr Asp Ile Cys Lys Ser	Trp Val Thr Thr Asp Glu Gly Pro	
20	25	30
Thr Trp Glu Phe Tyr Ala Cys Gln Pro	Lys Val Met Arg Leu Lys Asp	
35	40	45
Tyr Val Lys Val Lys Val Glu Pro Ser	Gly Ile Thr Cys Gly Asp Pro	
50	55	60
Pro Glu Arg Phe Cys Ser His Glu Asn	Pro Tyr Leu Cys Ser Asn Glu	
65	70	75
		80
Cys Asp Ala Ser Asn Pro Asp Leu Ala	His Pro Pro Arg Leu Met Phe	
85	90	95
Asp Lys Glu Glu Glu Gly Leu Ala Thr	Tyr Trp Gln Ser Ile Thr Trp	
100	105	110
Ser Arg Tyr Pro Ser Pro Leu Glu Ala	Asn Ile Thr Leu Ser Trp Asn	
115	120	125
Lys Thr Val Glu Leu Thr Asp Asp Val	Val Met Thr Phe Glu Tyr Gly	
130	135	140
Arg Pro Thr Val Met Val Leu Glu Lys	Ser Leu Asp Asn Gly Arg Thr	
145	150	155
		160
Trp Gln Pro Tyr Gln Phe Tyr Ala Glu	Asp Cys Met Glu Ala Phe Gly	
165	170	175
Met Ser Ala Arg Arg Ala Arg Asp	Met Ser Ser Ser Ser Ala His Arg	
180	185	190
Val Leu Cys Thr Glu Glu Tyr Ser Arg	Trp Ala Gly Ser Lys Lys Glu	
195	200	205
Lys His Val Arg Phe Glu Val Arg Asp	Arg Phe Ala Ile Phe Ala Gly	
210	215	220
Pro Asp Leu Arg Asn Met Asp Asn Leu	Tyr Thr Arg Leu Glu Ser Ala	
225	230	235
		240
Lys Gly Leu Lys Glu Phe Phe Thr Leu	Asp Leu Arg Met Arg Leu	

245	250	255
Leu Arg Pro Ala Leu Gly Gly Thr Tyr Val Gln Arg Glu Asn Leu Tyr		
260	265	270
Lys Tyr Phe Tyr Ala Ile Ser Asn Ile Glu Val Ile Gly Arg		
275	280	285
<210> 63		
<211> 533		
<212> PRT		
<213> Homo sapiens		
<400> 63		
Met Leu His Leu Leu Ala Leu Phe Leu His Cys Leu Pro Leu Ala Ser		
1	5	10
Gly Asp Tyr Asp Ile Cys Lys Ser Trp Val Thr Thr Asp Glu Gly Pro		
20	25	30
Thr Trp Glu Phe Tyr Ala Cys Gln Pro Lys Val Met Arg Leu Lys Asp		
35	40	45
Tyr Val Lys Val Lys Val Glu Pro Ser Gly Ile Thr Cys Gly Asp Pro		
50	55	60
Pro Glu Arg Phe Cys Ser His Glu Asn Pro Tyr Leu Cys Ser Asn Glu		
65	70	75
Cys Asp Ala Ser Asn Pro Asp Leu Ala His Pro Pro Arg Leu Met Phe		
85	90	95
Asp Lys Glu Glu Glu Gly Leu Ala Thr Tyr Trp Gln Ser Ile Thr Trp		
100	105	110
Ser Arg Tyr Pro Ser Pro Leu Glu Ala Asn Ile Thr Leu Ser Trp Asn		
115	120	125
Lys Thr Val Glu Leu Thr Asp Asp Val Val Met Thr Phe Glu Tyr Gly		
130	135	140
Arg Pro Thr Val Met Val Leu Glu Lys Ser Leu Asp Asn Gly Arg Thr		
145	150	155
Trp Gln Pro Tyr Gln Phe Tyr Ala Glu Asp Cys Met Glu Ala Phe Gly		
165	170	175
Met Ser Ala Arg Arg Ala Arg Asp Met Ser Ser Ser Ala His Arg		
180	185	190
Val Leu Cys Thr Glu Glu Tyr Ser Arg Trp Ala Gly Ser Lys Lys Glu		
195	200	205
Lys His Val Arg Phe Glu Val Arg Asp Arg Phe Ala Ile Phe Ala Gly		
210	215	220
Pro Asp Leu Arg Asn Met Asp Asn Leu Tyr Thr Arg Leu Glu Ser Ala		
225	230	235
Lys Gly Leu Lys Glu Phe Phe Thr Leu Thr Asp Leu Arg Met Arg Leu		
245	250	255
Leu Arg Pro Ala Leu Gly Gly Thr Tyr Val Gln Arg Glu Asn Leu Tyr		
260	265	270
Lys Tyr Phe Tyr Ala Ile Ser Asn Ile Glu Val Ile Gly Arg Cys Lys		
275	280	285
Cys Asn Leu His Ala Asn Leu Cys Ser Met Arg Glu Gly Ser Leu Gln		
290	295	300
Cys Glu Cys Glu His Asn Thr Thr Gly Pro Asp Cys Gly Lys Cys Lys		
305	310	315
Lys Asn Phe Arg Thr Arg Ser Trp Arg Ala Gly Ser Tyr Leu Pro Leu		
325	330	335
Pro His Gly Ser Pro Asn Ala Cys Thr Pro Pro Ser Pro Arg Glu Leu		
340	345	350
Gly Ala Asp Cys Glu Cys Tyr Gly His Ser Asn Arg Cys Ser Tyr Ile		
355	360	365
Asp Phe Leu Asn Val Val Thr Cys Val Ser Cys Lys His Asn Thr Arg		

370	375	380
Gly Gln His Cys Gln His Cys Arg Leu Gly Tyr Tyr Arg Asn Gly Ser		
385	390	395
Ala Glu Leu Asp Asp Glu Asn Val Cys Ile Glu Cys Asn Cys Asn Gln		400
405	410	415
Ile Gly Ser Val His Asp Arg Cys Asn Glu Thr Gly Phe Cys Glu Cys		
420	425	430
Arg Glu Gly Ala Ala Gly Pro Lys Cys Asp Asp Cys Leu Pro Thr His		
435	440	445
Tyr Trp Arg Gln Gly Cys Tyr Pro Asn Val Cys Asp Asp Asp Gln Leu		
450	455	460
Leu Cys Gln Asn Gly Gly Thr Cys Leu Gln Asn Gln Arg Cys Ala Cys		
465	470	475
Pro Arg Gly Tyr Thr Gly Val Arg Cys Glu Gln Pro Arg Cys Asp Pro		480
485	490	495
Ala Asp Asp Asp Gly Gly Leu Asp Cys Asp Arg Ala Pro Gly Ala Ala		
500	505	510
Pro Arg Pro Ala Thr Leu Leu Gly Cys Leu Leu Leu Leu Gly Leu Ala		
515	520	525
Ala Arg Leu Gly Arg		
530		

<210> 64
 <211> 495
 <212> PRT
 <213> Homo sapiens

<400> 64		
Met Phe Ala Asn Ser Pro Gly Cys Ser Asn Met Leu His Tyr Val Tyr		
1	5	10
Cys Ala Cys Gly His Gly Leu Gln Leu Val Arg Ser Val Ser Ser Ser		
20	25	30
Val Asp Glu Gly Gly Thr Cys His Cys Met Val His Leu Pro Asn Asn		
35	40	45
Pro Ile Pro Leu Glu Gln Leu Glu Gln Leu Gln Ser Thr Ala Gln Glu		
50	55	60
Leu Ile Cys Lys Tyr Glu Gln Lys Leu Ser Arg Cys Ala Arg Ala Ile		
65	70	75
Glu Asp Lys Asp Asn Glu Val Leu Glu Met Ser His Met Leu Lys Ser		
85	90	95
Trp Asn Pro Ser Ala Leu Ala Ser Pro Tyr Glu Asn Pro Gly Phe Asn		
100	105	110
Leu Leu Cys Leu Glu Leu Glu Gly Ala Gln Glu Leu Val Thr Gln Leu		
115	120	125
Lys Ala Met Gly Gly Val Ser Val Ala Gly Asp Leu Leu His Gln Leu		
130	135	140
Gln Ser Gln Val Thr Asn Ala Ser Leu Thr Leu Lys Leu Leu Ala Asp		
145	150	155
Ser Asp Gln Cys Ser Phe Gly Ala Leu Gln Gln Glu Val Asp Val Leu		
165	170	175
Glu Ser Gln Leu Ser Glu Cys Glu Arg Glu Lys Glu Lys Glu Gly Leu		
180	185	190
Trp Thr Pro Trp Thr Pro Pro Ala Ser Cys Ala His Gly Gly		
195	200	205
Leu Gln Glu Val Ser Lys Ser Leu Val Val Gln Leu Thr Arg Arg Gly		
210	215	220
Phe Ser Tyr Lys Ala Gly Pro Trp Gly Arg Asp Ser Ala Pro Asn Pro		
225	230	235
Ala Ser Ser Leu Tyr Trp Val Ala Pro Leu Arg Thr Asp Gly Arg Tyr		240

Phe	Asp	Tyr	Tyr	Arg	Leu	Pro	Pro	Ser	Tyr	Asn	Asp	Leu	Ala	Leu	Met
245					250									255	
260					265									270	
Lys	Asn	Tyr	Glu	Glu	Arg	Lys	Met	Gly	Tyr	Gly	Asp	Gly	Ser	Gly	Asn
275					280									285	
Val	Val	Tyr	Lys	Asn	Phe	Met	Tyr	Phe	Asn	Tyr	Cys	Gly	Thr	Ser	Asp
290					295									290	
Met	Ala	Lys	Met	Asp	Leu	Ser	Ser	Asn	Thr	Leu	Val	Leu	Trp	Arg	Leu
305					310						315			320	
Leu	Pro	Gly	Ala	Thr	Tyr	Asn	Asn	Arg	Phe	Ser	Cys	Ala	Gly	Val	Pro
325					330									335	
Trp	Lys	Asp	Leu	Asp	Phe	Ala	Gly	Asp	Glu	Lys	Gly	Leu	Trp	Val	Leu
340					345									350	
Tyr	Ala	Thr	Glu	Glu	Ser	Lys	Gly	Asn	Leu	Val	Val	Ser	Arg	Leu	Asn
355					360									365	
Ala	Ser	Thr	Leu	Glu	Val	Glu	Lys	Thr	Trp	Arg	Thr	Ser	Gln	Tyr	Lys
370					375									380	
Pro	Ala	Leu	Ser	Gly	Ala	Phe	Met	Ala	Cys	Gly	Val	Leu	Tyr	Ala	Leu
385					390						395			400	
His	Ser	Leu	Asn	Thr	His	Gln	Glu	Glu	Ile	Phe	Tyr	Ala	Phe	Asp	Thr
405					410									415	
Thr	Thr	Gly	Gln	Glu	Arg	Arg	Leu	Ser	Ile	Leu	Leu	Asp	Lys	Met	Leu
420					425									430	
Glu	Lys	Leu	Gln	Gly	Ile	Asn	Tyr	Cys	Pro	Ser	Asp	His	Lys	Pro	Tyr
435					440									445	
Val	Phe	Ser	Asp	Gly	Tyr	Leu	Ile	Asn	Tyr	Asp	Leu	Thr	Phe	Leu	Thr
450					455									460	
Met	Lys	Thr	Arg	Leu	Pro	Arg	Pro	Pro	Thr	Arg	Arg	Pro	Ser	Gly	Ala
465					470						475			480	
His	Ala	Pro	Pro	Lys	Pro	Val	Lys	Pro	Asn	Glu	Ala	Ser	Arg	Pro	
485					490									495	

<210> 65

<211> 350

<212> PRT

<213> Homo sapiens

<400> 65

Met	Arg	Asn	His	Lys	Lys	Val	Thr	Asn	Ala	Ser	Leu	Thr	Leu	Lys	Leu
1				5					10				15		
Leu	Ala	Asp	Ser	Asp	Gln	Cys	Ser	Phe	Gly	Ala	Leu	Gln	Gln	Glu	Val
20					25									30	
Asp	Val	Leu	Glu	Ser	Gln	Leu	Ser	Glu	Ser	Ser	Cys	Ala	His	Gly	Gly
35					40								45		
Leu	Gln	Glu	Val	Ser	Lys	Ser	Leu	Val	Val	Gln	Leu	Thr	Arg	Arg	Gly
50					55								60		
Phe	Ser	Tyr	Lys	Ala	Gly	Pro	Trp	Gly	Arg	Asp	Ser	Ala	Pro	Asn	Pro
						70					75			80	
65															
Ala	Ser	Ser	Leu	Tyr	Trp	Val	Ala	Pro	Leu	Arg	Thr	Asp	Gly	Ser	Tyr
85														95	
Gly	Cys	His	Pro	Ile	Ile	Leu	Asn	Ala	Gly	Thr	Trp	Pro	Arg	Tyr	Phe
100														110	
Asp	Tyr	Tyr	Arg	Leu	Cys	Lys	Ser	Tyr	Asn	Asp	Leu	Ala	Leu	Lys	
115														125	
Asn	Tyr	Glu	Glu	Arg	Lys	Met	Gly	Tyr	Gly	Asp	Gly	Ser	Gly	Asn	Val
130														140	
Val	Tyr	Lys	Asn	Phe	Met	Tyr	Phe	Asn	Tyr	Cys	Gly	Thr	Ser	Asp	Met
145														155	
Ala	Lys	Met	Asp	Leu	Ser	Ser	Asn	Thr	Leu	Val	Leu	Trp	Arg	Leu	Leu

165	170	175
Pro Gly Ala Thr Tyr Asn Asn Arg Phe Ser Cys Ala Gly Val Pro Trp		
180	185	190
Lys Asp Leu Asp Phe Ala Gly Asp Glu Lys Gly Leu Trp Val Leu Tyr		
195	200	205
Ala Thr Glu Glu Ser Lys Gly Asn Leu Val Val Ser Arg Leu Asn Ala		
210	215	220
Ser Thr Leu Glu Val Glu Lys Thr Trp Arg Thr Ser Gln Tyr Lys Pro		
225	230	235
Ala Leu Ser Gly Ala Phe Met Ala Cys Gly Val Leu Tyr Ala Leu His		
245	250	255
Ser Leu Asn Thr His Gln Glu Glu Ile Phe Tyr Ala Phe Asp Thr Thr		
260	265	270
Thr Gly Gln Glu Arg Arg Leu Ser Ile Leu Leu Asp Lys Met Leu Glu		
275	280	285
Lys Leu Gln Gly Ile Asn Tyr Cys Pro Ser Asp His Lys Pro Tyr Val		
290	295	300
Phe Ser Asp Gly Tyr Leu Ile Asn Tyr Asp Leu Thr Phe Leu Thr Met		
305	310	315
Lys Thr Arg Leu Pro Arg Pro Pro Thr Arg Arg Pro Ser Gly Ala His		
325	330	335
Ala Pro Pro Lys Pro Val Lys Pro Asn Glu Ala Ser Arg Pro		
340	345	350

<210> 66
 <211> 619
 <212> PRT
 <213> Homo sapiens

<400> 66			
Met Gly Arg Gly Arg Ala Leu Leu Pro Ile Glu Met Leu Gln Leu Ser			
1	5	10	15
Leu Arg Glu Glu Ser Asp Thr Ala Arg Met Gly Ala Gln Glu Gln Ile			
20	25	30	
Gly Leu Gln Asp Glu Ile Gln Ala Ala Asn Ala Gly Ile Ser Gly Ser			
35	40	45	
Pro Gly Val Asp Gly Val Val Asp Gly Gly Ser Ser Arg Gly Asp Pro			
50	55	60	
Ala Leu Thr Val Ser Val Cys Glu Val Pro Pro Val Arg Ser Pro Phe			
65	70	75	80
Arg Thr His Pro Gln Leu Pro Val Arg Leu Pro Arg Asn Leu Glu Phe			
85	90	95	
Ser Val Pro Glu Arg Arg Thr Leu Arg Asn Arg Leu Thr Ser Ala Thr			
100	105	110	
Leu Ala Pro Pro Thr Arg His Met Leu Leu Leu Leu Leu Leu Pro			
115	120	125	
Pro Leu Leu Cys Gly Arg Val Gly Ala Lys Glu Gln Lys Asp Tyr Leu			
130	135	140	
Leu Thr Met Gln Lys Ser Val Thr Val Gln Glu Gly Leu Cys Val Ser			
145	150	155	160
Val Leu Cys Ser Phe Ser Tyr Pro Gln Asn Gly Trp Thr Ala Ser Asp			
165	170	175	
Pro Val His Gly Tyr Trp Phe Arg Ala Gly Asp His Val Ser Arg Asn			
180	185	190	
Ile Pro Val Ala Thr Asn Asn Pro Ala Arg Ala Val Gln Glu Glu Thr			
195	200	205	
Arg Asp Arg Phe His Leu Leu Gly Asp Pro Gln Asn Lys Asp Cys Thr			
210	215	220	
Leu Ser Ile Arg Asp Thr Arg Glu Ser Asp Ala Gly Thr Tyr Val Phe			

225	230	235	240
Cys Val Glu Arg Gly Asn Met Lys Trp Asn Tyr Lys Tyr Asp Gln Leu			
245	250		
Ser Val Asn Val Thr Ala Leu Thr His Met Pro Thr Phe Ser Ile Pro			255
260	265		270
Gly Thr Leu Glu Ser Gly His Pro Arg Asn Leu Thr Cys Ser Val Pro			
275	280	285	
Trp Ala Cys Glu Gln Gly Thr Pro Pro Thr Ile Thr Trp Met Gly Ala			
290	295	300	
Ser Val Ser Ser Leu Asp Pro Thr Ile Thr Arg Ser Ser Met Leu Ser			
305	310	315	320
Leu Ile Pro Gln Pro Gln Asp His Gly Thr Ser Leu Thr Cys Gln Val			
325	330	335	
Thr Leu Pro Gly Ala Gly Val Thr Met Thr Arg Ala Val Arg Leu Asn			
340	345	350	
Ile Ser Tyr Pro Pro Gln Asn Leu Thr Met Thr Val Phe Gln Gly Asp			
355	360	365	
Gly Thr Ala Ser Thr Thr Leu Arg Asn Gly Ser Ala Leu Ser Val Leu			
370	375	380	
Glu Gly Gln Ser Leu His Leu Val Cys Ala Val Asp Ser Asn Pro Pro			
385	390	395	400
Ala Arg Leu Ser Trp Thr Trp Gly Ser Leu Thr Leu Ser Pro Ser Gln			
405	410	415	
Ser Ser Asn Leu Gly Val Leu Glu Leu Pro Arg Val His Val Lys Asp			
420	425	430	
Glu Gly Glu Phe Thr Cys Arg Ala Gln Asn Pro Leu Gly Ser Gln His			
435	440	445	
Ile Ser Leu Ser Leu Ser Leu Gln Asn Glu Tyr Thr Gly Lys Met Arg			
450	455	460	
Pro Ile Ser Gly Val Thr Leu Gly Ala Phe Gly Gly Ala Gly Ala Thr			
465	470	475	480
Ala Leu Val Phe Leu Tyr Phe Cys Ile Ile Phe Val Val Val Arg Ser			
485	490	495	
Cys Arg Lys Lys Ser Ala Arg Pro Ala Val Gly Val Gly Asp Thr Gly			
500	505	510	
Met Glu Asp Ala Asn Ala Val Arg Gly Ser Ala Ser Gln Met Glu Glu			
515	520	525	
Gly Thr Pro Gly Pro Pro Ser Trp Met Leu Ser Gly Ala Cys Trp Pro			
530	535	540	
His Cys Ser Ala Leu Thr Pro Phe Ser Ser Ser Ile Gln Gly Pro Leu			
545	550	555	560
Ile Glu Ser Pro Ala Asp Asp Ser Pro Pro His His Ala Pro Pro Ala			
565	570	575	
Leu Ala Thr Pro Ser Pro Glu Glu Gly Glu Ile Gln Tyr Ala Ser Leu			
580	585	590	
Ser Phe His Lys Ala Arg Pro Gln Tyr Pro Gln Glu Gln Glu Ala Ile			
595	600	605	
Gly Tyr Glu Tyr Ser Glu Ile Asn Ile Pro Lys			
610	615		

<210> 67
<211> 490
<212> PRT
<213> *Homo sapiens*

<400> 67
Met Leu Leu Leu Leu Leu Leu Pro Pro Leu Leu Cys Gly Arg Val
1 5 10 15
Gly Ala Lys Glu Gln Lys Asp Tyr Leu Leu Thr Met Gln Ivs Ser Val

20	25	30
Thr Val Gln Glu Gly Leu Cys Val Ser Val Leu Cys Ser Phe Ser Tyr		
35	40	45
Pro Gln Asn Gly Trp Thr Ala Ser Asp Pro Val His Gly Tyr Trp Phe		
50	55	60
Arg Ala Gly Asp His Val Ser Arg Asn Ile Pro Val Ala Thr Asn Asn		
65	70	75
Pro Ala Arg Ala Val Gln Glu Glu Thr Arg Asp Arg Phe His Leu Leu		
85	90	95
Gly Asp Pro Gln Asn Lys Asp Cys Thr Leu Ser Ile Arg Asp Thr Arg		
100	105	110
Glu Ser Asp Ala Gly Thr Tyr Val Phe Cys Val Glu Arg Gly Asn Met		
115	120	125
Lys Trp Asn Tyr Lys Tyr Asp Gln Leu Ser Val Asn Val Thr Ala Leu		
130	135	140
Thr His Met Pro Thr Phe Ser Ile Pro Gly Thr Leu Glu Ser Gly His		
145	150	155
Pro Arg Asn Leu Thr Cys Ser Val Pro Trp Ala Cys Glu Gln Gly Thr		
165	170	175
Pro Pro Thr Ile Thr Trp Met Gly Ala Ser Val Ser Ser Leu Asp Pro		
180	185	190
Thr Ile Thr Arg Ser Ser Met Leu Ser Leu Ile Pro Gln Pro Gln Asp		
195	200	205
His Gly Thr Ser Leu Thr Cys Gln Val Thr Leu Pro Gly Ala Gly Val		
210	215	220
Thr Met Thr Arg Ala Val Arg Leu Asn Ile Ser Tyr Pro Pro Gln Asn		
225	230	235
Leu Thr Met Thr Val Phe Gln Gly Asp Gly Thr Ala Ser Thr Thr Leu		
245	250	255
Arg Asn Gly Ser Ala Leu Ser Val Leu Glu Gly Gln Ser Leu His Leu		
260	265	270
Val Cys Ala Val Asp Ser Asn Pro Pro Ala Arg Leu Ser Trp Thr Trp		
275	280	285
Gly Ser Leu Thr Leu Ser Pro Ser Gln Ser Ser Asn Leu Gly Val Leu		
290	295	300
Glu Leu Pro Arg Val His Val Lys Asp Glu Gly Glu Phe Thr Cys Arg		
305	310	315
Ala Gln Asn Pro Leu Gly Ser Gln His Ile Ser Leu Ser Leu Ser Leu		
325	330	335
Gln Asn Glu Tyr Thr Gly Lys Met Arg Pro Ile Ser Gly Val Thr Leu		
340	345	350
Gly Ala Phe Gly Gly Ala Gly Ala Thr Ala Leu Val Phe Leu Tyr Phe		
355	360	365
Cys Ile Ile Phe Val Val Val Arg Ser Cys Arg Lys Lys Ser Ala Arg		
370	375	380
Pro Ala Val Gly Val Gly Asp Thr Gly Met Glu Asp Ala Asn Ala Val		
385	390	395
Arg Gly Ser Ala Ser Gln Gly Pro Leu Thr Glu Ser Trp Lys Asp Gly		
405	410	415
Asn Pro Leu Lys Lys Pro Pro Ala Val Ala Pro Ser Ser Gly Glu		
420	425	430
Glu Gly Glu Leu His Tyr Ala Thr Leu Ser Phe His Lys Val Lys Pro		
435	440	445
Gln Asp Pro Gln Gly Gln Glu Ala Thr Asp Ser Glu Tyr Ser Glu Ile		
450	455	460
Lys Ile His Lys Arg Glu Thr Ala Glu Thr Gln Ala Cys Leu Arg Asn		
465	470	475
His Asn Pro Ser Ser Lys Glu Val Arg Gly		
485	490	

<210> 68
 <211> 462
 <212> PRT
 <213> Homo sapiens

 <400> 68
 Met Leu Pro Leu Trp Thr Leu Ser Leu Leu Gly Ala Val Ala Gly
 1 5 10 15
 Lys Glu Val Cys Tyr Glu Arg Leu Gly Cys Phe Ser Asp Asp Ser Pro
 20 25 30
 Trp Ser Gly Ile Thr Glu Arg Pro Leu His Ile Leu Pro Trp Ser Pro
 35 40 45
 Lys Asp Val Asn Thr Arg Phe Leu Leu Tyr Thr Asn Glu Asn Pro Asn
 50 55 60
 Asn Phe Gln Glu Ile Ser Ala Val Asn Ser Ser Thr Ile Gln Ala Ser
 65 70 75 80
 Tyr Phe Gly Thr Asp Lys Ile Thr Arg Ile Asn Ile Ala Gly Trp Lys
 85 90 95
 Thr Asp Gly Lys Trp Gln Arg Asp Met Cys Asn Val Leu Leu Gln Leu
 100 105 110
 Glu Asp Ile Asn Cys Ile Asn Leu Asp Trp Ile Asn Gly Ser Arg Glu
 115 120 125
 Tyr Ile His Ala Val Asn Asn Leu Arg Val Val Gly Ala Glu Val Ala
 130 135 140
 Tyr Phe Ile Asp Val Leu Met Lys Phe Glu Tyr Ser Pro Ser Lys
 145 150 155 160
 Val His Leu Ile Gly His Ser Leu Gly Ala His Leu Ala Gly Glu Ala
 165 170 175
 Gly Ser Arg Ile Pro Gly Leu Gly Arg Ile Thr Gly Lys His Ala Leu
 180 185 190
 Gln Leu Gly Leu Glu Cys Ala Thr Glu Gly Tyr Leu Leu Ser Ala Thr
 195 200 205
 Leu Ala Asn Asn Val Asn Phe Val Asp Thr Asn His Met Asp Ala Thr
 210 215 220
 Pro Ile Ile Pro Gln Trp Met Arg Gly Thr Ser Gly Thr Ser Asn Pro
 225 230 235 240
 Leu Pro Val Thr Ser Ser Leu Cys Leu Trp Leu Ala Asp Leu Gly Ser
 245 250 255
 Val Ser Leu Val Cys Leu Trp Pro Glu Met Ala Ser Phe Phe Asp Cys
 260 265 270
 Asn His Ala Arg Ser Tyr Gln Phe Tyr Ala Glu Ser Ile Leu Asn Pro
 275 280 285
 Asp Ala Phe Ile Ala Tyr Pro Cys Arg Ser Tyr Thr Ser Phe Lys Ala
 290 295 300
 Gly Asn Cys Phe Phe Cys Ser Lys Glu Gly Cys Pro Thr Met Gly His
 305 310 315 320
 Phe Ala Asp Arg Phe His Phe Lys Asn Met Lys Thr Asn Gly Ser His
 325 330 335
 Tyr Phe Leu Asn Thr Gly Ser Leu Ser Pro Phe Ala Arg Trp Arg His
 340 345 350
 Lys Leu Ser Val Lys Leu Ser Gly Ser Glu Val Thr Gln Gly Thr Val
 355 360 365
 Phe Leu Arg Val Gly Gly Ala Val Arg Lys Thr Gly Glu Phe Ala Ile
 370 375 380
 Val Ser Gly Lys Leu Glu Pro Gly Met Thr Tyr Thr Lys Leu Ile Asp
 385 390 395 400
 Ala Asp Val Asn Val Gly Asn Ile Thr Ser Val Gln Phe Ile Trp Lys
 405 410 415

Lys His Leu Phe Glu Asp Ser Gln Asn Lys Leu Gly Ala Glu Met Val
 420 425 430
 Ile Asn Thr Ser Gly Lys Tyr Gly Tyr Lys Ser Thr Phe Cys Ser Gln
 435 440 445
 Asp Ile Met Gly Pro Asn Ile Leu Gln Asn Leu Lys Pro Cys
 450 455 460

<210> 69
 <211> 255
 <212> PRT
 <213> Homo sapiens

<400> 69

Met Val Leu Leu Leu Val Ile Leu Ile Pro Val Leu Val Ser Ser Ala
 1 5 10 15
 Gly Thr Ser Ala His Tyr Glu Met Leu Gly Thr Cys Arg Met Val Cys
 20 25 30
 Asp Pro Tyr Gly Gly Thr Lys Ala Pro Ser Thr Ala Ala Thr Pro Asp
 35 40 45
 Arg Gly Leu Met Gln Ser Leu Pro Thr Phe Ile Gln Gly Pro Lys Gly
 50 55 60
 Glu Ala Gly Arg Pro Gly Lys Ala Gly Pro Arg Gly Pro Pro Gly Glu
 65 70 75 80
 Pro Gly Pro Pro Gly Pro Met Gly Pro Pro Gly Glu Lys Gly Glu Pro
 85 90 95
 Gly Arg Gln Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Leu Asn Ala
 100 105 110
 Ala Gly Ala Ile Ser Ala Ala Thr Tyr Ser Thr Gly Pro Lys Ile Ala
 115 120 125
 Phe Tyr Ala Gly Leu Lys Arg Gln His Glu Gly Tyr Glu Val Leu Lys
 130 135 140
 Phe Asp Asp Val Val Thr Asn Leu Gly Asn His Tyr Asp Pro Thr Thr
 145 150 155 160
 Gly Lys Phe Thr Cys Ser Ile Pro Gly Ile Tyr Phe Phe Thr Tyr His
 165 170 175
 Val Leu Met Arg Gly Gly Asp Gly Thr Ser Met Trp Ala Asp Leu Cys
 180 185 190
 Lys Asn Asn Gln Val Arg Ala Ser Ala Ile Ala Gln Asp Ala Asp Gln
 195 200 205
 Asn Tyr Asp Tyr Ala Ser Asn Ser Val Val Leu His Leu Glu Pro Gly
 210 215 220
 Asp Glu Val Tyr Ile Lys Leu Asp Gly Gly Lys Ala His Gly Gly Asn
 225 230 235 240
 Asn Asn Lys Tyr Ser Thr Phe Ser Gly Phe Ile Ile Tyr Ala Asp
 245 250 255

<210> 70
 <211> 784
 <212> PRT
 <213> Homo sapiens

<400> 70

Met Glu Gly Asp Gly Gly Thr Pro Trp Ala Leu Ala Leu Arg Thr
 1 5 10 15
 Phe Asp Ala Gly Glu Phe Thr Gly Trp Glu Lys Val Gly Ser Gly Gly
 20 25 30
 Phe Gly Gln Val Tyr Lys Val Arg His Val His Trp Lys Thr Trp Leu
 35 40 45
 Ala Ile Lys Cys Ser Pro Ser Leu His Val Asp Asp Arg Glu Arg Met

50	55	60													
Glu	Leu	Leu	Glu	Glu	Ala	Lys	Lys	Met	Glu	Met	Ala	Lys	Phe	Arg	Tyr
65						70				75					80
Ile	Leu	Pro	Val	Tyr	Gly	Ile	Cys	Arg	Glu	Pro	Val	Gly	Leu	Val	Met
						85				90					95
Glu	Tyr	Met	Glu	Thr	Gly	Ser	Leu	Glu	Lys	Leu	Leu	Ala	Ser	Glu	Pro
						100			105					110	
Leu	Pro	Trp	Asp	Leu	Arg	Phe	Arg	Ile	Ile	His	Glu	Thr	Ala	Val	Gly
						115			120					125	
Met	Asn	Phe	Leu	His	Cys	Met	Ala	Pro	Pro	Leu	Leu	His	Leu	Asp	Leu
						130			135			140			
Lys	Pro	Ala	Asn	Ile	Leu	Leu	Asp	Ala	His	Tyr	His	Val	Lys	Ile	Ser
						145			150			155			160
Asp	Phe	Gly	Leu	Ala	Lys	Cys	Asn	Gly	Leu	Ser	His	Ser	His	Asp	Leu
						165			170			175			
Ser	Met	Asp	Gly	Leu	Phe	Gly	Thr	Ile	Ala	Tyr	Leu	Pro	Pro	Glu	Arg
						180			185			190			
Ile	Arg	Glu	Lys	Ser	Arg	Leu	Phe	Asp	Thr	Lys	His	Asp	Val	Tyr	Ser
						195			200			205			
Phe	Ala	Ile	Val	Ile	Trp	Gly	Val	Leu	Thr	Gln	Lys	Lys	Pro	Phe	Ala
						210			215			220			
Asp	Glu	Lys	Asn	Ile	Leu	His	Ile	Met	Val	Lys	Val	Val	Lys	Gly	His
						225			230			235			240
Arg	Pro	Glu	Leu	Pro	Pro	Val	Cys	Arg	Ala	Arg	Pro	Arg	Ala	Cys	Ser
						245			250			255			
His	Leu	Ile	Arg	Leu	Met	Gln	Arg	Cys	Trp	Gln	Gly	Asp	Pro	Arg	Val
						260			265			270			
Arg	Pro	Thr	Phe	Gln	Glu	Ile	Thr	Ser	Glu	Thr	Glu	Asp	Leu	Cys	Glu
						275			280			285			
Lys	Pro	Asp	Asp	Glu	Val	Lys	Glu	Thr	Ala	His	Asp	Leu	Asp	Val	Lys
						290			295			300			
Ser	Pro	Pro	Glu	Pro	Arg	Ser	Glu	Val	Val	Pro	Ala	Arg	Leu	Lys	Arg
						305			310			315			320
Ala	Ser	Ala	Pro	Thr	Phe	Asp	Asn	Asp	Tyr	Ser	Leu	Ser	Glu	Leu	Leu
						325			330			335			
Ser	Gln	Leu	Asp	Ser	Gly	Val	Ser	Gln	Ala	Val	Glu	Gly	Pro	Glu	Glu
						340			345			350			
Leu	Ser	Arg	Ser	Ser	Ser	Glu	Ser	Lys	Leu	Pro	Ser	Ser	Gly	Ser	Gly
						355			360			365			
Lys	Arg	Leu	Ser	Gly	Val	Ser	Ser	Val	Asp	Ser	Ala	Phe	Ser	Ser	Arg
						370			375			380			
Gly	Ser	Leu	Ser	Leu	Ser	Phe	Glu	Arg	Glu	Pro	Ser	Thr	Asp	Leu	
						385			390			395			400
Gly	Thr	Thr	Asp	Val	Gln	Lys	Lys	Leu	Val	Asp	Ala	Ile	Val	Ser	
						405			410			415			
Gly	Asp	Thr	Ser	Lys	Leu	Met	Lys	Ile	Leu	Gln	Pro	Gln	Asp	Val	Asp
						420			425			430			
Leu	Ala	Leu	Asp	Ser	Gly	Ala	Ser	Leu	Leu	His	Leu	Ala	Val	Glu	Ala
						435			440			445			
Gly	Gln	Glu	Glu	Cys	Ala	Lys	Trp	Leu	Leu	Leu	Asn	Asn	Ala	Asn	Pro
						450			455			460			
Asn	Leu	Ser	Asn	Arg	Arg	Gly	Ser	Thr	Pro	Leu	His	Met	Ala	Val	Glu
						465			470			475			480
Arg	Arg	Val	Arg	Gly	Val	Val	Glu	Leu	Leu	Leu	Ala	Arg	Lys	Ile	Ser
						485			490			495			
Val	Asn	Ala	Lys	Asp	Glu	Asp	Gln	Trp	Thr	Ala	Leu	His	Phe	Ala	Ala
						500			505			510			
Gln	Asn	Gly	Asp	Glu	Ser	Ser	Thr	Arg	Leu	Leu	Leu	Glu	Lys	Asn	Ala
						515			520			525			

Ser Val Asn Glu Val Asp Phe Glu Gly Arg Thr Pro Met His Val Ala
 530 535 540
 Cys Gln His Gly Gln Glu Asn Ile Val Arg Ile Leu Leu Arg Arg Gly
 545 550 555 560
 Val Asp Val Ser Leu Gln Gly Lys Asp Ala Trp Leu Pro Leu His Tyr
 565 570 575
 Ala Ala Trp Gln Gly His Leu Pro Ile Val Lys Leu Leu Ala Lys Gln
 580 585 590
 Pro Gly Val Ser Val Asn Ala Gln Thr Leu Asp Gly Arg Thr Pro Leu
 595 600 605
 His Leu Ala Ala Gln Arg Gly His Tyr Arg Val Ala Arg Ile Leu Ile
 610 615 620
 Asp Leu Cys Ser Asp Val Asn Val Cys Ser Leu Leu Ala Gln Thr Pro
 625 630 635 640
 Leu His Val Ala Ala Glu Thr Gly His Thr Ser Thr Ala Arg Leu Leu
 645 650 655
 Leu His Arg Gly Ala Gly Lys Glu Ala Met Thr Ser Asp Gly Tyr Thr
 660 665 670
 Ala Leu His Leu Ala Ala Arg Asn Gly His Leu Ala Thr Val Lys Leu
 675 680 685
 Leu Val Glu Glu Lys Ala Asp Val Leu Ala Arg Gly Pro Leu Asn Gln
 690 695 700
 Thr Ala Leu His Leu Ala Ala His Gly His Ser Glu Val Val Glu
 705 710 715 720
 Glu Leu Val Ser Ala Asp Val Ile Asp Leu Phe Asp Glu Gln Gly Leu
 725 730 735
 Ser Ala Leu His Leu Ala Ala Gln Gly Arg His Ala Gln Thr Val Glu
 740 745 750
 Thr Leu Leu Arg His Gly Ala His Ile Asn Leu Gln Ser Leu Lys Phe
 755 760 765
 Gln Gly Gly His Gly Pro Ala Ala Thr Leu Leu Arg Arg Ser Lys Thr
 770 775 780

<210> 71
 <211> 252
 <212> PRT
 <213> Homo sapiens

<400> 71

Met Ala Ala Pro Ala Leu Leu Leu Leu Leu Leu Pro Val Gly
 1 5 10 15
 Ala Trp Pro Gly Leu Pro Arg Arg Pro Cys Val His Cys Cys Arg Pro
 20 25 30
 Ala Trp Pro Pro Gly Pro Tyr Ala Arg Val Ser Asp Arg Asp Leu Trp
 35 40 45
 Arg Gly Asp Leu Trp Arg Gly Leu Pro Arg Val Arg Pro Thr Ile Asp
 50 55 60
 Ile Glu Ile Leu Lys Gly Glu Lys Gly Glu Ala Gly Val Arg Gly Arg
 65 70 75 80
 Ala Gly Arg Ser Gly Lys Glu Gly Pro Pro Gly Ala Arg Gly Leu Gln
 85 90 95
 Gly Arg Arg Gly Gln Lys Gly Gln Val Gly Pro Pro Gly Ala Ala Cys
 100 105 110
 Arg Arg Ala Tyr Ala Ala Phe Ser Val Gly Arg Arg Glu Gly Leu His
 115 120 125
 Ser Ser Asp His Phe Gln Ala Val Pro Phe Asp Thr Glu Leu Val Asn
 130 135 140
 Leu Asp Gly Ala Phe Asp Leu Ala Ala Gly Arg Phe Leu Cys Thr Val
 145 150 155 160

Pro Gly Val Tyr Phe Leu Ser Leu Asn Val His Thr Trp Asn Tyr Lys
 165 170 175
 Glu Thr Tyr Leu His Ile Met Leu Asn Arg Arg Pro Ala Ala Val Leu
 180 185 190
 Tyr Ala Gln Pro Ser Glu Arg Ser Val Met Gln Ala Gln Ser Leu Met
 195 200 205
 Leu Leu Leu Ala Ala Gly Asp Ala Val Trp Val Arg Met Phe Gln Arg
 210 215 220
 Asp Arg Asp Asn Ala Ile Tyr Gly Glu His Gly Asp Leu Tyr Ile Thr
 225 230 235 240
 Phe Ser Gly His Leu Val Lys Pro Ala Ala Glu Leu
 245 250

<210> 72
 <211> 593
 <212> PRT
 <213> Homo sapiens

<400> 72
 Met Pro Ser Ser Leu Phe Ala Asp Leu Glu Arg Asn Gly Ser Gly Gly
 1 5 10 15
 Gly Gly Gly Ser Ser Gly Gly Glu Thr Leu Asp Asp Gln Arg
 20 25 30
 Ala Leu Gln Leu Ala Leu Asp Gln Leu Ser Leu Leu Gly Leu Asp Ser
 35 40 45
 Asp Glu Gly Ala Ser Leu Tyr Asp Ser Glu Pro Arg Lys Lys Ser Val
 50 55 60
 Asn Met Thr Glu Cys Val Pro Val Pro Ser Ser Glu His Val Ala Glu
 65 70 75 80
 Ile Val Gly Arg Gln Gly Arg Ser Arg Arg Asp Gly Glu Leu Asp Pro
 85 90 95
 Ser Gly Ile Ser Pro Asp Asp Phe Ser Gly Ile Leu Gly Phe Gly Ser
 100 105 110
 Gly Arg Leu Gln Ser Leu Gly Glu Gly Gln Ala Ala Asn Gly Leu Phe
 115 120 125
 Leu Glu Arg Leu Ala Gly Gly Ile Arg Cys Pro Ala Arg Gly Ala Ala
 130 135 140
 Arg Gly Cys Lys Ile Lys Ala Leu Arg Ala Lys Thr Asn Thr Tyr Ile
 145 150 155 160
 Lys Thr Pro Val Arg Gly Glu Glu Pro Val Phe Val Val Thr Gly Arg
 165 170 175
 Lys Glu Asp Val Ala Met Ala Arg Arg Glu Ile Ile Ser Ala Ala Glu
 180 185 190
 His Phe Ser Met Ile Arg Ala Ser Arg Asn Lys Asn Thr Ala Leu Asn
 195 200 205
 Gly Ala Val Pro Gly Pro Pro Asn Leu Pro Gly Gln Thr Thr Ile Gln
 210 215 220
 Val Arg Val Pro Tyr Arg Val Val Gly Leu Val Val Gly Pro Lys Gly
 225 230 235 240
 Ala Thr Ile Lys Arg Ile Gln Gln Gln Thr His Thr Tyr Ile Val Thr
 245 250 255
 Pro Ser Arg Asp Lys Glu Pro Val Phe Glu Val Thr Gly Met Pro Glu
 260 265 270
 Asn Val Asp Arg Ala Arg Glu Ile Glu Ala His Ile Ala Leu Arg
 275 280 285
 Thr Gly Gly Ile Ile Glu Leu Thr Asp Glu Asn Asp Phe His Ala Asn
 290 295 300
 Gly Thr Asp Val Gly Phe Asp Leu His His Gly Ser Gly Gly Ala Ser
 305 310 315 320

Thr Asp Ser Tyr Phe Gly Gly Gly Thr Ser Ser Ser Ala Ala Ala Thr
 325 330 335
 Gln Arg Leu Ala Asp Tyr Ser Pro Pro Ser Pro Ala Leu Ser Phe Ala
 340 345 350
 His Asn Gly Asn Asn Asn Asn Gly Asn Gly Tyr Thr Tyr Thr Ala
 355 360 365
 Gly Gly Glu Ala Ser Val Pro Ser Pro Asp Gly Cys Pro Glu Leu Gln
 370 375 380
 Pro Thr Phe Asp Pro Ala Pro Ala Pro Pro Pro Gly Ala Pro Leu Ile
 385 390 395 400
 Trp Ala Gln Phe Glu Arg Ser Pro Gly Gly Pro Ala Ala Pro Val
 405 410 415
 Ser Ser Ser Cys Ser Ser Ala Ser Ser Ala Ser Ser Ser Ser
 420 425 430
 Val Val Phe Pro Gly Gly Ala Ser Ala Pro Ser Asn Ala Asn Leu
 435 440 445
 Gly Leu Leu Val His Arg Arg Leu His Pro Gly Thr Ser Cys Pro Arg
 450 455 460
 Leu Ser Pro Pro Leu His Met Ala Pro Gly Ala Gly Glu His His Leu
 465 470 475 480
 Ala Arg Arg Val Arg Ser Asp Pro Gly Gly Gly Leu Ala Tyr Ala
 485 490 495
 Ala Tyr Ala Asn Gly Leu Gly Ala Gln Leu Pro Gly Leu Gln Pro Ser
 500 505 510
 Asp Thr Ser Gly Ser
 515 520 525
 Ser Ser Ser Ser Gly Leu Arg Arg Lys Gly Ser Arg Asp Cys Ser Val
 530 535 540
 Cys Phe Glu Ser Glu Val Ile Ala Ala Leu Val Pro Cys Gly His Asn
 545 550 555 560
 Leu Phe Cys Met Glu Cys Ala Asn Arg Ile Cys Glu Lys Ser Glu Pro
 565 570 575
 Glu Cys Pro Val Cys His Thr Ala Val Thr Gln Ala Ile Arg Ile Phe
 580 585 590
 Ser

<210> 73
 <211> 472
 <212> PRT
 <213> Homo sapiens

<400> 73

Met Pro Ser Ser Leu Phe Ala Asp Leu Glu Arg Asn Gly Ser Gly Gly
 1 5 10 15
 Gly Gly Gly Ser Ser Gly Gly Gly Glu Thr Leu Asp Asp Gln Arg
 20 25 30
 Ala Leu Gln Leu Ala Leu Asp Gln Leu Ser Leu Leu Gly Leu Asp Ser
 35 40 45
 Asp Glu Gly Ala Ser Leu Tyr Asp Ser Glu Pro Arg Lys Lys Ser Val
 50 55 60
 Asn Met Thr Glu Cys Val Pro Val Pro Ser Ser Glu His Val Ala Glu
 65 70 75 80
 Ile Val Gly Arg Gln Gly Cys Lys Ile Lys Ala Leu Arg Ala Lys Thr
 85 90 95
 Asn Thr Tyr Ile Lys Thr Pro Val Arg Gly Glu Glu Pro Val Phe Val
 100 105 110
 Val Thr Gly Arg Lys Glu Asp Val Ala Met Ala Arg Arg Glu Ile Ile
 115 120 125

Ser Ala Ala Glu His Phe Ser Met Ile Arg Ala Ser Arg Asn Lys Asn
 130 135 140
 Thr Ala Leu Asn Gly Ala Val Pro Gly Pro Pro Asn Leu Pro Gly Gln
 145 150 155 160
 Thr Thr Ile Gln Val Arg Val Pro Tyr Arg Val Val Gly Leu Val Val
 165 170 175
 Gly Pro Lys Gly Ala Thr Ile Lys Arg Ile Gln Gln Gln Thr His Thr
 180 185 190
 Tyr Ile Val Thr Pro Ser Arg Asp Lys Glu Pro Val Phe Glu Val Thr
 195 200 205
 Gly Met Pro Glu Asn Val Asp Arg Ala Arg Glu Glu Ile Glu Ala His
 210 215 220
 Ile Ala Leu Arg Thr Gly Gly Ile Ile Glu Leu Thr Asp Glu Asn Asp
 225 230 235 240
 Phe His Ala Asn Gly Thr Asp Val Gly Phe Asp Leu His His Gly Ser
 245 250 255
 Gly Gly Ser Gly Pro Gly Ser Leu Trp Ser Lys Pro Thr Pro Ser Ile
 260 265 270
 Thr Pro Thr Pro Gly Arg Lys Pro Phe Ser Ser Tyr Arg Asn Asp Ser
 275 280 285
 Ser Ser Ser Leu Gly Ser Ala Ser Thr Asp Ser Tyr Phe Gly Gly Gly
 290 295 300
 Thr Ser Ser Ser Ala Ala Ala Thr Gln Arg Leu Ala Asp Tyr Ser Pro
 305 310 315 320
 Ala Pro Ser Asn Ala Asn Leu Gly Leu Leu Val His Arg Arg Leu His
 325 330 335
 Pro Gly Thr Ser Cys Pro Arg Leu Ser Pro Pro Leu His Met Ala Pro
 340 345 350
 Gly Ala Gly Glu His His Leu Ala Arg Arg Val Arg Ser Asp Pro Gly
 355 360 365
 Gly Gly Gly Leu Ala Tyr Ala Ala Tyr Ala Asn Gly Leu Gly Ala Gln
 370 375 380
 Leu Pro Gly Leu Gln Pro Ser Asp Thr Ser Gly Ser Ser Ser Ser Ser
 385 390 395 400
 Ser Ser Ser Ser Ser Ser Ser Ser Gly Leu Arg Arg Lys
 405 410 415
 Gly Ser Arg Asp Cys Ser Val Cys Phe Glu Ser Glu Val Ile Ala Ala
 420 425 430
 Leu Val Pro Cys Gly His Asn Leu Phe Cys Met Glu Cys Ala Asn Arg
 435 440 445
 Ile Cys Glu Lys Ser Glu Pro Glu Cys Pro Val Cys His Thr Ala Val
 450 455 460
 Thr Gln Ala Ile Arg Ile Phe Ser
 465 470

<210> 74
 <211> 607
 <212> PRT
 <213> Homo sapiens

<400> 74

Met Trp Gly Leu Val Arg Leu Leu Ala Trp Leu Gly Gly Trp Gly
 1 5 10 15
 Cys Met Gly Arg Leu Ala Ala Pro Ala Arg Ala Trp Ala Gly Ser Arg
 20 25 30
 Glu His Pro Gly Pro Ala Leu Leu Arg Thr Arg Arg Ser Trp Val Trp
 35 40 45
 Asn Gln Phe Phe Val Ile Glu Glu Tyr Ala Gly Pro Glu Pro Val Leu
 50 55 60

Ile Gly Lys Leu His Ser Asp Val Asp Arg Gly Glu Gly Arg Thr Lys
 65 70 75 80
 Tyr Leu Leu Thr Gly Glu Gly Ala Gly Thr Val Phe Val Ile Asp Glu
 85 90 95
 Ala Thr Gly Asn Ile His Val Thr Lys Ser Leu Asp Arg Glu Glu Lys
 100 105 110
 Ala Gln Tyr Val Leu Leu Ala Gln Ala Val Asp Arg Ala Ser Asn Arg
 115 120 125
 Pro Leu Glu Pro Pro Ser Glu Phe Ile Ile Lys Val Gln Asp Ile Asn
 130 135 140
 Asp Asn Pro Pro Ile Phe Pro Leu Gly Pro Tyr His Ala Thr Val Pro
 145 150 155 160
 Glu Met Ser Asn Val Gly Thr Ser Val Ile Gln Val Thr Ala His Asp
 165 170 175
 Ala Asp Asp Pro Ser Tyr Gly Asn Ser Ala Lys Leu Val Tyr Thr Val
 180 185 190
 Leu Asp Gly Leu Pro Phe Ser Val Asp Pro Gln Thr Gly Val Val
 195 200 205
 Arg Thr Ala Ile Pro Asn Met Asp Arg Glu Thr Gln Glu Glu Phe Leu
 210 215 220
 Val Val Ile Gln Ala Lys Asp Met Gly Gly His Met Gly Gly Leu Ser
 225 230 235 240
 Gly Ser Thr Thr Val Thr Val Thr Leu Ser Asp Val Asn Asp Asn Pro
 245 250 255
 Pro Lys Phe Pro Gln Ser Leu Tyr Gln Phe Ser Val Val Glu Thr Ala
 260 265 270
 Gly Pro Gly Thr Leu Val Gly Arg Leu Arg Ala Gln Asp Pro Asp Leu
 275 280 285
 Gly Asp Asn Ala Leu Met Ala Tyr Ser Ile Leu Asp Gly Glu Gly Ser
 290 295 300
 Glu Ala Phe Ser Ile Ser Thr Asp Leu Gln Gly Arg Asp Gly Leu Leu
 305 310 315 320
 Thr Val Arg Lys Pro Leu Asp Phe Glu Ser Gln Arg Ser Tyr Ser Phe
 325 330 335
 Arg Val Glu Ala Thr Asn Thr Leu Ile Asp Pro Ala Tyr Leu Arg Arg
 340 345 350
 Gly Pro Phe Lys Asp Val Ala Ser Val Arg Val Ala Val Gln Asp Ala
 355 360 365
 Pro Glu Pro Pro Ala Phe Thr Gln Ala Ala Tyr His Leu Thr Val Pro
 370 375 380
 Glu Asn Lys Ala Pro Gly Thr Leu Val Gly Gln Ile Ser Ala Ala Asp
 385 390 395 400
 Leu Asp Ser Pro Ala Ser Pro Ile Arg Tyr Ser Ile Leu Pro His Ser
 405 410 415
 Asp Pro Glu Arg Cys Phe Ser Ile Gln Pro Glu Glu Gly Thr Ile His
 420 425 430
 Thr Ala Ala Pro Leu Asp Arg Glu Ala Arg Ala Trp His Asn Leu Thr
 435 440 445
 Val Leu Ala Thr Glu Leu Val Pro Tyr Thr Pro Ala Tyr Ala Ser Gly
 450 455 460
 Ala Pro Pro Pro Phe Cys Leu His Thr Ala Tyr Glu Asn Cys Pro Cys
 465 470 475 480
 Ile Cys Gly Tyr Leu Asn Val Ser Val Lys Ala Tyr Met Asn Val His
 485 490 495
 Met Trp Ala Met Val Leu Val Phe Ala Glu His Lys Gly Gly Arg
 500 505 510
 Gly Pro Gly Arg Gln Ala Val Asp Gly Gln Lys Gln Ser Thr Arg Trp
 515 520 525
 Glu Leu Ser Gln Asn Cys Asn Tyr Leu Pro Lys Ser Arg Glu Gly Val

530	535	540
His Pro Gly Thr Ser Met Arg Ala Gln Ala Ser Gln	Leu Gln Gly Ser	
545	550	555
Arg Gly Thr His Arg Asn Cys Thr Arg Ile Ala Cys His Thr Arg Val		560
565	570	575
Asn Pro Ile Leu Tyr His Ser Pro Thr Pro Gly His Arg Thr Thr Tyr		
580	585	590
Thr Cys Gly His Glu Tyr Ala Pro Ser Tyr Ala Glu Ser Asn Thr		
595	600	605
 <210> 75		
<211> 781		
<212> PRT		
<213> Homo sapiens		
 <400> 75		
Met Trp Gly Leu Val Arg Leu Leu Ala Trp Leu Gly Gly Trp Gly		
1	5	10
Cys Met Gly Arg Leu Ala Ala Pro Ala Arg Ala Trp Ala Gly Ser Arg		15
20	25	30
Glu His Pro Gly Pro Ala Leu Leu Arg Thr Arg Arg Ser Trp Val Trp		
35	40	45
Asn Gln Phe Phe Val Ile Glu Glu Tyr Ala Gly Pro Glu Pro Val Leu		
50	55	60
Ile Gly Lys Leu His Ser Asp Val Asp Arg Gly Glu Gly Arg Thr Lys		
65	70	75
Tyr Leu Leu Thr Gly Glu Gly Ala Gly Thr Val Phe Val Ile Asp Glu		80
85	90	95
Ala Thr Gly Asn Ile His Val Thr Lys Ser Leu Asp Arg Glu Glu Lys		
100	105	110
Ala Gln Tyr Val Leu Leu Ala Gln Ala Val Asp Arg Ala Ser Asn Arg		
115	120	125
Pro Leu Glu Pro Pro Ser Glu Phe Ile Ile Lys Val Gln Asp Ile Asn		
130	135	140
Asp Asn Pro Pro Ile Phe Pro Leu Gly Pro Tyr His Ala Thr Val Pro		
145	150	155
Glu Met Ser Asn Val Gly Thr Ser Val Ile Gln Val Thr Ala His Asp		160
165	170	175
Ala Asp Asp Pro Ser Tyr Gly Asn Ser Ala Lys Leu Val Tyr Thr Val		
180	185	190
Leu Asp Gly Leu Pro Phe Ser Val Asp Pro Gln Thr Gly Val Val		
195	200	205
Arg Thr Ala Ile Pro Asn Met Asp Arg Glu Thr Gln Glu Phe Leu		
210	215	220
Val Val Ile Gln Ala Lys Asp Met Gly Gly His Met Gly Gly Leu Ser		
225	230	235
Gly Ser Thr Thr Val Thr Val Thr Leu Ser Asp Val Asn Asp Asn Pro		240
245	250	255
Pro Lys Phe Pro Gln Ser Leu Tyr Gln Phe Ser Val Val Glu Thr Ala		
260	265	270
Gly Pro Gly Thr Leu Val Gly Arg Leu Arg Ala Gln Asp Pro Asp Leu		
275	280	285
Gly Asp Asn Ala Leu Met Ala Tyr Ser Ile Leu Asp Gly Glu Gly Ser		
290	295	300
Glu Ala Phe Ser Ile Ser Thr Asp Leu Gln Gly Arg Asp Gly Leu Leu		
305	310	315
Thr Val Arg Lys Pro Leu Asp Phe Glu Ser Gln Arg Ser Tyr Ser Phe		320
325	330	335
Arg Val Glu Ala Thr Asn Thr Leu Ile Asp Pro Ala Tyr Leu Arg Arg		

	340	345	350
Gly Pro Phe Lys Asp Val Ala Ser Val Arg Val Ala Val Gln Asp Ala			
355	360	365	
Pro Glu Pro Pro Ala Phe Thr Gln Ala Ala Tyr His Leu Thr Val Pro			
370	375	380	
Glu Asn Lys Ala Pro Gly Thr Leu Val Gly Gln Ile Ser Ala Ala Asp			
385	390	395	400
Leu Asp Ser Pro Ala Ser Pro Ile Arg Tyr Ser Ile Leu Pro His Ser			
405	410	415	
Asp Pro Glu Arg Cys Phe Ser Ile Gln Pro Glu Glu Gly Thr Ile His			
420	425	430	
Thr Ala Ala Pro Leu Asp Arg Glu Ala Arg Ala Trp His Asn Leu Thr			
435	440	445	
Val Leu Ala Thr Glu Leu Asp Ser Ser Ala Gln Ala Ser Arg Val Gln			
450	455	460	
Val Ala Ile Gln Thr Leu Asp Glu Asn Asp Asn Ala Pro Gln Leu Ala			
465	470	475	480
Glu Pro Tyr Asp Thr Phe Val Cys Asp Ser Ala Ala Pro Gly Gln Leu			
485	490	495	
Ile Gln Val Ile Arg Ala Leu Asp Arg Asp Glu Val Gly Asn Ser Ser			
500	505	510	
His Val Ser Phe Gln Gly Pro Leu Gly Pro Asp Ala Asn Phe Thr Val			
515	520	525	
Gln Asp Asn Arg Asp Gly Ser Ala Ser Leu Leu Leu Pro Ser Arg Pro			
530	535	540	
Ala Pro Pro Arg His Ala Pro Tyr Leu Val Pro Ile Glu Leu Trp Asp			
545	550	555	560
Trp Gly Gln Pro Ala Leu Ser Ser Thr Ala Thr Val Thr Val Ser Val			
565	570	575	
Cys Arg Cys Gln Pro Asp Gly Ser Val Ala Ser Cys Trp Pro Glu Ala			
580	585	590	
His Leu Ser Ala Ala Gly Leu Ser Thr Gly Ala Leu Leu Ala Ile Ile			
595	600	605	
Thr Cys Val Gly Ala Leu Ala Leu Val Val Leu Phe Val Ala Leu			
610	615	620	
Arg Arg Gln Lys Gln Glu Ala Leu Met Val Leu Glu Glu Asp Val			
625	630	635	640
Arg Glu Asn Ile Ile Thr Tyr Asp Asp Glu Gly Gly Glu Glu Asp			
645	650	655	
Thr Glu Ala Phe Asp Ile Thr Ala Leu Gln Asn Pro Asp Gly Ala Ala			
660	665	670	
Pro Pro Ala Pro Gly Pro Pro Ala Arg Arg Asp Val Leu Pro Arg Ala			
675	680	685	
Arg Val Ser Arg Gln Pro Arg Pro Pro Gly Pro Ala Asp Val Ala Gln			
690	695	700	
Leu Leu Ala Leu Arg Leu Arg Glu Ala Asp Glu Asp Pro Gly Val Pro			
705	710	715	720
Pro Tyr Asp Ser Val Gln Val Tyr Gly Tyr Glu Gly Arg Gly Ser Ser			
725	730	735	
Cys Gly Ser Leu Ser Ser Leu Gly Ser Gly Ser Glu Ala Gly Gly Ala			
740	745	750	
Pro Gly Pro Ala Glu Pro Leu Asp Asp Trp Gly Pro Leu Phe Arg Thr			
755	760	765	
Leu Ala Glu Leu Tyr Gly Ala Lys Glu Pro Pro Ala Pro			
770	775	780	

<210> 76
 <211> 640
 <212> PRT

<213> Homo sapiens

<400> 76

Met Ala Arg Gly His Tyr Ile Tyr Val Asp Thr Ser Phe Gly Lys Gln
 1 5 10 15
 Gly Glu Lys Ala Val Leu Leu Ser Pro Asp Leu Gln Ala Glu Glu Trp
 20 25 30
 Ser Cys Leu Arg Leu Val Tyr Gln Ile Thr Thr Ser Ser Glu Ser Leu
 35 40 45
 Ser Asp Pro Ser Gln Leu Asn Leu Tyr Met Arg Phe Glu Asp Glu Ser
 50 55 60
 Phe Asp Arg Leu Leu Trp Ser Ala Lys Glu Pro Ser Asp Ser Trp Leu
 65 70 75 80
 Ile Ala Ser Leu Asp Leu Gln Asn Ser Ser Lys Lys Phe Lys Ile Leu
 85 90 95
 Ile Glu Gly Val Leu Gly Gln Gly Asn Thr Ala Ser Ile Ala Leu Phe
 100 105 110
 Glu Ile Lys Met Thr Thr Gly Tyr Cys Ile Glu Cys Asp Phe Glu Glu
 115 120 125
 Asn His Leu Cys Gly Phe Val Asn Arg Trp Asn Pro Asn Val Asn Trp
 130 135 140
 Phe Val Gly Gly Ser Ile Arg Asn Val His Ser Ile Leu Pro Gln
 145 150 155 160
 Asp His Thr Phe Lys Ser Glu Leu Gly His Tyr Met Tyr Val Asp Ser
 165 170 175
 Val Tyr Val Lys His Phe Gln Glu Val Ala Gln Leu Ile Ser Pro Leu
 180 185 190
 Thr Thr Ala Pro Met Ala Gly Cys Leu Ser Phe Tyr Tyr Gln Ile Gln
 195 200 205
 Gln Gly Asn Asp Asn Val Phe Ser Leu Tyr Thr Arg Asp Val Ala Gly
 210 215 220
 Leu Tyr Glu Glu Ile Trp Lys Ala Asp Arg Pro Gly Asn Ala Ala Trp
 225 230 235 240
 Asn Leu Ala Glu Val Glu Phe Thr Cys His Phe Pro Leu Gln Val Ile
 245 250 255
 Phe Glu Val Ala Phe Asn Gly Pro Lys Gly Gly Tyr Val Ala Leu Asp
 260 265 270
 Asp Ile Ser Phe Ser Pro Val His Cys Gln Asn Gln Thr Glu Leu Leu
 275 280 285
 Phe Ser Ala Val Glu Ala Ser Cys Asn Phe Glu Gln Asp Leu Cys Asn
 290 295 300
 Phe Tyr Gln Asp Lys Glu Gly Pro Gly Trp Thr Arg Val Lys Val Lys
 305 310 315 320
 Pro Asn Met Tyr Arg Ala Gly Asp His Thr Thr Gly Leu Gly Tyr Tyr
 325 330 335
 Leu Leu Ala Asn Thr Lys Phe Thr Ser Gln Pro Gly Tyr Ile Gly Arg
 340 345 350
 Leu Tyr Gly Pro Ser Leu Pro Gly Asn Leu Gln Tyr Cys Leu Arg Phe
 355 360 365
 His Tyr Ala Ile Tyr Gly Phe Leu Lys Met Ser Asp Thr Leu Ala Val
 370 375 380
 Tyr Ile Phe Glu Glu Asn His Val Val Gln Glu Lys Ile Trp Ser Val
 385 390 395 400
 Leu Glu Ser Pro Arg Gly Val Trp Met Gln Ala Glu Ile Thr Phe Lys
 405 410 415
 Lys Pro Met Pro Thr Lys Val Val Phe Met Ser Leu Cys Lys Ser Phe
 420 425 430
 Trp Asp Cys Gly Leu Val Ala Leu Asp Asp Ile Thr Ile Gln Leu Gly
 435 440 445

Ser Cys Ser Ser Ser Glu Lys Leu Pro Pro Pro Pro Gly Glu Cys Thr
 450 455 460
 Phe Glu Gln Asp Glu Cys Thr Phe Thr Gln Glu Lys Arg Asn Arg Ser
 465 470 475 480
 Ser Trp His Arg Arg Arg Gly Glu Thr Pro Thr Ser Tyr Thr Gly Pro
 485 490 495
 Lys Gly Asp His Thr Thr Gly Val Gly Tyr Tyr Met Tyr Ile Glu Ala
 500 505 510
 Ser His Met Val Tyr Gly Gln Lys Ala Arg Leu Leu Ser Arg Pro Leu
 515 520 525
 Arg Gly Val Ser Gly Lys His Cys Leu Thr Phe Phe Tyr His Met Tyr
 530 535 540
 Gly Gly Gly Thr Gly Leu Leu Ser Val Tyr Leu Lys Lys Glu Glu Asp
 545 550 555 560
 Ser Glu Glu Ser Leu Leu Trp Arg Arg Arg Gly Glu Gln Ser Ile Ser
 565 570 575
 Trp Leu Arg Ala Leu Ile Glu Tyr Ser Cys Glu Arg Gln His Gln Ile
 580 585 590
 Ile Phe Glu Ala Ile Arg Gly Val Ser Ile Arg Ser Asp Ile Ala Ile
 595 600 605
 Asp Asp Val Lys Phe Gln Ala Gly Pro Cys Gly Glu Met Glu Asp Thr
 610 615 620
 Thr Gln Gln Ser Ser Gly Tyr Ser Glu Asp Leu Asn Glu Ile Glu Tyr
 625 630 635 640

<210> 77
 <211> 686
 <212> PRT
 <213> Homo sapiens

<400> 77

Met Leu Leu Arg Gly Val Leu Leu Ala Leu Gln Ala Leu Gln Leu Ala
 1 5 10 15
 Gly Ala Leu Asp Leu Pro Ala Gly Ser Cys Ala Phe Glu Glu Ser Thr
 20 25 30
 Cys Gly Phe Asp Ser Val Leu Ala Ser Leu Pro Trp Ile Leu Asn Glu
 35 40 45
 Glu Gly His Tyr Ile Tyr Val Asp Thr Ser Phe Gly Lys Gln Gly Glu
 50 55 60
 Lys Ala Val Leu Leu Ser Pro Asp Leu Gln Ala Glu Glu Trp Ser Cys
 65 70 75 80
 Leu Arg Leu Val Tyr Gln Ile Thr Thr Ser Ser Glu Ser Leu Ser Asp
 85 90 95
 Pro Ser Gln Leu Asn Leu Tyr Met Arg Phe Glu Asp Glu Ser Phe Asp
 100 105 110
 Arg Leu Leu Trp Ser Ala Lys Glu Pro Ser Asp Ser Trp Leu Ile Ala
 115 120 125
 Ser Leu Asp Leu Gln Asn Ser Ser Lys Lys Phe Lys Ile Leu Ile Glu
 130 135 140
 Gly Val Leu Gly Gln Gly Asn Thr Ala Ser Ile Ala Leu Phe Glu Ile
 145 150 155 160
 Lys Met Thr Thr Gly Tyr Cys Ile Glu Cys Asp Phe Glu Glu Asn His
 165 170 175
 Leu Cys Gly Phe Val Asn Arg Trp Asn Pro Asn Val Asn Trp Phe Val
 180 185 190
 Gly Gly Gly Ser Ile Arg Asn Val His Ser Ile Leu Pro Gln Asp His
 195 200 205
 Thr Phe Lys Ser Glu Leu Gly His Tyr Met Tyr Val Asp Ser Val Tyr
 210 215 220

Val Lys His Phe Gln Glu Val Ala Gln Leu Ile Ser Pro Leu Thr Thr
 225 230 235 240
 Ala Pro Met Ala Gly Cys Leu Ser Phe Tyr Tyr Gln Ile Gln Gln Gly
 245 250 255
 Asn Asp Asn Val Phe Ser Leu Tyr Thr Arg Asp Val Ala Gly Leu Tyr
 260 265 270
 Glu Glu Ile Trp Lys Ala Asp Arg Pro Gly Asn Ala Ala Trp Asn Leu
 275 280 285
 Ala Glu Val Glu Phe Thr Cys His Phe Pro Leu Gln Val Ile Phe Glu
 290 295 300
 Val Ala Phe Asn Gly Pro Lys Gly Gly Tyr Val Ala Leu Asp Asp Ile
 305 310 315 320
 Ser Phe Ser Pro Val His Cys Gln Asn Gln Thr Glu Leu Leu Phe Ser
 325 330 335
 Ala Val Glu Ala Ser Cys Asn Phe Glu Gln Asp Leu Cys Asn Phe Tyr
 340 345 350
 Gln Asp Lys Glu Gly Pro Gly Trp Thr Arg Val Lys Val Lys Pro Asn
 355 360 365
 Met Tyr Arg Ala Gly Asp His Thr Thr Gly Leu Gly Tyr Tyr Leu Leu
 370 375 380
 Ala Asn Thr Lys Phe Thr Ser Gln Pro Gly Tyr Ile Gly Arg Leu Tyr
 385 390 395 400
 Gly Pro Ser Leu Pro Gly Asn Leu Gln Tyr Cys Leu Arg Phe His Tyr
 405 410 415
 Ala Ile Tyr Gly Phe Leu Lys Met Ser Asp Thr Leu Ala Val Tyr Ile
 420 425 430
 Phe Glu Glu Asn His Val Val Gln Glu Lys Ile Trp Ser Val Leu Glu
 435 440 445
 Ser Pro Arg Gly Val Trp Met Gln Ala Glu Ile Thr Phe Lys Lys Pro
 450 455 460
 Met Pro Thr Lys Val Val Phe Met Ser Leu Cys Lys Ser Phe Trp Asp
 465 470 475 480
 Cys Gly Leu Val Ala Leu Asp Asp Ile Thr Ile Gln Leu Gly Ser Cys
 485 490 495
 Ser Ser Ser Glu Lys Leu Pro Pro Pro Gly Glu Cys Thr Phe Glu
 500 505 510
 Gln Asp Glu Cys Thr Phe Thr Gln Glu Lys Arg Asn Arg Ser Ser Trp
 515 520 525
 His Arg Arg Arg Gly Glu Thr Pro Thr Ser Tyr Thr Gly Pro Lys Gly
 530 535 540
 Asp His Thr Thr Gly Val Gly Tyr Tyr Met Tyr Ile Glu Ala Ser His
 545 550 555 560
 Met Val Tyr Gly Gln Lys Ala Arg Leu Leu Ser Arg Pro Leu Arg Gly
 565 570 575
 Val Ser Gly Lys His Cys Leu Thr Phe Phe Tyr His Met Tyr Gly Gly
 580 585 590
 Gly Thr Gly Leu Leu Ser Val Tyr Leu Lys Lys Glu Glu Asp Ser Glu
 595 600 605
 Glu Ser Leu Leu Trp Arg Arg Gly Glu Gln Ser Ile Ser Trp Leu
 610 615 620
 Arg Ala Leu Ile Glu Tyr Ser Cys Glu Arg Gln His Gln Ile Ile Phe
 625 630 635 640
 Glu Ala Ile Arg Gly Val Ser Ile Arg Ser Asp Ile Ala Ile Asp Asp
 645 650 655
 Val Lys Phe Gln Ala Gly Pro Cys Gly Glu Met Glu Asp Thr Thr Gln
 660 665 670
 Gln Ser Ser Gly Tyr Ser Glu Asp Leu Asn Glu Ile Glu Tyr
 675 680 685

<210> 78
<211> 154
<212> PRT
<213> Homo sapiens

<400> 78
Met Thr Leu Ser Pro Thr Gln Pro Pro Leu Phe His Leu Pro Tyr Val
1 5 10 15
Gln Lys Cys Phe Ile Pro Thr Val Glu Gln Leu Thr Leu, Gly Ile Pro
20 25 30
Cys Gln Asn His Gly Glu Ile Asp His Gly Gln Asp Ile Phe Pro Ala
35 40 45
Glu Lys Leu Cys His Leu Gln Asp Cys Lys Val Asn Leu His Arg Ala
50 55 60
Ala Cys Gly Glu Cys Ile Val Ala Pro Lys Thr Ser Ser Phe Pro Tyr
65 70 75 80
Cys Gln Gly Thr Cys Leu Thr Leu Asn Ser Glu Leu His Gln Ser Asn
85 90 95
Phe Ala Leu Lys Val Cys Thr Ile Arg Gly Glu Cys Leu Leu Ile Cys
100 105 110
Ser Trp Leu Phe Gln Thr Cys Ser Pro Thr Lys Val Ile Leu Phe Ser
115 120 125
Leu Thr Val Gln Asp Asp Glu Arg Lys Met Ser Val His Cys Val Asn
130 135 140
Ala Ser Leu Ile Glu Lys Cys Gly Cys Ser
145 150

INTERNATIONAL SEARCH REPORT

Int'l application No.
PCT/US01/13360

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C07H 21/04; C12P 21/06; C12N 9/00, 1/20, 15/00
US CL: 435/69.1, 183, 252.2, 320.1; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 183, 252.2, 320.1; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
BIOSIS, CAPLUS, MEDLINE, EMBASE, GENBANK, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	CARNINCI, P et al. Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes, Genome Res., October 2000, Vol.10, No.10, pages 1617-1630, see entire article.	1-7
A, P	WO 00/55350 A1 (HUMAN GENOME SCIENCES, INC.) 21 September 2000 (21-9-00).	1-7
A	WO 95/30428 A1 (HUMAN GENOME SCIENCES, INC.) 16 November 1995 (11-16-95).	1-7
A	US 5,830,744 A (ROSEN et al.) 03 November 1998 (11-03-98).	1-7

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 JULY 2001

Date of mailing of the international search report

02 AUG 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized Officer

MAMUNATH RAO

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/18860

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. 1-7, SEQ ID NO:1 and 40

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/13360

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 18.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

- 1) Polynucleotide sequences with SEQ ID NOs 1 through 39.
- 2) Polypeptide sequences with SEQ ID NOs: 40-78.

The following claims are generic: Claims 1-7

The species listed above do not relate to a single inventive concept under PCT Rule 18.1 because, under PCT Rule 18.2, the species lack the same or corresponding special technical features for the following reasons: Each of the above polynucleotide and polypeptide sequences are patentably distinct from each other as they have different structure and function.